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Abstract
The effectiveness of the treatment of cancer using radiotherapy or cytotoxic 
drugs is limited by lack of selectivity for cancer cells. One approach towards 
improving cancer therapy, therefore, is to sensitise tumour cells to the cytotoxic 
effects of radiotherapy and chemotherapy. This can be achieved through the 
inhibition of DNA repair processes. Poly(ADP-ribose) polymerase (PARP) is an 
abundant, chromatin-bound enzyme which is activated by binding to DNA 
strand-breaks and catalyses the synthesis of polymers of ADP-ribose from NAD+. 
The cellular functions of PARP are not fully understood but it appears that the 
enzyme is involved in DNA repair. Inhibitors of PARP may, therefore, be of use 
in the treatment of cancer as potentiators of radiotherapy and chemotherapy. The 
design and synthesis of potential inhibitors of PARP has been studied. Analogues 
of NAD+ with appropriately located electrophilic side chains have been 
synthesised as potential irreversible inhibitors of PARP.
Several novel benzamide derivatives have been synthesised and evaluated for 
their effect on PARP activity. Two benzamides with electrophilic side chains 
have been prepared. The first, 3-chloromethylbenzamide, was a moderately 
potent inhibitor of PARP, causing 62% inhibition at 10.5 jxM. The second, 3- 
(oxiran-2-yl)benzamide was a very potent PARP inhibitor, one of the most potent 
of its benzamide class, causing 88% inhibition of PARP activity at 9.2 pM.
Various methods of synthesis of isoquinolinones have been investigated and 
several novel isoquinolin-l-one derivatives have been prepared. The successful 
preparation of 5-bromoisoquinolinone and 5-iodoisoquinolinone allowed 
investigation of the C-metallation of isoquinolinones. 3-(l-Oxoisoquinolin-5- 
yl)propenoic acid was prepared using the palladium-catalysed Heck reaction. 
This potentially irreversible inhibitor reduced PARP activity by 81% at 11.6 pM. 
These results indicate the potential for the development of new, more potent 
PARP inhibitors.
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Radiation therapy has been used in the treatment of cancer since the late 19th 
century, shortly after the discovery of X-rays. Techniques have been developed 
and improved and radiotherapy is now widely used, alone and in combination 
with surgery in the treatment of many primary cancers. As with the 
chemotherapy of cancer, the main limitation of radiotherapy is the damage 
caused to normal cells. Both treatments, by the nature of their action, will 
damage cells which are rapidly dividing. This includes cells in the skin, 
gastrointestinal tract, bone marrow and blood vessels as well as the targeted 
tumour cells. Therefore, improvement of radiotherapy depends upon increasing 
the radiosensitivity and radioresponsiveness of tumour cells relative to that of the 
surrounding normal cells.
1.1 Mechanism of Action
The main types of radiation used in radiotherapy are X-rays and gamma rays. 
These are both types of ionising radiation, i.e. the radiation causes ejection of a 
fast electron from the target molecule and subsequent production of an ion. 
These species react with other molecules to form ions and free radicals.1,2 Direct 
damage due to radiation acting on macromolecules such as DNA occurs. 
However, since the predominant molecule present in biological systems is water, 
it is radicals produced from water that are the most important.1 The excited 
species and radicals derived from the interaction of radiation with water are 
shown in Figure 1. These radicals interact with organic molecules (DNA, RNA, 
proteins) within the cell, represented by R in Figure 1. In the presence of oxygen 
a wider range of radicals is produced and more damage occurs.
l
Figure 1: Radicals generated in the chain reaction following interaction of
ionising radiation with water and organic molecules.
hv
H20  -------- > H 20 + + e"
h 2o + + h 2o —► H 30 + + OH*
e' + H20 -------- ► e 'a q -------- ► OH + H •
e' + H 30 + -►  H 20  + H *
2 OH’ ----- ► H 20 2
OH*2 H* -------- ► H 2 - -  -► H 20  + OH *
H*
II20 2 *- H 20  + OH*
In the presence of oxygen:-
H* + 0 2 -------- ► H 0 2 ► H 20 2 + 0 2
. H+
H 02 + e -------- ► HO 2 -------- ► H 20
With organic molecules:-
R + OH* —-----►ROH *
R + OH *------- R *+ H 20
R* + 0 2 -------- ► RC) *2 -------- ► R + O J
■ ■ ^-» R 0 2H + R'*
Where the DNA has been directly damaged by the radiation, radical anionic and 
cationic sites are formed. In well-oxygenated cells, oxygen molecules can 
abstract a proton from the radical anions leaving radical cations with a long 
enough life to allow serious DNA damage. In the absence of oxygen the electron 
from the radical anion combines with the radical cation and no damage results. In
2
both scenarios, more damage takes place in the presence of oxygen. This is 
generally known as the oxygen effect and has been widely measured using the 
oxygen enhancement ratio (OER). This is the ratio of radiation doses given to 
cells hypoxically or in air to produce a given level of cell killing. The oxygen 
effect is significant because solid tumours are very poorly vascularised. There 
are, therefore, regions within the tumour where the cells are hypoxic owing to 
their limited blood supply and are consequently relatively radioresistant.
1.1.1 Cytotoxicity
The cytotoxicity caused by radiation has been measured in many studies and is 
expressed in terms of the fraction of cells surviving following a specific dose of 
radiation. Survival is measured by the ability of the cells to proliferate following 
the radiation dose. Figure 2 shows a typical survival curve. After an initial 
shoulder to the curve, the surviving fraction decreases exponentially with 
increasing dose. Therefore, in the dosage range of this linear portion, a given 
dose will kill a fixed fraction of the population, regardless of the initial number 
of cells. The shouldered portion of the graph is generally thought to be due to 
sub-lethal damage3,4 (SLD). In this dose range the cellular repair processes are 
able to repair the damage caused by the radiation and allow the cells to recover. 
However, at higher doses, cellular repair processes become saturated, are not 
able to repair the damage effectively and it becomes lethal.5 It has been shown 
that there is a good correlation between the steepness of the initial slope of the 










Figure 2: Typical dose-response curve for the survival of irradiated cells
1.1.2 DNA Damage
It is generally accepted that the lesions, produced by ionising radiation, which 
result in cell-death involve DNA.7 DNA double-strand breaks (DSB) have been 
particularly implicated.5 It is also thought that multiple lesions produced within a 
small region of the genome, known as "locally multiply damaged sites" 
(LMDS),5,8 may be important. Experiments have shown1 that increasing the dose 
of radiation increases the proportion of lower molecular weight DNA on sucrose 
density-gradient analysis. This reflects an increase in the extent of strand- 
breakage. At lower radiation doses, the majority of lesions are rapidly repaired;9 
this is reflected in the shouldered region of the survival curve (Figure 2). 
However, when the number of DSBs is increased, repair processes become less 
efficient and the DNA remains damaged, resulting in cell-death. Inhibition of 
DNA repair processes would lead to an increase in cell-kill and, consequently, 
improvement of radiotherapy.
4
1.2 Clinical Aspects of Radiotherapy
The dose of radiation used to treat a tumour is limited by the damage it will cause 
to the surrounding, normal tissue. The dose needs to be carefully optimised so as 
to produce the maximum tumour response with minimum tissue toxicity. There 
are three distinct types of toxicity that can occur in response to radiotherapy; 
transient toxicity, occurring during or shortly after therapy, early changes and late 
changes which may manifest themselves many years after the radiotherapy has 
finished. Therapy can be adjusted in response to the early injuries seen; however, 
the late changes are much less predictable and are therefore difficult to avoid.
The method used by radiotherapists to increase the therapeutic index of the 
radiotherapy of tumours, is fractionated dosage. This method has been used since 
the 1920s and involves giving a series of doses of radiation at daily intervals, for 
five days of the week, over a period of three to six weeks. The principle behind 
this approach depends mainly on the observation that, although the normal tissue 
and tumour cells suffer similar damage, the normal cells appear to be able to 
recover more quickly.10 Three main factors influence fractionated therapy; 
recovery from SLD, repopulation, and re-oxygenation. Repopulation occurs more 
readily in normal tissues than in tumours. There is migration of untreated cells 
from the surrounding tissue to the treated areas and an increase in proliferation in 
response to cell death. Re-oxygenation of the tumour tissue is an important 
factor, since the hypoxic cells are more radioresistant. This effect occurs during 
the course of the treatment, as the tumour cells are killed and the tumour size 
decreases. Tumour cells that were originally distant from capillaries are brought 
closer and are oxygenated. This increases their radiosensitivity.
The disadvantage of fractionated therapy is that, although the early toxicity is 
limited by giving smaller individual doses, the total dose of radiation given over 
the course of the treatment is much larger. For longer courses of treatment, the
5
total number of cells that must be killed increases due to the repair of SLD and 
recovery of the tumour cells. It seems likely that exposure to greater overall 
quantities of radiation will increase the amount of late injury to normal tissue. 
Several approaches have been made to try to increase the therapeutic index.
1.3 Modification of Radiation Effects
The relative radioresistance of hypoxic tumour cells is the major cause of failure 
of local control of cancer by radiotherapy. The radiation dose required to produce 
a given effect is about three times greater for hypoxic than aerobic cells.11 
Therefore, approaches to improve radiotherapy have focused on reducing the 
radioresistance of hypoxic cells.
1.3.1 Densely Ionising Radiation
Densely ionising radiation such as neutrons, negative n mesons and accelerated 
heavy ions have a much smaller oxygen effect than conventional x-rays and 
gamma rays.1,2,12 Negative 7t mesons also have the advantage that they penetrate 
the tissue and deliver the dose deeper beneath the skin therefore minimising 
tissue damage in the path through the skin to the tumour.
1.3.2 Radioprotectors
The oxygen effect can be minimised by protecting oxygenated tissues.1 
Radioprotectors have been developed to decrease radical production in normal 
tissues. Sulphydiyl compounds such as cysteamine and WR-2721, shown in 







Electron-affinic radiosensitisers have been widely studied.12,13,14 Also known as 
oxygen mimetics, these compounds can diffuse into hypoxic tumour cells and 
cause damage to DNA by a mechanism similar to that of oxygen. Metronidazole 
was first shown to sensitise hypoxic Chinese hamster cells to radiation in 
1973.15,16 Many nitroheterocycles have since been evaluated as oxygen mimetics, 
the most successful being the 2-nitroimidazoles. Etanidazole and 














Other compounds have been found to sensitise tumour cells to the effects of 
radiation. Calcium antagonists have been evaluated,18 the aim being to increase 
the blood flow in the tumour in order to reduce hypoxia and therefore increase 
radiosensitivity. Flunarizine (Figure 4) produced only a 20% reduction in 
hypoxia but produced significant sensitisation of tumours at a wide range of 
doses.14
Another example is clofibrate, an antilipidaemic drug.19 It was firstly thought 
that the radiosensitising properties of clofibrate were wholly due to its action of 
reducing the affinity of haemoglobin for oxygen, therefore increasing the 
availability of oxygen to hypoxic regions. However, when less toxic analogues of 
clofibrate were tested, although the effect on haemoglobin was still present, the 
radiosensitising properties were much less marked. It was concluded that other 
mechanisms must also be involved in the radiosensitisation observed with 
clofibrate.
Figure 5 shows the effect that electron-affinic and the miscellaneous sensitisers 
discussed, have on the radiation survival curve. Since there is still repair of sub- 
lethal damage, there is still a shoulder to the curve and the curve is simply moved 
to the left. The gradient of the shouldered portion of the curve is particularly 
important in determining the success of the radiotherapy. Therefore an ideal 
sensitiser would cause increased killing in this low-dose range. By inhibiting 
DNA repair of sub-lethal damage and potentially lethal damage, cell-death is 
increased at both small and large doses. The third curve in Figure 5 shows the 
effect of a DNA repair inhibitor on the radiation survival curve.
Figure 5: Schematic radiation dose-response curves fo r  the effects o f electron 







“ DNA repair inhibitor
DNA repair involves a number of complex enzymatic processes and it is not yet 
clear which of these are important following radiation damage.8 Figure 6 shows 
several inhibitors that are known to interfere with DNA repair and their probable 
sites of action in DNA repair pathways. Most of the compounds shown have 
been evaluated as radiosensitisers. Kelland et a f  found 3-aminobenzamide 
(3AB), hydroxyurea (HU), and 9-p-D-arabinofuranosyladenosine (ara A) to be 
radiosensitisers of human carcinoma cells. Aphidicolin and novobiocin did not 
exhibit a significant effect. Ward and Blakely20 also found HU and 1-|3-D- 
arabinofuranosylcytosine (ara C) increased the radiosensitivity of HeLa cells. 
3AB is an inhibitor of the enzyme poly(ADP-ribose) polymerase.21 This thesis is 
concerned with this enzyme, its role in DNA repair and its inhibition.
9
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Poly(ADP-ribose) polymerase (PARP), also known as poly(ADP-ribose) 
synthetase and ADP-ribosyl transferase, is an abundant nuclear enzyme. It is 
present in almost all animal tissue, plants and lower eucaryotes, but lacking in 
several terminally differentiated cells and in yeasts.22 PARP is a multifunctional 
enzyme which requires DNA strand breaks for activity.23'25 The enzyme catalyses 
the transfer of ADP-ribose units from its substrate; nicotinamide adenine 
dinucleotide (NAD+), to a limited number of protein acceptors. These are partly 
nuclear proteins involved in chromatin architecture and DNA metabolism 
(heteromodification), but the main protein to be poly(ADP-ribosyl)ated is PARP 
itself (automodification).26,27 The exact biological role of PARP is not yet clear, 
despite much research over the last 30 years. In addition to the speculation that 
PARP may be involved in cell proliferation, differentiation and transformation, 
evidence shows that the enzyme plays an important part in the reaction of the cell 
to DNA damage. It is this involvement that has led to an interest in PARP as a 
target for the design of chemosensitisers and radiosensitisers.
2.1 Structural Features of Poly(ADP-ribose) Polymerase
Approximately 90% of PARP molecules are located in the cell nucleus, bound 
tightly to chromatin 23 There are in the region of one million molecules per
OHnucleus. PARP was first purified in 1977 by Okayoma and co-workers from rat 
liver nuclei. The enzyme has since been purified to homogeneity from many
O'Xtissues originating in a variety of different animals. More recently, the gene 
encoding for human PARP, which is on chromosome 1, has been cloned. This 
was achieved, firstly, by Smulson and his group.29 Other laboratories followed 
and now cDNA sequences of PARP from several species including mammals,
11
fish and insects, have been determined (summarised in ref. 30). The 
identification of the amino acid sequences of PARP from different sources has 
shown that the enzyme is highly conserved, particularly in the region of the 
protein that binds NAD+.
Human PARP consists of a single polypeptide chain of 1014 amino acid 
residues.31 The protein has a predicted mass of 113 kDa, but the measured mass 
of the purified enzyme is often 116 kDa, therefore both values are quoted in the 
literature. Limited proteolysis of PARP gives three functional domains: A 46
kDa amino-terminal fragment, containing the DNA binding domain (DBD); a 
central 22 kDa fragment containing the automodification sites; and a 54 kDa 
carboxyl terminal region containing the catalytic domain. This is shown 
schematically in Figure 7.
DNA binding Domain Automodification 




Figure 7: Schematic view o f the three functional domains o f human PARP, 
obtained by mild trypsin and papain digestion '
2.1.1 The DNA Binding Domain
PARP is activated by binding to DNA strand breaks. Experiments have shown 
that PARP binds preferentially at DNA breaks, symmetrically covering seven or 
eight nucleotides on each side of the break.34 When the DNA break is single 
stranded, there is a V-shaped bend in the DNA and PARP has been shown to 
bind at the apex.35 Zahradk and Ebisuzaki36 found that PARP is a metalloenzyme 
and requires zinc for activity. Further work has shown binding of PARP to DNA
12
is zinc dependent and that PARP has two zinc "fingers" in its DBD.37 The zinc 
fingers are regions in the protein where a zinc ion binds to four amino acid 
residues to form a loop in the polypeptide chain. These motifs are seen in several 
other nucleotide binding proteins. The two zinc fingers have been named f I and 
f II (see Figure 7). The cDNA fragment encoding the zinc fingers was cloned 
and expressed in E. coli by Gradwohl34 et al. Site-directed mutagenesis was used 
to change the structure of the zinc fingers and the effect on DNA binding was 
then measured. It was found that when f II was disrupted DNA binding was 
drastically reduced, whereas alteration of the peptide in the f I region had little 
effect on DNA binding. In addition to having the stronger DNA binding, f II also 
seems to play a role in the recognition of single-stranded DNA breaks.34 It is 
interesting to note that it has been recently found that the human DNA ligase HI 
enzyme has a very similar zinc finger to those found in PARP.38 This may also 
serve for preferential binding at DNA single strand breaks.39
2.1.2 The Automodification Domain
There are several glutamate residues in the PARP molecule that act as anchor 
points for poly(ADP-ribose) synthesis. These amino acids are mainly found in 
the region between the binding and the catalytic domains. Studies have suggested 
that two PARP molecules form a dimer at the DNA strand break and the 
poly(ADP-ribosyl)ation automodification is intermolecular.26,27
2.1.3 The Catalytic Domain
The NAD+ binding site is found on the C-terminal domain of PARP. This is the 
most conserved region of the enzyme. The binding site also shows homology 
with NAD+ binding sites in several other enzymes.39 Cloning techniques have 
allowed the catalytic domain of PARP to be isolated and purified.37 This isolated 
domain contains all of the catalytic functionality of the enzyme. It can carry out
13
all of the enzymatic processes associated with the full length enzyme but 
independently of DNA strand breaks. Polymers are formed slowly (0.2% of the 
rate of the complete enzyme)39 and automodification can occur, indicating that 
there are some automodification sites on this domain.32 Site-directed mutagenesis 
experiments were carried out to try to determine which residues in the domain 
are important for NAD+ binding and activity. Two models were proposed for the 
structure of the active site. Marsischky et a f°  suggested that the corresponding 
enzymatic regions of PARP and the mono(ADP-ribosyl)ating bacterial toxins 
(see section 2.2) have similarities. They investigated the Glu998 residue on human 
PARP, since the corresponding glutamic residue in several toxins is known to be 
important for activity. Glu998 mutations produced a reduction in catalytic activity 
of the enzyme, although there was no significant change in the Km of NAD+. 
Simonin41 et al noted catalytic fragment sequence similarities between PARP 
and NAD(P)-dependent leucine and glutamate dehydrogenases. This group 
concluded that residues Lys893 and Asp993 are directly involved in the attachment 
of the first ADP-ribosyl residue from NAD+. The crystal structure of the catalytic 
fragment of PARP from chicken has recently been elucidated,42 although is not 
fully reported. The protein is composed of two structural parts; an a-helical N- 
terminal domain and a C-terminal domain bearing the NAD+ active site. It now 
seems clear that the PARP catalytic domain is most similar to that of the 
bacterial toxins, for example, diphtheria toxin and pertussis toxin. PARP has an 
additional a-helical domain, which, it is suggested, may relay the activation 
signal issued on DNA binding. The structure of the active site with a known 
PARP inhibitor bound was also elucidated. This is discussed later in Chapter 3. It 
is noteworthy that, although these structural similarities have been observed 
between PARP and the mono(ADP-ribose) transferases, there seem to be no 
structural similarities between the inhibitors of the enzymes (see Chapter 3).
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2.2 Enzymatic Functions of Poly(ADP-ribose) Polymerase
2.2.1 ADP-Ribosylation Reactions
ADP-ribosylation is one of the most general ways by which living organisms 
modify their protein structures and functions.43 A number of enzymes carry out 
this posttranslational modification of proteins which uses NAD+ as a donor of the 
modification group. There are two major groups of ADP-ribosylation reactions; 
those which result in mono(ADP-ribosyl)ation and those which result in 
poly(ADP-ribosyl)ation. Although this project is concerned mainly with 
poly(ADP-ribosyl)ation, it is important to realise the similarities and differences 
between these two processes.
2.2.1.1 Mono(ADP-ribosyl)ation
Mono(ADP-ribosyl)ation was first demonstrated using diphtheria toxin, an 
exotoxin produced by Corynebacterium diphtheriae.u  The toxin is a 
mono(ADP-ribose) transferase enzyme which catalyses the mono(ADP- 
ribosyl)ation of elongation factor 2 (EF2). EF2 is involved in protein synthesis in 
eucaryotic cells. Its modification, by diphtheria toxin, results in the inhibition of 
protein synthesis, leading to the death of the host cell. There are several bacterial 
toxins that are mono(ADP-ribosyl) transferases. They all modify a specific amino 
acid acceptor site on their target proteins. There are three distinct classes:-
a) Diphthamide-specific ADP-ribosylation: (Diphthamide is a hypermodified 
histidine residue on EF2). Diphtheria toxin and pseudomonas exotoxin A45 are 
members of this group.
b) Arginine-specific ADP-ribosylation: Examples are cholera toxin A and 
Escherichia coli heat-labile enterotoxin. These enzymes specifically modify 
an arginine residue of a GTP binding protein, Gsa 46
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c) Cysteine-specific ADP-ribosylation: Pertussis toxin47 produced by
Bordetella pertussis carries out mono(ADP-ribosyl)ation of a cysteine residue 
on its target membrane-bound protein resulting in the activation of adenylate 
cyclase.
More recently mono(ADP-ribosyl) transferase enzymes have been found in 
animal tissues. Several enzymes have been identified and are present in most 
cellular compartments; cytosol, plasma membrane and cell nucleus.43,46 
Histidine-, cysteine-, and arginine- specific mono(ADP-ribosyl) transferases have 
been found in mammalian cells, but those found in nuclei have all been arginine- 
specific. The purpose of mono(ADP-ribosyl)ation in mammalian cells is less 
certain than for the bacterial toxins; it is thought that it has some regulatory 
function within the cell.
All of these mono(ADP-ribosyl)ation reactions form N-glycosides; the enzyme 
interacts with a side-chain nitrogen on the amino acid acceptor site. This is in 
contrast to PARP which forms O-glycosides, usually interacting with a glutamic 
acid carboxyl group.
Crystal structures of some of the bacterial toxin mono(ADP-ribosyl)transferases 
have been elucidated45,48,49 These have been compared with the recently 
elucidated crystal structure of the catalytic domain of PARP 42 Evidence to date 
suggests that the family of enzymes carrying out ADP-ribosylation reactions 
share a very structurally similar NAD+ binding site.
2.2.1.2 Poly(ADP-ribosyl)ation
Poly(ADP-ribose) was first identified in 196650 and its structure is well 
understood. The polymer is made up of ADP-ribosyl units as shown in Figure 8.
16
A A
I I i— R R—R Rt 




A 2 "f t r
-R R—R R—R R—R R—R R—  
I I I I I I I I I I
P—P P—P P—P P—P P—P
protein
Figure 8: Structure of poly(ADP-ribose). A, R and P represent the adenine, 
ribose and phosphate subunits, respectively.
PARP uses nicotinamide adenine dinucleotide 
(NAD+) as a source of these units. The structure 
of NAD+ is shown in Figure 9. The molecule 
consists of a nicotinamide group linked to the 1' 
position of a ribose molecule, which is attached 
to a second ribose molecule via two phosphate 
groups. At the 1" position of this ribose group 
is an adenine molecule. Therefore in the 
formation of the poly(ADP-ribose) the bond 
between nicotinamide and ribose must be 
broken. The polymer has branches at around a 
frequency of about one per 30-50 ADP-ribose 
residues.43 To produce these polymers PARP catalyses three different 
reactions:-23
1) Initiation






Figure 9: Structure o f NAD
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2) Elongation
PARP transfers the ADP-ribose portion of NAD+ to the mono(ADP-ribosyl)ated 
protein, linking the second ADP-ribose unit by an a (l"—>2') glycosidic bond to 
the adenine ribose of the preceding ADP-ribose unit.
3) Branching
In this reaction the ADP-ribose portion of NAD+ is transferred to a ribose residue 
in the polymer chain which does not have an adenine molecule attached directly 
to it, {i.e. the ribose that was originally attached to nicotinamide in NAD+). A 
I1"—>2" glycosidic link is formed.51
2.2.2 Protein Acceptors of PoIy(ADP-ribose)
Although PARP itself is the main protein acceptor for poly(ADP-ribosyl)ation52 
(automodification), several other enzymes have been reported to be poly(ADP- 
ribosyl)ated. Histone HI is the main example, others are given in Table 1.
The effect of modification by PARP is, in general, inhibition. It is not clear what 
the significance of this modification is in physiological terms. The extent of 
poly(ADP-ribosyl)ation of other nuclear proteins is small in comparison to 
automodification. It has been suggested that the inhibition seen is due to steric 
interference and charge repulsion by polymer chains.39,53 Many of the 
experiments have been in vitro and there is evidence to suggest that the degree of 
poly(ADP-ribosyl)ation of proteins other than PARP itself is much lower in 
vivo.22 The role that histone HI has to play in the enzymatic mechanism of PARP 
is still unclear.39,54 This is discussed later in section 2.2.3.
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Table 1: Substrates for poly(ADP-ribose)
Protein Effect of do!v(ADP- 
ribosvllation
Reference
Poly(ADP-ribose)polymerase, PARP INHIBITION 52
Ca2+,Mg2+ endonuclease INHIBITION 55
DNA polymerase a INHIBITION 56
DNA polymerase (3 INHIBITION 56
Terminal deoxynucleotide transferase INHIBITION 56
DNA ligase II INHIBITION 56
Topoisomerase I INHIBITION 57,58
Topoisomerase II INHIBITION 59
RNA polymerase II INHIBITION 60
Ribonuclease INHIBITION 61
Prolyl hydroxylase INHIBITION 62
Histone HI UNKNOWN 63,64
Histone H2B UNKNOWN 65
HMG proteins UNKNOWN 63
SV40 T antigen UNKNOWN 66
Adenoviral DNA binding protein UNKNOWN 66
2.2.3 Regulation of Poly(ADP-ribosyl)ation
2.2.3.1 DNA Strand Breaks
Activation of PARP requires DNA strand-breaks. These may be caused directly 
as a consequence of DNA damage, e.g. ionising radiation; or indirectly following 
enzymatic incision. Benjamin and Gill25 showed that the extent of poly(ADP- 
ribosyl)ation is completely dependent on the number of strand breaks and is not 
sequence specific. They used PARP extracted from calf thymus and measured the 
extent of poly(ADP-ribosyl)ation following the addition of plasmid DNA with 
different types of DNA damage. It was found that the DNA must be double­
stranded, as single-stranded DNA does not support poly(ADP-ribose) synthesis.
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The type of strand break also affects the degree of PARP activation; double­
strand breaks with flush ends are the most effective, followed by double-strand 
breaks with unpaired nucleotides at the ends, followed by single-strand breaks.
2.23.2 Poly(ADP-ribose) Glycohydrolase (PARG)
Once PARP is bound to the site of DNA damage rapid polymer synthesis occurs. 
Several thousands of molecules of NAD+ are converted at each strand break.25 If 
the synthesis of these stable polymers was allowed to continue without control, 
the cell would soon become depleted of NAD+, which would lead to ATP 
depletion and cell death. However the polymers produced have a very short half 
life and are largely degraded within one or two minutes of being synthesised. The 
main enzyme involved in the degradation of poly(ADP-ribose) is poly(ADP- 
ribose) glycohydrolase (PARG). PARG, a 59 kDa protein, has been isolated and 
purified from several different tissues.43,67 Until more recently not much was 
known about the enzyme. There is now increased interest in its role in the 
regulation of poly(ADP-ribosyl)ation. A second cytosolic form of the enzyme 
was recently isolated from the guinea pig liver.68 This enzyme is structurally 
different and has slightly different properties to the nuclear form. The role of this 
second form of PARG is still to be determined.
PARG acts by breaking the ribose-ribose bonds of the poly(ADP-ribose) 
polymer. Until recently the enzyme was thought to have a mainly exoglycosidic 
action, i.e. cleaving one ADP-ribose unit at a time from the end of the polymer 
chain. Brochu and co-workers,69 however, showed that, in vitro, acting on long, 
free polymers, PARG also exhibits endoglycosidic activity and can cleave the 
polymer to liberate large fragments of polymer rather than single ADP-ribose 
units. The final ADP-ribose unit is cleaved from the acceptor protein by a second 
enzyme, ADP-ribosyl protein lyase. It is also possible for phosphate-phosphate 
bonds to be cleaved by phosphodiesterase enzymes.69
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In experiments67 using both bound and free poly(ADP-ribose), it was found that 
the degradation of large polymers by PARG is biphasic and the degradation of 
short polymer chains occurs at a much lower rate. A long polymer chain of 
twenty or more ADP-ribose units is degraded quickly until it is about half the 
original size. Degradation of the remaining short polymer is at about 5% of the 
rate of the original degradation. It was found that the Km for the large polymers is 
about 100 times smaller than that for small polymers. These results suggest that 
PARG regulates differentially the levels of small and large polymers in the cell. 
Although the exact mechanism and function of PARG are not yet known it is 
clear that it is as equally important as PARP in the control of poly(ADP- 
ribosyl)ation. The accumulation of stable poly(ADP-ribose) chains would 
eventually cause intolerable interference with DNA replication and 
transcription.39 Study of the actions of PARG may be facilitated by the use of 
specific inhibitors. Slama et al10 have reported the synthesis of adenosine 
diphosphate (hydroxymethyl)pyrrolidinediol (Figure 10). This analogue of ADP- 
ribose was tested for inhibition of PARG, PARP and NADiarginine mono(ADP- 
ribosyl) transferase A. The compound was found to be a specific inhibitor of 
PARG with an IC50 of 0.12 pM; more than 10,000 times its activity for either 





Figure 10: Structure o f Adenosine Diphosphate (Hydroxymethyl)pyrrolidinediol
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2.2.33 Automodification
It is well understood that the most significant target for poly(ADP-ribosyl)ation 
is PARP itself. As many as 28 polymers may be bound to a PARP molecule and 
each polymer chain contains up to 200 units.71 Two groups26,27 carried out kinetic 
and stoichiometric studies on the automodification reaction. Both reached the 
conclusion that automodification is an intermolecular reaction, with the optimal 
ratio of PARP to DNA being 2:1 for maximum PARP activity.27 It is thought that 
two molecules form a dimer at the DNA binding site protecting one and a half 
turns of double helix. The automodification domain of Drosphila PARP was 
cloned in 199372 and found to contain a leucine zipper motif. Leucine zippers 
consist of a repetition of leucine residues at every seventh position and are 
involved in protein-protein interactions. It was suggested that this region might 
mediate the homodimerisation. However this motif is not conserved in vertebrate 
PARP, making it doubtful that this is the mechanism by which the dimer forms. 
Experiments26,27 seem to favour a model of automodification that involves one 
PARP molecule of the dimer being activated and carrying out the poly(ADP- 
ribosyl)ation of the second member dimeric pair. There is, therefore a catalytic 
PARP molecule and an acceptor PARP molecule in each dimer.
Automodification follows a processive reaction mode. On initial activation of 
PARP, a distinct pattern of polymers on a small number of polymerase molecules 
is produced and, as the reaction proceeds, more PARP is poly(ADP- 
ribosyl)ated.54
The effect of automodification on PARP is inhibition. This is thought to be due 
to the electrostatic repulsion between the large, charged polymer chains and the 
DNA, which causes PARP to leave the DNA strand-break and become inactive. 
In 1982 two groups24,73 investigated this effect. The poly(ADP-ribosyl)ation 
increases up to a "repulsion" point at which the negative charge of the polymer is
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so high that it leaves the negatively charged DNA and activation no longer 
occurs. Addition of PARG restores PARP activity by removal of the charged 
polymer chains.73 The repulsion point is also increased by addition of Mg2+ ions, 
which can neutralise the negative charges, and histones, which may shield the 
polymer from the DNA and/or act as acceptors of polymers.24
2.2.3.4 Histones
The role of histones in poly(ADP-ribosyl)ation and the events that follow is not 
yet known, but some researchers in the field believe that these proteins are 
involved in the regulation of poly(ADP-ribosyl)ation and the repair of DNA 
damage that follows. Histones are fairly small, positively charged proteins. They 
are the principal structural proteins of eucaryotic chromosomes and are present in 
large numbers (about 60 million of each type per cell). The positive charges, due 
to a high proportion of lysine and arginine residues, help the proteins to bind 
tightly to DNA. Histones H2A, H2B, H3 and H4 are present in the nucleosides. 
HI molecules, larger, less well conserved proteins, hold the nucleosides together, 
condensing the chromatin. It has been shown that histones can be poly(ADP- 
ribosyl)ated, HI has been studied and an ADP-ribose binding site identified.64 
However, it is not clear whether direct poly(ADP-ribosyl)ation of histones takes 
place in vivo. It does not seem likely that histones bound to DNA act as polymer 
acceptors, in vitro experiments have shown that free histones are modified in 
favour of bound histones and high histone concentrations are required.24 It is 
thought that fragments of poly(ADP-ribose) that have been cleaved from 
automodified PARP can bind non-covalently to proteins such as histones,64 this 
would be facilitated by the electrostatic attraction between the oppositely charged 
molecules. Indeed, Althaus54 suggests that the negatively charged polymers 
compete with DNA for histone binding. The experiments carried out by his 
research group showed that the branching points of poly(ADP-ribose) polymers 
have a particularly high binding affinity for histones.
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Many groups have shown that histone HI can increase the activity of PARP 
when added to an in vitro system.24,73,74 This was found to be due to the histone 
apparently increasing the affinity of PARP for DNA, probably by neutralising the 
electrostatic repulsion between the DNA and the polymer chain.24,73
Naegeli and Althaus74 carried out in vitro experiments in which they measured 
the effect of different histones on the number and size of poly(ADP-ribose) 
polymers produced by PARP. They found that the histones appeared, not only to 
stimulate PARP activity, but to regulate the polymer pattern and size. Each 
histone induced PARP to synthesise a specific polymer size pattern. There was 
evidence that this apparent regulatory effect of the histones was independent of 
their potential acceptor function. The significance of this effect in vivo is not 
known. The significance of these results is also hard to assess since the 
experimental system did not include PARG, which would degrade the polymers 
present.
2.2.3.5 Possible Mechanisms for the Role of Poly(ADP-ribose) Polymerase in 
DNA Strand Break Rejoining.
There are two main ideas that have been proposed to explain the events 
following the occurrence of DNA strand breaks. The two mechanisms are similar 
but differ mainly in the role that histones are given. Both are explained briefly 
below.
2.2.3.5.1 Histone-Shuttle Mechanism
In this mechanism, the PARP automodification reaction serves to shuttle histones 
off and back onto DNA. Althaus54 and his group put forward this idea and have 
carried out many experiments to investigate it.
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Investigations of the non-covalent interaction between histones and poly(ADP- 
ribose) have shown that they are stronger and more specific than would be 
expected of purely electrostatic interactions. Of many basic proteins tested, 
histones were the only ones which bound to the polymer.75 The automodified 
polymerase was found to compete with DNA for histone-binding, the polymers 
bound to PARP having greater affinity for the histones than did the free 
polymers.76
PARP binds to the DNA strand break and is activated. Automodification takes 
place. The long polymer chains attract histones bound to nearby DNA. The 
histone-polymer-polymerase complex that then forms dissociates from the DNA. 
This leaves the damaged region of the DNA accessible to other enzymes, namely 
DNA-repair enzymes that carry out excision repair. PARG quickly degrades the 
long polymers, eliminating the histone binding sites. The histones shuttle back to 
the DNA and the condensed chromatin structure is resumed. The remaining short 
chains on PARP are slowly removed, returning the enzyme to its original form. 
This is pictured schematically in Figure 11.
Other groups are gradually accepting this idea and acknowledging that histones 
play a part in the process. Poirier, Brochu69 and co-workers suggest a similar 
mechanism but conclude from previous work that, in situations of high 
poly(ADP-ribose) turnover, histone HI is probably covalently poly(ADP- 
ribosyl)ated.77,78
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Figure 11: Schematic diagram to show the mechanism of histone-shuttling at 











Satoh, Poirier and Lindahl79 proposed a slightly different mechanism for 
poly(ADP-ribosyl)ation following the occurrence of DNA strand breaks. In this 
mechanism, the actions of PARP and PARG cycle PARP on and off the DNA.
In their experiments, they used a DNA-free extract from normal cells with 
purified PARP and PARG added. Plasmid DNA containing one y-ray induced 
SSB was introduced. 3-Aminobenzamide and ADP-dihydroxypyrrolidine70 were
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used as inhibitors of PARP and PARG respectively. They found that quite short 
polymers on automodified PARP were satisfactory to cause dissociation from 
DNA and allow DNA repair. This questions the purpose of the long polymers 
synthesised by PARP on activation. In their paper, these workers79 suggest that 
the synthesis of long polymers might be to prevent accidental recombination 
events in regions of tandem repeat sequences in the DNA, by electrostatically 
preventing recombination with other DNA regions close to the damaged site. In 
their mechanism, PARP binds to the damaged DNA and is activated. 
Automodification takes place and these long polymer chains are quickly 
degraded by PARG endoglycosidically. Because there are numerous 
automodification sites the short polymers remaining are still enough to cause the 
dissociation of PARP from DNA. The DNA break is now free for DNA repair 
enzymes to act. The short polymers on PARP are slowly degraded by PARG and 
PARP is able to bind to any further DNA strand breaks. This is shown 
schematically in Figure 12.
When histones were introduced into this system no significant differences in the 
DNA repair that took place were noted.
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2.3 Consequences of Poly(ADP-ribosyI)ation in the Cell and Possible 
Functions of PARP
The role that PARP plays in the cell is not yet known. In 1980, poly(ADP- 
ribosylation was linked with DNA excision repair.72 Since this report, there have 
been several hundred papers investigating the role PARP plays in cellular 
recovery following DNA damage. The evidence for involvement of poly(ADP- 
ribosyl)ation in DNA repair is discussed in more detail in section 2.3.9.
Following activation of PARP the main measurable effect on the cell is a drop in 
the level of NAD+. Another immediate effect is a relaxation of the structure of 
chromatin.81,82 This is due to poly(ADP-ribosyl)ation of the structural proteins 
making up the chromosome. The large, negatively charged chains cause the 
structure to open out and it is likely that some of the histones are displaced from 
the DNA (see sections 2.2.3.4 and 2.2.3.5.1). This effect is reversed by the action 
of PARG. The involvement of PARP with DNA strand breaks and chromatin 
structure has led to investigations into the effect of PARP in DNA replication 
and cellular differentiation, as well as in DNA repair.
To study the effect PARP has in the cell the main approach has been to measure 
the effect of inhibiting PARP. Several techniques have been used to do this, the 
main approaches are outlined below.
2.3.1 Techniques used to study PARP actions
Chemical inhibition of PARP is the oldest and still most widely used method of 
studying the effects PARP might potentially have in the cell. The classical 
inhibitor, used in the majority of studies where PARP inhibition is required, is 3- 
aminobenzamide (3AB). This and other inhibitors are discussed in detail in 
Chapter 3.
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More recently molecular biological techniques have been used to decrease PARP 
activity in the cell. One approach used is to cause over-expression of the cDNA 
encoding the DNA binding site of PARP in mammalian cells. The protein 
produced competes with the full enzyme for DNA binding, therefore acting as a 
competitive inhibitor of PARP.30,83 The results obtained have been similar to 
those obtained using 3-aminobenzamide, the classical inhibitor of PARP.
A depletion of PARP can be achieved by inducing the expression of PARP 
antisense RNA in cells.84 This is done by transfecting the cDNA for human 
PARP in the antisense orientation, under an inducible promoter. Addition of 
dexamethasone to the cells induces production of the antisense RNA which binds 
to PARP mRNA causing the selective lowering of the production of PARP 
protein. These cells still contain 104 PARP molecules.
Complete loss of PARP activity has been engineered by inactivating the gene 
encoding for PARP in the mouse germline.85 Mice are produced with no PARP 
and no method of synthesising poly(ADP-ribose) polymerase. This method may 
be a useful way of investigating the in vivo role of PARP.
2.3.2 Role of PARP in Carcinogenesis
Inhibition of PARP has been shown to increase and suppress carcinogenesis in 
various experiments. A strong link has been shown to exist between PARP and 
tumorigenesis in vivo and transformations in vitro. Such experiments have used 
various carcinogens and tumour promoters. The results have been very variable 
and no clear pattern has emerged as to whether inhibitors of PARP enhance or 
suppress the carcinogenesis. These experiments are reviewed by Boulikas.86
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2.3.3 Role of PARP in Chromosome Aberrations and Sister Chromatid 
Exchange
Inhibition of PARP alone was found not to induce chromosome aberrations. 
However, following exposure to ionising radiation or alkylating agents, 
inhibitors of PARP were shown to potentiate the induction of aberrations.58
One effect of PARP inhibition that has not given conflicting results is that on 
sister chromatid exchange (SCE). PARP inhibitors have been shown in several
co
different experiments to cause a dose-dependent increase in SCE. SCE was also 
increased in cells with PARP activity inhibited by expression of DBD protein.87 
Poly(ADP-ribosyl)ation might play an important role in preventing SCE and 
maintaining chromosome structure. This may be achieved, as suggested by Satoh 
et al,79 by stopping other DNA strands from approaching the damaged area, by 
the production of long, negatively charged poly(ADP-ribose) polymers.
2.3.4 Role of PARP in Gene Amplification
Gene amplification is the mechanism by which cells become resistant to selective 
agents by increasing their levels of specific proteins. PARP has been implicated 
in this process. An increase in gene amplification was seen in cells expressing 
PARP antisense RNA.88 Other experiments using inhibitors have produced 
conflicting results.58,89
2.3.5 Role of PARP in DNA Replication
There are several pieces of evidence linking poly(ADP-ribosyl)ation with DNA 
replication. There is an increase in activity of PARP and levels of poly(ADP- 
ribose) in the phase of the cycle when replication takes place (S phase). Activity 
is also higher in actively dividing cells as compared to quiescent cells.86 Several
31
proteins involved in replication are acceptors for poly(ADP-ribose). These 
include SV40 large T antigen, topoisomerases and DNA polymerases (see Table 
1). PARP is associated with DNA polymerase a  and stimulates the enzyme by 
this physical association.90 Activation of PARP and subsequent poly(ADP- 
ribosyl)ation has been shown to inhibit DNA polymerase a, 8 and e.91 PARP has 
recently been confirmed to be a component of the multiprotein DNA replication 
complex.92 It is possible that PARP functions as a molecular nick sensor 
associated with the replication fork. The enzyme controls the progression of the 
replication fork; when DNA damage is present, PARP is activated and inhibits 
replication, ensuring that lesions are not replicated before repair has taken place.
2.3.6 Role of PARP in Cellular Differentiation
PARP seems to be involved in terminal differentiation of cells. PARP inhibitors 
inhibit the differentiation of 3T3-L1 cells into adipocytes,92 as does the 
expression of antisense RNA in the preadipocyte.93 There appears to be a 
transient increase in PARP activity that is essential for entry to the differentiation 
programme.92 This was also seen in eucaryotic differentiation demonstrated in 
human lymphocytes94 and was found to coincide with a rapid rejoining of single­
strand breaks present in quiescent lymphocytes. Induction of HL-60 cells with 
retinoic acid or dimethylsulphoxide was followed, 12-24 hours later, by an 
increase in PARP mRNA. A corresponding decrease occurred on terminal 
differentiation of the cells into granulocytes.92 The exact role that PARP plays in 
this process is as yet unknown.
2.3.7 Role of PARP in Viral Replication
Gaken and co-workers95 found that the infection of a retrovirus into mammalian 
cells was blocked by inhibition of PARP activity. Inhibitors, antisense RNA and 
DBD techniques were used to inhibit PARP activity and all three methods gave
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similar results. It was found that the inhibition occurred in the step in which the 
retroviral DNA is introduced into the host DNA. It appears that PARP is required 
to act with the virus-encoded integrase protein (IN) in order for the incorporation 
of the viral DNA into the host genome.
2.3.8 Role of PARP in Apoptosis
Apoptosis is an active cell death that occurs in both normal and tumour cell 
populations. It involves a programmed pathway that leads to removal of the 
apoptotic cells by phagocytosis. Apoptosis can be triggered physiologically or 
pathologically, following mild stress. It is distinct from the passive cell death that 
follows high doses of damage to the cell, i.e. necrosis. Apoptosis can be blocked, 
in mild stress conditions, by metabolic inhibitors, increasing cell survival.96 It is 
thought that apoptosis might be a mechanism of eliminating potentially mutant 
cells that have been sub-lethally hit by a DNA-damaging agent. PARP, it has 
been suggested, might somehow quantify the DNA damage and translate it into a 
message of cell suicide.96
The area of apoptosis, in general, has attracted a great deal of research in the last 
few years. There is growing evidence that dysregulation of apoptosis may lead to 
several human diseases, including cancer, rheumatoid arthritis and degenerative 
neuronal diseases such as Alzheimer's disease and Parkinson's disease.97,98 It is 
also important in the treatment of cancer, since tumour cell killing by anticancer 
drugs90 and by radiotherapy100 probably involves apoptosis. The exact events in 
apoptosis have not yet been elucidated and the role of PARP is not clear. Many 
experiments have been carried out in a number of different cell systems using a 
wide range of apoptosis-inducing agents. The main observations and theories 
involving PARP are described below.
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Biochemically, the characteristic most commonly associated with apoptosis is 
intemucleosomal cleavage of DNA by Ca2+/Mg2+-dependent endonuclease. A 
way of measuring apoptosis is to examine cell morphology; the nuclei of 
apoptotic cells are fragmented and present in numerous vesicles. There is 
typically DNA fragmentation, such that the DNA has a ladder-like pattern on gel 
electrophoresis. This DNA fragmentation causes activation of PARP and 
synthesis of poly(ADP-ribose) polymers, resulting in a lowering of 
concentrations of NAD+ in the cell. This activation of PARP occurs whatever 
type of stress has caused the apoptosis. Inhibition of this activation of PARP will 
prevent the depletion in NAD+ but will not prevent apoptosis.96 Therefore, 
apoptosis induced in human myeloid leukaemia cells, by cycloheximide or cell 
ageing, stress which does not cause immediate DNA damage, is not prevented by 
incubation with PARP inhibitors.96 However, when apoptosis is induced by an 
agent that does cause DNA damage, such as mild doses of hydrogen peroxide or 
hyperthermia, the drop in cellular NAD+ levels is biphasic. The first sharp drop 
in the NAD+ level is due to the activation of PARP as a result of DNA damage 
caused directly by the stress. The levels then recover, just as apoptosis begins to 
be detectable, indicating that the DNA strand breaks have been rejoined. The 
apoptotic fragmentation of the DNA causes a second drop in NAD+. When the 
PARP inhibitor 3AB is present, the NAD+ levels are preserved, the extent of 
apoptosis is reduced and cell survival is considerably increased. These results 
seem to suggest that the initial poly(ADP-ribosyl)ation activated by mild DNA 
damage is required for the induction of apoptosis. There are, however, other 
pathways to apoptosis for which poly(ADP-ribosyl)ation is not required. The 
activation of PARP by the fragmented DNA appears to be circumstantial and not 
critical in the apoptotic process.
It was originally proposed that a mechanism of cell suicide might be through 
NAD+ depletion caused by PARP activated by extensive cell damage. Since ATP 
is required to convert nicotinamide back to NAD+ and NAD+ is required in the
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production of ATP, this would lead to a depletion of ATP and cell death.101 This 
is more likely to be a passive death caused by less mild stress conditions. It has 
also been shown that, in thymocytes undergoing irradiation-induced apoptosis, 
there was a decrease in PARP enzyme activity.102 This is due to a cleavage of 
PARP that takes place in the early stages of apoptosis. Experiments on HL60 
human leukaemia cells, with apoptosis induced by the anticancer drug 
etoposide,102 showed that there is an initial activation of PARP and a fall in 
NAD+ levels just before PARP cleavage takes place, but by the time the DNA 
fragments start to appear, a large number of PARP molecules have already been 
cleaved.
The cleavage of PARP is now recognised as being one of the early signs of 
apoptosis. The 116 kDa PARP protein is specifically cleaved into two fragments 
of about 85 and 25 kDa.102 The large fragment contains the automodification 
domain and the catalytic domain. It retains the ability to synthesise poly(ADP- 
ribose), although at a much lower rate and not through activation by DNA 
damage. The small amino-terminal fragment contains the DNA-binding domain. 
It has been suggested that this fragment may act as a competitive inhibitor of any 
intact PARP that might be present, enhancing DNA fragmentation.39 Recently 
the protease, prICE (also known as Yama, CPP32P or apopain), that carries out 
this cleavage of PARP has been identified.103,104 prICE is one of the family of 
interleukin 1-p-con verting (ICE) / ced-3 enzymes. These proteases are thought to 
be involved in the initiation of the active phase of apoptosis;103 indeed inhibition 
of prICE has been shown to abolish all manifestations of apoptosis, including 
PARP cleavage and DNA fragmentation.103 It is not certain whether PARP is 
part of a signalling system for apoptosis or whether the cleavage of PARP is just 
part of a general protein cleavage that occurs at the beginning of apoptosis. Other 
proteins have been shown to be cleaved during apoptosis by similar
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A possible consequence of the cleavage of PARP might be the derepression of 
the Ca2+/Mg2+-dependent endonuclease that causes the DNA fragmentation seen 
in apoptosis. Poly(ADP-ribosyl)ation of the endonuclease inhibits the enzyme; it 
has been suggested that when PARP is cleaved the inhibition is removed and 
allows the enzyme to attack the DNA.107 Rice et alm  found that apoptosis could 
be induced in human leukaemia cells, by the addition of C-nitroso-ligands of 
PARP. This was explained as follows: The C-nitroso compounds bind to one of 
the zinc fingers on PARP's DBD so inactivating it. The Ca2+/Mg2+-dependent 
endonuclease, normally kept in a latent state by poly(ADP-ribosyl)ation, is 
derepressed, DNA degradation takes place and cell death follows.
The most recent work has focused on the regulation of prICE. It has been shown 
that granzyme B, a protein produced by cytotoxic T-cells, activates prICE, 
through the cleavage of its precursor.109,110 Another group of proteins, the Bcl-2 
family, have also been shown to regulate apoptosis induced by a number of 
agents including nitric oxide (NO), ara C, etoposide and mitoxantrone.99,111 
Overexpression of Bcl-2 blocks the cleavage of PARP and apoptosis.99,111
Experiments involving PARP inhibitors have given conflicting results. 3AB has 
been shown to increase,112 reduce,96,113 or not to alter114 the extent of apoptosis. 
Variations in experimental conditions, cell type and apoptosis inducers may be 
the cause of these discrepancies. In dominant negative mutant cells, in which the 
DBD of PARP is overexpressed, there were found to be increased levels of 
apoptosis.87 Experiments using cells from mice lacking the PARP gene115 
showed decreased apoptosis at low concentrations. At low concentrations of NO, 
apoptosis was induced in normal cells and was reduced by the presence of 3AB. 
The cells lacking PARP did not show signs of apoptosis at this concentration. 
However at higher concentrations, NO induced apoptosis in the PARP-deficient 
cells, and in the normal cells, 3AB was not successful in preventing apoptosis. It 
appears in this system NO induces apoptosis through PARP-dependent pathways
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at low concentrations, but at higher concentrations an alternative pathway takes 
over.
It is clear from the experimental data gathered so far that PARP plays some part 
in apoptosis. However the complexity of the process has not allowed any firm 
conclusions to be drawn.
2.3.9 Role of PARP in DNA repair
It has been known since the 1950s that alkylating agents and radiation lower 
cellular NAD+ levels.22 In 1975,116’117 this depletion of NAD+ was shown to be 
due to the activation of PARP by DNA damage caused by agents such as 
streptozotocin.
It was soon found that agents causing DNA damage in general; alkylating 
chemicals, X-rays and DNA hydrolysing enzymes all increase the activity of 
PARP.22,118 It was deduced that PARP might play an important role in DNA 
repair. In 1980, Benjamin and Gill24 found that PARP is completely dependent 
on strand breaks for activity and the initial rate of synthesis of poly(ADP-ribose) 
increases linearly with X-ray dose given or dose of endonuclease added. In the 
same year, Durkacz et alm concluded that poly(ADP-ribose) participates in DNA 
excision repair, when they found that PARP inhibitors prevented the rejoining of 
DNA strand breaks caused by dimethyl sulphate (DMS). The same effect was 
achieved by depleting NAD+ levels, showing that the process is dependent on 
polymer formation. The PARP inhibitors consequently potentiated the 
cytotoxicity of DMS.
Excision repair can be divided into two types:- nucleotide-excision repair and 
base-excision repair. Nucleotide-excision repair is carried out following damage 
by UV light and chemicals producing relatively bulky lesions in the DNA helix.
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The lesion is excised with a number of undamaged nucleotides to give a repair 
patch of 25-40 nucleotides. Base-excision repair follows damage to DNA by 
ionising radiation or methylating/ethylating compounds. Here the repair patch is 
much shorter. Ahnstrom and Ljungman119 found that 3AB increased the number 
of transient DNA strand breaks in cells treated with methylating and ethylating 
agents, but had little effect on UV light or chemicals triggering nucleotide- 
excision repair, e.g. 7-bromomethylbenzanthracene. Other groups also concluded 
that PARP seems to be involved in base-excision and not nucleotide-excision 
repair:58,120,121 These studies have shown that PARP inhibitors have little effect 
on UV-induced cytotoxicity and it is generally accepted that repair of UV 
damage is not regulated by poly(ADP-ribosyl)ation.
Excision repair of DNA damage can be summarised into three basic steps: The 
damaged region is firstly excised by nuclease enzymes. DNA polymerase then 
binds to the 3-OH terminal of the cut strand and synthesises DNA to fill the gap. 
DNA ligase enzymes then seal the nick in the damaged strand. Experiments have 
shown that poly(ADP-ribose) synthesis is involved in the ligation step.80,120 
Following doses of DMS, assays of repair synthesis showed that the PARP 
inhibitor, 3AB, had no effect at low doses and caused stimulation of repair 
synthesis at high doses of DMS. 120 Poly(ADP-ribosyl)ation, therefore, is not 
required for the polymerisation step in excision repair. 3AB was, however, found 
to cause a delay in strand-break rejoining80,120 (the ligation stage). This 
persistence of strand-breaks may allow nick-translation, giving larger repair 
patches under certain conditions. This may explain the increase in DNA repair 
synthesis seen at higher DMS doses in the presence of 3AB. Similar results have 
been seen with other alkylating agents.22
Following the conclusion that PARP has a role in the ligation step of excision 
repair following DNA damage by alkylating agents, the effect of poly(ADP- 
ribose) on ligase enzymes was investigated. Creissen and Shall122 investigated
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the effect of DMS on ligase activity. They found that treatment of cells with 
DMS increased ligase II activity and this increase was blocked by PARP 
inhibitors. They concluded that following DNA damage and activation of PARP, 
either ligase II or a closely related protein is poly(ADP-ribosyl)ated and this 
causes activation of the ligase enzyme. Other experiments have since shown that 
the direct poly(ADP-ribosyl)ation of ligase II results in its inhibition56 (see Table 
1), therefore disagreeing with this hypothesis. Ohashi et al123 proposed that 
histones were also involved in the mechanism. They showed that in the resting 
state histones inhibit ligase activity. This inhibition is reversed by the 
automodification of PARP. They suggested that when DNA damage occurs 
PARP is activated, automodification takes place, this somehow reverses the 
histone inhibition of ligase and results in ligase activation and repair of the DNA. 
The activation of the ligase enzyme may be as a result of the dissociation of the 
histones from the DNA, due to the neutralisation of their charges by the polymer 
chains, making the DNA more accessible to ligase. Ligase has also been shown 
to have an affinity for poly(ADP-ribose) and this may facilitate its positioning 
near the site of damage. This fits in with the histone-shuttle mechanism for 
PARP discussed in section 2.2.3.5.I.
The evidence for a role for poly(ADP-ribose) in the repair of DNA damage 
following ionising radiation is less clear. There is certainly an increase in PARP 
activity following the treatment of cells with gamma or X-ray radiation. 
However, a clear demonstration of inhibition of strand-break rejoining by PARP 
inhibitors has not been given. This may be due to the low net level of SSB's after 
irradiation and difficulty in following the repair. DMS treatment results in many 
more strand breaks and less sensitive methods of analysis can be used. Reports of 
experiments using 3AB have given conflicting results. The inhibitor has been 
shown to inhibit repair following gamma irradiation,22 have no reproducible 
effect120 on DNA strand-breaks following gamma irradiation and also to increase 
strand rejoining following gamma irradiation. 124 Further evidence is required to
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show whether or not the synthesis of poly(ADP-ribose) following DNA damage 
by ionising radiation has a role in repair of the damage. Cell killing by x-rays and 
gamma radiation has been shown, by several groups, to be enhanced by the 
inhibition of PARP in a dose dependent way. 125*130 In most cases this has been 
attributed to an inhibition of DNA repair and cellular recovery but by what 
mechanism is not clear.
Stevnsner et alm  carried out studies using human HeLa cells with 
dexamethasone-inducible PARP antisense transcripts, in which the cellular 
PARP content is reduced by 90% on induction. They found that, in agreement 
with studies using inhibitors, repair of UV damage was not altered from that in 
control cells. However, the PARP deficient cells were deficient in gene-specific 
repair of alkylation damage and showed an increased susceptibility to nitrogen 
mustard agents. Here, the repair of specific, essential genes was measured rather 
than the genome as a whole. This work indicates that PARP activity is required 
for cellular recovery from alkylating agents.
Tra/ij-dominant inhibition of poly(ADP-ribosyl)ation by overexpression of the 
PARP DBD resulted in sensitisation to gamma radiation and the alkylating agent 
N-methyl-N'-nitro-N-nitrosoguanidine (MNNG) . 30 This was shown to be due to a 
disturbance in the cellular recovery from the damage. Again damage by UV 
radiation was not affected.
PARP deficient "knock-out" mice, which have no PARP and cannot produce 
poly(ADP-ribose), are otherwise healthy and fertile.85 This indicates that PARP 
does not play an essential role in cellular proliferation, differentiation or 
development. Cells from the mice show normal DNA repair after UV irradiation 
and, more surprisingly, after treatment with an alkylating agent.85 However, 
proliferation of primary fibroblasts and thymocytes following gamma irradiation 
was impaired. The mutant mice are susceptible to spontaneous development of
40
\ "
skin diseases and the investigators conclude that, although PARP does not seem 
to be essential for normal chromatin function, it might play a part in response to 
environmental stress. 85 These results seem to disagree with the many studies 
carried out using inhibitors and other techniques which lower PARP levels but 
do not completely abolish PARP content.
Satoh et a / 132,133 have also recently reported that their findings have brought them 
to the conclusion that PARP has an incidental and negative role in DNA excision 
repair. In an in vitro system using cell extracts, they found that complete removal 
of PARP improved DNA-repair of gamma radiation lesions. This is explained by 
the fact that PARP interferes with base-excision repair by binding to the 
damaged site. Release of PARP facilitates DNA repair (see non-histone 
mechanism for PARP in section 2.2.3.5.2). 3AB inhibits DNA repair by 
inhibiting the automodification of PARP and therefore its release from the DNA 
strand-break.
Despite the confusing evidence, it seems that likely that PARP plays a role, 
however subtle, in the reaction of the cell to DNA damage. Discrepancies 
between results may be due to the very wide range of experimental techniques, 
cell systems, and DNA damaging agents. Recently, Mizumoto and Farber 
pointed out that "cytotoxicity" in replicating cells commonly refers to an 
inhibition of cell growth, rather than to cell killing. 134 In their study they found 
that at lower levels of DNA damage [2.5 mM TV-methyl-N-nitrosourea (MNU)], 
3AB potentiated cell growth inhibition, supposedly by limiting DNA repair 
mechanisms. However, when more extensive damage was present (> 5 mM 
MNU), cell kill was achieved by depletion of ATP, due to excessive poly(ADP- 
ribosyl)ation, rather than by DNA strand-breaks. In this case, 3AB prevents cell 
death by preventing the depletion of ATP. These observations further confuse the 
issue, as does the suspected involvement of PARP in apoptotic pathways.
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The fact remains that PARP inhibitors, in the vast majority of studies, have 
brought about sensitisation of cells to radiation and alkylating agents. The recent 
studies in "knock out" mice make PARP inhibitors more desirable as 
radiosensitisers and chemosensitisers. The study indicates that PARP plays a 
non-essential role in normal chromatin function, therefore a specific PARP 
inhibitor should not have any intrinsic cytotoxic effects. In the next chapter, 




3. Inhibitors of Poly(ADP-ribose) Polymerase
3.1 Poly (ADP-ribose) Polymerase Inhibitors as Chemosensitisers and 
Radiosensitisers
With the discovery that poly(ADP-ribose) polymerase seems to be involved in 
DNA excision repair,80 came the revelation that PARP inhibitors can potentiate 
the cytotoxicity of DNA-damaging agents.80,120,121 Such inhibitors are, therefore, 
prime targets for the design of radiosensitisers and chemosensitisers for the 
treatment of cancer. Experiments so far have been largely in vitro and the 
inhibitors used have often lacked specificity and/or potency. However, results 
suggest that a specific, potent inhibitor of PARP might be useful in the 
potentiation of radiotherapy and chemotherapy.39
3.1.1 Chemosensitisation
Durkacz et a / 80 first reported that 3 AB increased the cytotoxicity of the alkylating 
agent DMS in LI 210 mouse leukaemia lymphoblast cells. The cells were treated 
with increasing doses of DMS either alone or in the continuous presence of 3 AB 
or its analogue 3-aminobenzoic acid which is not an inhibitor of PARP. A 
concentration of 90 pM DMS was needed to reduce survival to 10% in the 
absence of 3AB, whereas in the presence of 3AB, 22 jllM  was found to be 
sufficient. 3-Aminobenzoic acid did not have any effect on the cytotoxicity of 
DMS. Several other in vitro studies on different cell lines using alkylating agents, 
such as DMS,22 MNNG,22,135,136 MNU,22 methyl methanesulphonate 
(MMS) 135,136 and temozolomide, 137,138 have provided similar results. The effect 
of PARP inhibition on the cytotoxicity of bifunctional alkylating agents, however 
is much smaller. 135,137 3AB was found to potentiate l-(2-chloroethyl)-l-
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nitrosourea or busulfan cell killing by only 0.9 to 1.5-fold. 135 The benzamides 
have also been found to potentiate the cytotoxicity of the S-phase acting drug 6 - 
thioguanine (TG) . 139,140 However, TG does not produce a decrease in NAD+ 
levels in the cell, indicating that PARP is not activated. This potentiation of 
cytotoxicity is not thought to be through the inhibition of DNA repair. In 
addition, higher doses of 3AB can protect the cell against TG toxicity. 139
Reports of demonstration of chemosensitisation by PARP inhibitors in vivo are 
much less abundant. Although the most successful potentiation of cytotoxicity 
has been seen with mono-functional alkylating agents in vitro, equivalent 
experiments in vivo have not been reported. Experiments demonstrating 
potentiation, by 3AB, of the cytotoxicity of agents such as bleomycin125 and 
cisplatin141 on the Ehrlich ascites tumour have been carried out. However, at the 
doses generally used, 3AB is known to cause a marked hypothermia;142 this may 
affect the results seen. This highlights the main problem with these experiments; 
especially those carried out using early non-specific inhibitors of PARP such as 
thymidine and pyrazinamide (these agents will be discussed later in the chapter).
The lack of specificity and potency of the early PARP inhibitors means that it is 
difficult to assess whether any chemosensitisation seen is the result of PARP 
inhibition. The concentrations of the benzamides used in these studies are often 
in the millimolar range, whereas the PARP inhibitory IC50 values are in the 
micromolar range. At these higher concentrations, these inhibitors have been 
shown to cause inhibition of cell growth143 and interference with metabolic 
processes such as glucose metabolism and purine biosynthesis. 143 Certainly, in 
the case of the potentiation of TG cytotoxicity by 3AB, inhibition of de novo 
purine biosynthesis has been implicated as the mechanism rather than PARP 
inhibition. 139,140
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The lack of specificity of chemotherapeutic agents also implies that any 
therapeutically useful chemosensitiser has to be specific for tumour cells and 
must not cause potentiation of damage to normal cells.
More recently, Boulton et all3S carried out experiments in vitro measuring the 
potentiation of temozolomide cytotoxicity by various PARP inhibitors. Two of 
the compounds tested were about 50-fold more potent PARP inhibitors than was 
3AB. The study showed that the sensitisation of the cells to the temozolomide 
toxicity was dependent on the potency of the sensitiser as a PARP inhibitor. 
Therefore, much lower concentrations of these newer generation inhibitors can 
be used, with less risk of other non-specific effects occurring in the cell.
3.1.2 Radiosensitisation
Many studies in vitro have shown that inhibitors of PARP can increase the 
sensitivity of cells to X-ray and gamma radiation.22,125’128 Earlier studies, 120 
however, only reported a marginal enhancement of killing or no effect at all. This 
is attributed to the fact that there was not sufficient time allowed for the inhibitor 
to be taken up by the cells or that the concentration of inhibitor was too low. 125 
The effect of the inhibitor also has to be measured within the two hours 
following irradiation since this is when PARP is active and repair is taking place. 
Therefore, studies using higher concentrations of inhibitors for shorter times 
were more successful. 125 The radiosensitisation seen is dependent on the potency 
of the PARP inhibitor. Ben-Hur129 showed that, although the benzamides do 
inhibit glucose metabolism, he found no correlation between effectiveness in 
inhibiting PARP and effectiveness in inhibiting glucose metabolism, despite a 
correlation between the inhibitory potential of PARP and the enhancement of 
radiation response. This indicates that it is the inhibition of PARP that is causing 
the radiosensitisation and not any other effect of the inhibitors. Even higher 
concentrations of PARP inhibitors seem to be needed for radiosensitisation than
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for chemosensitisation. It is thought that a higher level of inhibition of PARP 
may be required since even a low level of PARP activity is sufficient for 
recovery to take place. 145
The effect of 3AB on the survival curve of cell populations, following treatment 
with ionising irradiation, is to reduce the shoulder of the curve and decrease the 
gradient (as shown in Figure 5). This would be therapeutically desirable if 
achieved in vivo.
Nicotinamide and pyrazinamide are both weak inhibitors of PARP and have been 
shown to produce potentiation of radiation effects in vivo.14,146,141 However, this 
is thought to be largely due to their ability to alter tumour blood flow and 
decrease hypoxia. Nicotinamide, in combination with carbogen breathing therapy 
and radiotherapy, is now in Phase II trials for the treatment of tumours. 147,148 A 
recent study suggests that, although reduction in hypoxia is the main mechanism 
of action, inhibition of DNA repair is responsible for part of the effect seen. 148
Experiments with benzamides have been carried out in vivo. 3AB and several 
other benzamide derivatives were shown to potentiate the effects of X-rays in the 
EMT- 6  tumour system. 3AB was also shown to cause an increase in tumour 
growth delay in the Greene melanoma in hamsters. 145 One of the newer PARP 
inhibitors, 3,4-dihydro-5-methylisoquinolin-l-one (PD128763) has been shown 
to be active in vivo as a radiosensitiser. 14 It produced a 1.4-1.6 fold increase in 
cell kill in various murine tumours and increased growth delay by 10-15 days, 
compared to radiotherapy alone. It also brought about tumour regression which 
was not seen with radiation alone. 145
These results, especially those in which newer PARP inhibitors have been used 
suggest that selective, potent PARP inhibitors are ideal candidates for 
development as radiosensitisers and chemosensitisers in the treatment of cancer.
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3.2 The Development of Inhibitors of Poly(ADP-ribose) Polymerase
Many compounds have been tested for their ability to inhibit PARP. It is difficult 
to compare individual studies since a great variety of assay methods and 
conditions, cell lines and inhibitor and NAD+ concentrations have been used. 
These factors must be taken into consideration when comparing inhibitors.
Most of the inhibitors of PARP tested so far are competitive, reversible inhibitors 
that bind to the NAD+ binding site of the enzyme. As explained in Chapter Two, 
PARP binds the NAD+ molecule and catalyses its cleavage; adding the ADP- 
ribose portion to the poly(ADP-ribose) chain and releasing the nicotinamide 
portion. This is shown in Figure 13; there is nucleophilic attack of the anomeric 
carbon by a site on the acceptor protein and cleavage of the carbon-nitrogen 
bond. The mechanism probably proceeds via the oxonium ion shown.











Figure 13: Possible Mechanism for the Cleavage ofNAD+ by Poly(ADP-ribose) 
Polymerase. (Nu is a nucleophilic site on PARP or histone.) _________
It is therefore no surprise that the first compounds found to inhibit PARP were 
nicotinamides. 149 Thymidine, which has some structural similarities to NAD+, 
was also found to inhibit PARP. 150 Theophylline and other xanthines were also 
among some of the inhibitors first discovered and used. These compounds and 
their analogues were among the thirty three compounds tested by Sims et al151 In
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this study, the effect on PARP activity, as indicated by incorporation of 
radioactivity from [3H]NAD+ into acid insoluble material, was measured. The 
effect of the inhibitors on lowering of NAD+ levels following treatment of 
lymphocytes with MNNG was also measured. The inhibitors were all present at a 
concentration of 2 mM, except for theobromine at 1 mM. This was a useful study 
in that several compounds were compared in the same system at equivalent 
concentrations. Certain structure activity relationships can be concluded from the 
study.
Nicotinamide Analogues: Benzamide Analogues:
X O N H 2 .CONH2Or Ol
N N CONH2
NH2
Nicotinamide Picolinamide Benzamide 3-Aminobenzamide
(89%) (86%) (96%) (96%)
CONH2
Pyrazinamide Analogues: Purine Analogues:










Figure 14: Some early PARP inhibitors and their percentage inhibition values, 
as tested by Sims et al.i5; All compounds were tested at a concentration of 2 mM, 
except for theobromine which was present at 1 mM.
Some examples of the compounds tested are shown in Figure 14 along with their 
percentage inhibition values. Nicotinamide itself was the most potent of the 
nicotinamide analogues tested (89% inhibition). In this series, it was found that 
an unsubstituted amide group was required for activity but its position in the
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pyridine ring did not seem to be crucial; 8 6 % inhibition was achieved with 
picolinamide. The aromaticity of the ring was also essential for activity and 
substitution of the ring nitrogen resulted in a loss of activity.
Pyrazinamide, which has a similar structure to nicotinamide but with two 
heterocyclic nitrogen atoms, was a reasonably good inhibitor (78%). Other 
analogues in this series were not active. The extra ring nitrogen is tolerated but 
the amide group, again, was found to be essential for activity, with a second 
amide group ortho to the first resulting in a loss of activity.
Purine analogues theophylline and theobromine were found to be good inhibitors 
of PARP (89% and 81% inhibition respectively) although caffeine only inhibited 
PARP activity by 35%.
Although these compounds are reasonable inhibitors of PARP, they lack 
specificity and have been shown to affect other cellular processes: Nicotinamides 
affect the synthesis of NAD+ and may deplete cellular phosphoribosyl 
diphosphate pools. Thymidine inhibits DNA synthesis by depleting dCTP 
concentrations in the cell. Methylated xanthines are known to affect cyclic 
diphosphodiesterase21 Therefore, more specific inhibitors had to be found. 
Benzamide is a close analogue of nicotinamide but does not have the ring 
nitrogen and so cannot be metabolised by NAD-biosynthetic enzymes. In the 
study by Sims and his co-workers, 151 benzamide inhibited PARP activity by 
96%, as did the 3-amino analogue, 3AB. In the series of analogues tested here the 
carbamoyl group was found to be essential for activity; 3-aminobenzoic acid was 
devoid of activity. Activity was also decreased when there was substitution in 
either the 2- or the 4- position of benzamide. These results agreed with those of 
Purnell and Whish who earlier investigated a series of benzamides.21
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Benzamide was first shown to be an inhibitor of PARP by Shall in 1975.152 
Although this compound is a good, specific inhibitor of PARP, it is a 
hydrophobic molecule. The poor solubility of benzamide in aqueous solutions 
made physiological studies difficult; this led Pumell and Whish to examine the 
activity of less hydrophobic analogues of benzamide.21 Their results are shown in 
Table 2 below. PARP activity was measured by the incorporation of radioactivity 
from [3H]NAD+ into acid insoluble material and the inhibition was expressed as 
a percentage of total inhibition. Much lower concentrations of inhibitor were 
used in this study than that of Sims;151 concentrations of 50 jiM of inhibitor were 
used, which was equimolar with the substrate NAD+. All the 3-substituted 
benzamides, with the exception of 3-nitrobenzamide, were found to be potent, 
with over 90% inhibition achieved at 50 |iM. These benzamides have their 
substituent in the position corresponding to the ring-nitrogen in nicotinamide.
Table 2: Compounds tested by Pumell and Whish21 for their effect on PARP 
activity. Inhibition was measured at a concentration of 50 mM and expressed as 








































This study also confirmed the theory that a free carbamoyl group is required for 
activity. The benzoic acid derivatives showed no activity, although the 
acetophenones showed some activity. Another study by the same group153 found 
that 56% inhibition of PARP was achieved by 3-methoxyacetophenone at 
50 pM. This indicates that the carbonyl group conjugated to the aromatic ring is 
important for activity. In agreement with the study by Sims and co-workers, 151 
substitution of the nicotinamide ring nitrogen results in a loss of activity. 
Acylation of the amino group of 3-aminobenzamide (3AB), however, seems to 
give an increase in potency; 3-acetoamidobenzamide exhibited 98% inhibition of 
PARP.
3AB and 3-methoxybenzamide were highlighted as potentially useful PARP 
inhibitors for in vitro and in vivo studies. Kj values of 1.8 ± 0.2 pM and 1.5 ± 0.3 
pM were calculated for 3AB and 3-methoxybenzamide, respectively. These 
compounds were found by this group to be physiologically specific. More recent 
reports have shown that 3AB can interfere with cell growth143 and with 
metabolic processes such as glucose metabolism and purine biosynthesis. 144 
However, these studies used very high concentrations of 3AB; in the millimolar, 
rather than the micromolar, range. In fact, 3AB has since become the standard 
and most widely used PARP inhibitor. It should be pointed out that weaker, less 
specific inhibitors, such as nicotinamide, have been used in PARP investigations 
and care must be taken when drawing conclusions from such studies.
The specificity of the benzamides and some of the earlier inhibitors was 
investigated by Rankin et al. 154 This group measured inhibition of the two other 
classes of enzyme that consume NAD+; mono(ADP-ribosyl)transferases and 
NAD+ glycohydrolases. IC50 values (the concentration of inhibitor required to 
inhibit the enzyme activity by 50%) were measured for 20 compounds, for 
PARP, mono(ADP-ribosyl)transferase A, and NAD+ glycohydrolase. Some
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examples of the results are shown in Table 3. The benzamides were fairly 
specific inhibitors of PARP with 500 to 1000-fold more activity for PARP than 
for the mono(ADP-ribosyl)transferase. The IC50 value for benzamide for the 
inhibition of NAD+ glycohydrolase was 40 mM. There would, therefore, be no 
inhibition of this enzyme at the concentrations used to inhibit PARP. In the cases 
of nicotinamide, thymidine and theophylline, the IC50 values for the two ADP- 
ribosylating enzymes are much closer.
Table 3: Effect o f some selected compounds on PARP, in vitro and in vivo and 



























A second useful observation was made in this study: The IC50 values for the 
benzamide PARP inhibitors in vitro were very similar to values obtained in intact 
cells. However, for the other inhibitors tested, such as nicotinamide and 5- 
bromodeoxyuridine, 3 to 5-fold higher concentrations were required in vivo to 
achieve the equivalent inhibition as in the in vitro system. This suggests that it 
should be possible to achieve PARP inhibition in intact cells using micromolar 
concentrations of benzamide inhibitors in the culture medium.
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Sestili et al155 carried out further investigations into the structure activity 
relationships (SAR) for the benzamides. In this study, however, PARP activity 
was not measured directly. Activity was assessed by measuring the effect of the 
inhibitor, present at 5 mM concentrations, on the rejoining of DNA SSB, 
following treatment with MMS. The effect was expressed by comparison with 
benzamide itself. This method of assessment should give similar results to those 
obtained by the direct measurement of PARP inhibition. However, it should be 
remembered that the exact role of PARP in DNA repair is not yet known and the 
two methods should be treated separately.
Figure 15: Benzamide analogues and their effect on the rejoining o f DNA SSB
produced by MMS as tested by Sestili et al.755 Relative potencies with respect to 
benzamide are given in parentheses.
CONH2
R
c o n h 2
NHR
HN
R = H, Benzamide (1)
R = 3-NH2> 3-Aminobenzamide (0.72) 
R = 2-NH2* 2-Aminobenzamide (0)
R = 4-NH2,4-Aminobenzamide (0)
R = 3 -NO2 , 3-Nitrobenzamide (0.07)
R = CH3, 3-N-Methylaminobenzamide (0.57) 







R = CH3, 3 -N-Acetylaminobenzamide (3.62)
R = C2H5 , 3-N-Propionylaminobenzamide (4.25)
R = SO2NH2, Benzenesulphonamide (0) 
R = CO2H, Benzoic Acid (0)
R = CSNH2 , Thiobenzamide (0 )
This investigation confirmed results seen before and added to SAR information. 
♦ For benzamides substitution must be in the 3- position to retain activity.
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♦ Substitution with a nitro group resulted in a significant loss of activity, 
implying that electron-withdrawing groups decrease activity
♦ Alkylation of the amino group of 3AB results in a loss of activity but 
acetylation significantly enhances activity.
♦ The aromatic ring is essential for activity; the saturated analogue of 
benzamide, cyclohexane, is devoid of activity.
♦ The unsubstituted carbonyl group is essential for activity; replacement of the 
amide oxygen or carbon atom with sulphur resulted in a loss of activity.
This group reported that thiophene-3-carboxamide was only weakly active in this 
assay. In a further study, in which sulphur containing benzamides were tested for 
their effect on NAD+ depletion following treatment of cells with H2O2, 
thiophene-3-carboxamide was again found to be much less active than the parent 
benzamide. 156 This is surprising, since thiophene-3-carboxamide is regarded as a 
close isostere of benzamide. Work being carried out in our laboratories suggests 
that the thiophene-carboxamides are good PARP inhibitors; 80% inhibition of 
PARP was achieved using 5-aminothiophene-2-carboxamide at a concentration 
of 10 nM . 157
The investigations of nicotinamide and benzamide analogues as PARP inhibitors 
show that the carbamoyl group is essential for activity. Suto et a / 158 designed 
compounds in which the conformation of this amide group is restricted, with a 
view to determining the preferred binding conformation. Figure 16 shows two 








(R-H) (preferred when 
R'=CH3, Et, propyl, etc.)
Figure 16: Possible conformations of the amide group in benzamide7 Wanalogues. A is the conformation needed for good PARP inhibition.
The conformation pictured in structure A can be fixed by joining the nitrogen to 
the benzene ring via an ethane or an ethene bridge, to give a 3,4- 
dihydroisoquinolin-l-one or and isoquinolin-l-one. Suto and his colleagues 
tested several 5-, 6 - 7- and 8 -substituted 3,4-dihydroisoquinolin-l-ones and 5- 
substituted isoquinolin-l-ones. The 5-substituted compounds in each series 
showed very high activity as PARP inhibitors, with IC50 values less than 1 pM in 
most cases. These results are shown in Table 4.
Table 4: Some isoquinolinone and dihydroisoquinolinone inhibitors o f PARP. As 
















3,4-Dihydro-5-hydroxyisoquinolin-l-one was the most active compound tested 
with an IC50 of 0.1 |iM. Some 90-fold more active than 3AB as tested in the 
same assay. As in the benzamide series, the nitro-substituted analogues were 
significantly weaker inhibitors.
This dramatic increase in activity indicated that this conformation is preferred for 
binding. This was further confirmed by the second part of the study in which 2,3- 
disubstituted benzamides were synthesised and tested. Compounds had either a 
methoxy or hydroxyl group in the 3-position and various alkyl groups in the 2- 
position. All of the compounds tested were devoid of activity except for
3 -Hydroxy-2 -methylbenzamide which was a very weak inhibitor with an IC50 of 
590 jiM. This is compared to an IC50 value of 2.0 pM measured for the 
unsubstituted 3-hydroxybenzamide. The larger substituents in the 2-position 
force the amide into the conformation shown in B (Figure 16) which is not 
favoured for binding to the enzyme.
The 3,4-dihydroisoquinolin-l-ones were also tested for their effect on the cell 
survival curve, following treatment with X-ray irradiation. These compounds 
were found to reduce significantly the shoulder and the gradient of the curve and 
act as radiosensitisers in vitro. As mentioned earlier, 3,4-dihydro-5- 











Figure 17: PARP inhibitors in which the conformation of the amide group is 
restricted. The structural core common to all of these compounds and the 
benzamide inhibitors is shown in bold.
Other compounds in which the 3-substituted benzamide core is present, with the 
conformation of the amide group fixed covalently, are shown in Figure 17. All of 
these groups of compounds are very potent PARP inhibitors.
2-Methyl-4 [3//]-quinazolinone was extracted from a culture of Bacillus cereus 
by Yoshida et al}59 This compound was tested and found to produce a 50% 
reduction in PARP activity at 1.1 |iM. Kinetic studies showed that this 
compound is a competitive inhibitor of PARP, with a Ki value of 1.1 |iM. Two 
further quinazolinones have been tested by Griffin et al.160 8-Hydroxy-2- 
methylquinazolin-4-one was synthesised and tested and found to give 92% 
inhibition of PARP at a concentration of 10 jiM; the IC50 value measured was 
0.44 ±0.13. This is one of the best known inhibitors of PARP, with activity in 
the same range as the isoquinolinones. 8-Hydroxy-2,3-dimethylquinazolin-4-one
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was also tested, but as would be expected, the substitution of the "amide" 
nitrogen brings about a loss of activity (11% inhibition was observed at 10 pM). 
8-Hydroxy-2-methylquinazolin-4-one has also been shown to enhance strand 
breaks produced by temozolomide (a monofunctional alkylating agent) and to
• • • 138increase its toxicity in vitro.
2-Methylquinazolin-4-one was also included in a comprehensive study carried 
out by Banasik and his colleagues in 1992.161 In this study, in the region of 150 
compounds were tested, firstly for activity as PARP inhibitors and secondly, for 
inhibition of an arginine-specific mono(ADP-ribosyl) transferase from hen 
heterophils. A wide range of compounds were tested including nicotinamide, 
several benzamides and some of the heterocycles pictured in Figure 17. IC50 
values were measured. For 2-methylquinazolin-4-one, the IC50 value measured 
was 5.6 pM; significantly greater than the value obtained in the earlier study. 159 
This was also the case for many of the benzamides; e.g. 3AB had an IC50 of 22 
pM in this system, compared to 9.0 pM 158 and 5.4 pM 154 measured in other 
assays. This illustrates the variation in results that can be seen for different assay 
conditions and substrate concentrations. In this study, benzamide was found to be 
205-fold more active as a PARP inhibitor than as an inhibitor of mono(ADP- 
ribosyl)transferase, whereas 3-hydroxybenzamide was more specific with 989- 
fold more activity against PARP. 5-Hydroxyisoquinolinone was also found to be 
extremely specific for PARP, the IC50 value measured for PARP was 0.39 pM, 
compared to a value of 890 pM for the mono(ADP-ribosyl)transferase. Another 
important outcome of this screening for PARP activity was the discovery of four 
potent inhibitors. These are 1 ,8 -naphthalimide [IC50 1.4 pM]; 4-amino-1,8- 
naphthalimide [IC50 0.18 mM]; 6(5#)-phenanthridinone [IC50 0.30 pM]; and 2 - 
nitro-6(5//)-phenanthridinone [0.35 pM]. These compounds are large planar 
structures based on the isoquinolinone structure with fused substituents (see 
Figure 17). They contain the amide group in its fixed, active conformation. 
6(5if)-Phenanthridinone was around 3000 times more specific for PARP. The
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best inhibitor of mono(ADP-ribosyl)transferase in this study was vitamin Ki 
(IC50 1.9 \lM).
The final compound shown in Figure 17 is 2-phenylbenzoxazole-4-
carboxamide. 160 This compound is slightly different to the others in that the 
amide group conformation is fixed by hydrogen-bonding interactions rather than 
a covalent bridge. The IC50 value measured for this compound was 2.1 jiM.
Again the benzamide activity has been improved upon by fixing the
conformation of the amide.
Studies on benzamide PARP 
inhibitors have shown that 
relatively bulky groups can be 
substituted in the 3-position 
without loss of activity. Indeed, 
NAD+ itself has an ADP-ribose 
group in the equivalent position. 
The ribose-nucleoside binding domain requirements have been considered. 
Figure 18 shows the structure of benzamide riboside. This compound is a C- 
glycoside analogue of the nicotinamide ribonucleotide of NAD+. This compound 
was synthesised and tested for PARP inhibition. 162 However, PARP inhibition 
could not be evaluated due to the cytotoxic effect of the compound at nanomolar 
concentrations. It is thought that the analogue might be taken up into the NAD+ 
biosynthetic cycle and interferes with NAD+ dependent processes, enzymes using 
NAD+ as a cofactor and possibly energy metabolism. Benzamide riboside may be 
of use as a cytotoxic drug for cancer chemotherapy.
Griffin et al160 synthesised and tested several compounds of the form shown in 
Figure 19. These O-alkyloxybenzamides and benzyloxybenzamides were 
generally of around the same PARP inhibitory activity as the parent compound 3- 
hydroxybenzamide. The results confirmed that a bulky group at the 3- position of
Figure 18: Structure of Benzamide riboside





benzamide does not affect activity but none of the side chains tested gave a 










Figure 19: O-Alkyloxy- and O-Benzyloxybenzamide PARP inhibitors.160
(a) is the general structure; two examples of inhibitors are shown. Percentage
PARP inhibition measured at concentrations o f 10 pM are shown in parentheses.
A final group of compounds that should be mentioned is that of thymidine 
analogues. Thymidine was one of the first PARP inhibitors discovered but, due 
to its weak and non-specific action, is not of much practical use. However, in 
1992, a large number of nucleoside analogues of deoxythymidine and 
deoxyuridine were screened. 163 It was found that compounds with a combination 
of substituents at the 5-position of the pyrimidine ring and the 3'- or 5'-position 
of the deoxyribose, were generally the most potent inhibitors. 3,-Amino-2,,3'- 
dideoxy-(£)-5-(2-bromovinyl)uridine and 5'-azido-2',5'-dideoxy-5-ethyluridine 
were among the most potent PARP inhibitors with IQ values of 0.7 pM and 0.8 
pM, respectively (Figure 20). Most of the analogues tested also have antiviral 
and/or anticancer activities which may suggest they are non-specific and have 
multiple effects in the cell; or may imply as the authors suggest, that PARP is 
involved in viral reproduction (see section 2.3.7). Further work needs to be done 
to see if any of the other potent PARP inhibitors have antiviral activity.
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Figure 20: Nucleoside analogues of thymidine. Two of the most potent PARP 
inhibitors as tested by Pivazyan et 2I . 163
3'Amino-2',3'dideoxy-(E)-
5-(2-bromovinyl)uridine ^ -Azido-2,5 -dideoxy-5-ethyluridine
Ki = 0.7 \iM Ki = 0 8 ^
3.3 Summary of Structure-Activity Relationships and Binding Predictions
The characteristics which SAR studies have shown are required to give good 
PARP inhibition are summarised in Figure 21. The recent elucidation of the 
crystal structure of the catalytic fragment of chicken PARP42 has provided more 
information about inhibitor binding to PARP. The crystal structure of PARP with 
the inhibitor PD128763 (3,4-dihydro-5-methylisoquinolin-l-one) bound was also 
claimed. This is one of the most potent inhibitors known indicating a strong 
interaction with the binding site on the enzyme.
The crystal structure showed that two hydrogen bonds form from the carbamoyl 
group to the peptide backbone of residue Gly863 of PARP and from the oxygen 
atom to the side chain of Ser904. The conformation of the amide group is 
important for these interactions with the active site. This agrees with the SAR 
established and the fact that compounds in which the amide group is fixed in this 
conformation, are significantly more potent inhibitors than those with a free 
amide group. Results have shown that the nitrogen of the amide must be 
unsubstituted for activity:- this is because the group is required to make a 
hydrogen bond in the active site. It has been shown, using molecular orbital
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calculations, that, in the benzamide series, the ability of the carbonyl oxygen to 
donate n electrons correlates well with inhibitory activity. 145 This has been 
shown, in the crystal structure study to be an important binding interaction. This 
interaction is improved by an electron-rich benzene ring in conjugation with the 
carbonyl group. This is evident in the weak activity of 3-nitrobenzamide and 





Glu988 R Bulky substituents 
permitted here
R is not an electron- 
withdrawing group
Figure 21: Schematic diagram of the PARP NAD+ binding site with inhibitor 
bound. Structural requirements for inhibitory activity are shown in italics.______
As well as these hydrogen bonding interactions the crystal structure indicates a 
non-polar interaction between Tyr907 and the aromatic ring(s). This interaction 
might contribute to the increased activity of the larger, planar, fused ring 
molecules.
q OQ
The carboxylate group of Glu has been known to be important for PARP 
catalytic activity for some time40 (see also section 2.1.3). The crystal structure
o
showed that the distance from this group to the methyl group of PD128763 is 4A. 
This position in the inhibitor molecule is equivalent to the anomeric carbon 
attached to the nicotinamide ring of NAD+. The authors conclude that at this 
location the Glu988 residue could function either as a general base facilitating 
nucleophilic attack of the anomeric carbon of NAD+ and cleavage of the C-N
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bond. This was the mechanism put forward by Marsischky et al.40 Alternatively, 
the Glu988 could function to stabilise an intermediate oxocarbenium ion at the 
anomeric position of NAD+ (shown in Figure 13). This mechanism was proposed 
for ADP-ribosylation by diphtheria toxin. 164 Experimental evidence for the 
second possibility is provided by Slama and Simmons165,166 who synthesised an 
analogue of NAD+ with a 2,3-dihydroxycyclopentane ring in place of the ribose 
ring. In this analogue there is no oxygen atom adjacent to the anomeric carbon 
and the oxocarbenium ion cannot form. It was found that this analogue was an 
inhibitor of NAD+ glycohydrolase and ADP-ribosyl transferase enzymes, 
attributed to the fact that the C-N bond could not be cleaved. The first 
mechanism, in which there is direct nucleophilic attack of the anomeric carbon, 
does not require the participation of the ribose oxygen. These results therefore 
favour the formation of the oxocarbenium ion.
This information on structure activity relationships of PARP inhibitors and the 
crystal structure of the NAD+ binding site of the enzyme should enable further 
potential inhibitors to be designed. One reservation which must be expressed 
about the utility of the crystal structure is the claim that the NAD+ binding site is 
very similar to that of diphtheria toxin, a mono(ADP-ribosyl)ating enzyme. This 
contrasts with the widely differing structure-activity requirements for inhibition 
of the two enzymes. There is, indeed, a need for more specific, potent, soluble 
PARP inhibitors both as biochemical tools for the determination of PARP 




4. Aims of the Study
The PARP inhibitors that have been tested so far have been competitive and 
reversible inhibitors. They compete with NAD+ for its binding site on the PARP 
catalytic domain. Once bound, the inhibitor does not contain the C-N bond 
present in NAD+ and cannot be cleaved and therefore inhibits the enzyme. 
However this inhibition can be overcome by the addition of more NAD+, which 
displaces the inhibitor. The aim of this study was to synthesise irreversible 
inhibitors of PARP as well as improving potency and specificity.
In designing potential irreversible inhibitors, the mechanism of ADP-ribosylation 
was examined. This is shown in Figure 13. When NAD+ is bound the 
oxocarbenium ion is thought to form, stabilised by Glu988. A nucleophilic site on 
the acceptor protein or on the growing poly(ADP-ribose)chain then attacks the 
ribose Cl carbon and the ADP-ribose unit is bound. In the majority of cases, the 
nucleophile will be on the automodification domain of a second PARP molecule, 
in other cases on a histone. An NAD+ analogue with an electrophile in the same 
spatial location as the ribose anomeric carbon (Cl) should act as a potential 
inhibitor of PARP. The analogue would be recognised by PARP and would bind 
to the NAD+ binding site. The nucleophile on the acceptor protein would then 
attack the electrophile in the ribose Cl position. The acceptor protein is then 
covalently bound to the inhibitor and the active site is blocked. This is shown in 
Figure 22. The electrophilic group is shown as a leaving group attached to the 
benzylic carbon in order to demonstrate the mechanism.
Using the SAR information that has accumulated from studies of PARP 
inhibitors, molecules were chosen which consisted of the 3-substituted
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Figure 22: Schematic diagram of the proposed irreversible inhibition o f PARP. 
LG represents a leaving group. Nu represents a nucleophilic site on the 
acceptor protein
The aim was to make both 3-substituted benzamides and 5-substituted 
isoquinolin-l-ones with electrophilic substituents of the general form shown in 
Figure 23.
Studies have shown that fairly bulky groups are tolerated in this position. The 
aim was to create analogues with larger substituents; possibly with hydroxyl 
groups present or cyclic groups, to imitate the ribose portion of NAD+. Increased 
interaction with the ADP-ribose-binding region of the active site might create a 
more potent inhibitor. Strongly electron-withdrawing substituents were to be 
avoided, since studies have shown that this may result in a loss of activity.
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oE
Figure 23: General structure of potential irreversible PARP inhibitors 
synthesised, where E is an electrophile.
Ideally an inhibitor should be water soluble at micromolar and preferably 
millimolar concentrations. This was also taken into consideration.
For asymmetric molecules the aim was to synthesise, stereoselectively, both 
enantiomers, and compare their relative activities as PARP inhibitors. It was 
predicted that the form which corresponds better to the stereochemistry of NAD+ 
will be the active enantiomer.
Potential inhibitors were synthesised and then tested in vitro for inhibition of 
PARP. For successful candidates IC50 values were estimated and for potential 




As explained in Chapter Four, the original aim of the project was to synthesise 
analogues of NAD+ with an electrophilic substituent, of the form shown in 
Figure 23. The compounds synthesised can be divided into two groups; 
benzamides, which are discussed in this chapter, and isoquinolinones, which are 
discussed in Chapter Six. In the first instance, a benzamide with a simple 
electrophilic side chain is discussed. This potential inhibitor is of the type shown 
in the proposed mechanism for irreversible inhibition in Figure 22. The next 
group of targets are single enantiomers of analogues of NAD+. These have a 
heterocyclic group to correspond to the ribose portion of the NAD+ molecule. 
Finally, the approaches taken towards an aziridine target compound are 
discussed.
The first target compound was 3-chloromethylbenzamide 1. This is a benzamide 
with an electrophilic group in the 3-position; the benzylic carbon is susceptible to 
nucleophilic attack and the chloride ion is a good leaving group. Therefore 1 is a 
potential irreversible inhibitor. The benzamide 1 was synthesised in one step 
from the corresponding acid chloride 2 as shown in Scheme 1.
The acid chloride 2 was treated with ammonia; a standard method for preparing 






conditions. This was necessary because there are two positions which can 
undergo nucleophilic attack by ammonia. Substitution occurs readily at the 
carbonyl carbon of the acyl chloride group and in less mild conditions 
nucleophilic attack at the chloromethyl carbon is also possible. The reaction was 
followed carefully to ensure that only the acyl halide group was converted.
The next group of benzamides that were investigated were those with a chiral 
centre at the benzylic carbon. It was our hypothesis that the stereochemistry at 
this position might be important for PARP inhibitory activity, since at the 
equivalent position in NAD+ (the anomeric carbon) there is also a chiral centre 
(Figure 24). For a good binding interaction with the PARP NAD+ binding 
domain, the inhibitor should have stereochemistry corresponding to that in NAD+ 
and present an oxygen atom in a region of space corresponding to the oxygen of 




Figure 24: Target compounds. NAD+ analogues with a chiral centre equivalent 
to the anomeric carbon in NAD+.
Figure 24 shows two target compounds of this series; a cyclic sulphate 3, a 1,3- 
dioxolane 4 and an epoxide 5. The arrangement of atoms around the benzylic 
carbon in these NAD+ analogues is analogous to the arrangement of groups 
around the anomeric carbon in NAD+. They also have a cyclic structure in the
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space occupied by ribose in NAD+. The cyclic sulphate 3 and epoxide 5 are 
electrophilic and should act as irreversible inhibitors, as explained in Chapter 
Four.
The retrosynthetic analysis in Scheme 2 shows that all of these compounds, 3, 4 
and 5 can be synthesised from the corresponding diol 6. Two approaches for the 
stereocontrolled synthesis of the diol 6 were considered. The first method 
investigated was to make the diol from the alkene 7 using Sharpless asymmetric 
dihydroxylation methodology.168'170 The second approach was to obtain the diol 
6 by the asymmetric reduction of the protected hydroxyketone 8. The amide 
group does not necessarily have to be present in the intermediate structures. A 
cyano group was used as a synthon for the amide group and the nitrile analogues 
were often converted to amides towards the end of the synthesis.
.c o n h 2
.co n h 2
.co n h 2
.c o n h 2




In the case of both approaches, 3-acetylbenzonitrile 9 was chosen as the starting 
material for this set of compounds. The nitrile group is easily converted to the 
required amide group, the acetyl group provides a two carbon chain and has an
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oxygen atom adjacent to the benzylic carbon. This nitrile 9 was prepared by 
diazotisation of 3-aminoacetophenone 10 and treatment of the diazonium salt 




This is a variation on the Sandmeyer Reaction, in which the substitution of the 
diazo group with a cyano group is catalysed by a copper (I) salt. The mechanism 
for the reaction is thought to be as shown in Scheme 4 below.167
ArN2+ CN~~ + CuCN --------► Ar *+ N 2 + Cu(CN)2
At* + Cu(CN) 2 --------► ArCN + CuCN
Scheme 4
In the first step, the diazonium ion is reduced by the cuprous ion resulting in the 
formation of an aryl radical. This requires an excess of cyanide ions; these are 
provided by the potassium cyanide. In the second step, the aryl radical abstracts a 
cyanide radical from the copper (II) salt, reducing it to the original copper (I) 
cyanide.
A fair yield of the nitrile 9 was obtained, although the process was not very clean 
and difficulty in separation of the product from the highly coloured by-products 
may have led to a loss of yield.
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A suitable procedure was required to convert the cyano group into the desired 
carbamoyl group. Nitriles can be hydrolysed partially to amides or completely to 
carboxylic acids. There are a number of procedures for stopping the hydrolysis at 
the amide stage. These include using concentrated sulphuric acid; hydrochloric 
acid;171 acetic acid and boron fluoride;172 sodium hydroxide in dimethyl 
sulphoxide;173 hydrogen peroxide and sodium hydroxide174 and manganese 
dioxide in dichloromethane. After examination of the literature, the sodium 
hydroxide and hydrogen peroxide method was chosen. This a reasonably mild 
and straightforward method and has been employed in a standard synthesis of 
toluamide.174
Indeed, this method proved effective for the partial hydrolysis of benzonitrile 9, 
giving the corresponding amide 11 in almost quantitative yield. (Scheme 5). This 













A mechanism proposed by Beckwith175 for this reaction is shown in Scheme 6 
below. There is firstly nucleophilic addition of a peroxide ion to the C=N group. 
This is followed by the transfer of a hydride ion from a second hydrogen 
peroxide molecule to the intermediate peroxyimine, resulting in the formation of 
the amide, molecular oxygen and water.
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o
Scheme 6
The first approach to form the enantiomerically pure diol 6 involved the 
synthesis of the styrene derivative 7 which was then to be asymmetrically 
dihydroxylated using the method of Sharpless.168-170 This method was developed 
from the reaction shown in Scheme 7.
v°
o' V  » ? H ? HR3
RlX _ V R3 QsQ4> RM  H20 > Rl\ J  L 1
k /  K R4  R2 R4  R2 R4
Scheme 7
Here osmium tetroxide is used to carry out the dihydroxylation of an alkene, by 
forming a cyclic osmate with the alkene which is then hydrolysed to give the 
diol. The use of chiral ligand catalysts allows the stereochemistry of the reaction 
to be controlled and only catalytic amounts of osmium tetroxide are required. 
The chiral ligands are mostly derivatives of quinidine and quinine which bind to 
the osmium tetroxide and control the direction from which the oxygens approach 
the double bond of the alkene. Therefore, whether the quinine ligand or the 
quinidine ligand is used, determines the enantiomer obtained. Enantiomeric 
excesses are dependent on the ligand used and the substrate and can vary from 
20% to 99%.168,169 More recently, new classes of ligands have improved 
enantioselectivity; recently both (R)- and (S^-phenylethane-1,2-diol were
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synthesised by asymmetric dihydroxylations of styrene, both with an 
enantiomeric excess of 97%.170
To synthesise the alkene 7, the route taken was to reduce the acetophenone 9 to 
give the alcohol 12; this could then be dehydrated to give 3-cyanostyrene. An 
analogous route for 4-cyanostyrene is described by Marvel and Overberger.176 
Alternatively, reduction of the ketone of 11 would give the alcohol 13 (Scheme 
5), which could be dehydrated to give 7.
The reduction of 9 was carried out using sodium borohydride in ethanol to give 
(±)-3-(l-hydroxyethyl)benzonitrile 12 (Scheme 8). Sodium borohydride is a 
relatively selective reducing agent; it reduces aldehydes and ketones to alcohols 
without affecting halogeno, cyano, nitro, amido and alkoxycarbonyl groups. 
Initially this reaction was carried out at room temperature, although these 
attempts were successful, the apparent degradation of the product on the 
chromatography column led to very low yields. Later it was found that addition 











3-Acetylbenzamide 11 was also reduced using this method to give 13 (shown in 
Scheme 5). Benzamides 11 and 13 were both tested for activity as PARP 
inhibitors; although they were not intended target compounds, their activities 
have not yet been reported in the literature.
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When problems were encountered with the purification of 12, another route to 
the enantiomeric diols was considered and work continued in this direction. This 
approach involved using biotransformations to carry out the asymmetric 
synthesis. Biotransformations are often very effective and cheap methods of 
carrying out enantioselective syntheses. The reduction of carbonyl compounds by 
baker's yeast (Saccharomyces cerevisiae) is one of the most widely used 
biotransformations for the preparation of enantiomerically pure alcohols.177 
Aromatic a-hydroxyketones have been reported to be asymmetrically reduced to 
diols by baker's yeast.178'180 For example 2-hydroxyacetophenone 14 is reduced 
to (^)-phenylethane-1,2-diol 15 in high yield and high optical purity178,179 
(Scheme 9).
Scheme 9179
It was proposed that this method should produce the corresponding (/?)-diol 16 
from the a-hydroxyketone 17 in the benzonitrile series. In fact, for the target 
compounds shown in Figure 24 we require the (S) enantiomer of the diol; 
however, it was also desirable to have the potentially inactive opposite 
enantiomer.
As part of their work on hypervalent iodine, Moriarty et alm  reported a "one- 
pot" method for the preparation of a-hydroxyketones. Various aromatic, 
heteroaromatic and aliphatic ketones, mainly of the form R-COCH3, were treated 
with [bis(trifluoroacetoxy)]iodobenzene under acidic conditions to give the 
corresponding a-hydroxyketones. A possible mechanism is shown in Scheme 10.
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Scheme 10
The enol form of the ketone reacts with the [bis(trifluoroacetoxy]iodobenzene 
displacing one of the trifluoroacetoxy ligands. This intermediate is then attacked 
by water and the hypervalent iodine moiety is displaced to give the a- 
hydroxyketone. The yields obtained by Moriarty were quite variable, ranging 
from 21% to 94%. The results for the substituted aromatic ketones investigated 





Table 5: a-Hydroxy ketones synthesised by direct a-hydroxylation of the 
corresponding methyl ketones using bis(trifluoroacetoxy)iodobenzene under
j  0 1acidic conditions. Results from Moriarty et al.









Since this method appeared to work reasonably well for aromatic ketones, the a- 
hydroxyketone, 3-(2-hydroxyacetyl)benzonitrile 17 was prepared in a similar way 
(Scheme 11).
PhI(OCOCF3) 2 / CF3CO2H
CH3C N /H 2O 
Yield 28 %
Scheme 11
Unfortunately, the yields obtained in several attempts were fairly low (25-28%). 
By comparison with Table 5, this may be the case for aromatic compounds with 
electron-withdrawing groups on the ring in that 4-nitroacetophenone also gave a 
fairly poor yield (29%). Moriarty reported that 4-nitrobenzoic acid (29%) was 
also produced in the reaction as a result of over-oxidation. In the case of the 3- 
cyano-derivative Scheme 11, a carboxylic acid was detected (*H NMR) as a by­
product but was not isolated. Despite the fairly low yield, this method is a 
convenient route to the desired a-hydroxyketone 17.
As shown in Scheme 12, the a-hydroxyketone 17 was then treated with baker's 





The mixture of fermenting yeast and the ketone 17 was stirred at about 30°C for 
seven days. The low concentration of substrate meant that it was not possible to 
follow the reaction by TLC. Extraction of the product may have also been 
inefficient, since the diol 16 is relatively polar and some may have been left 
behind in the large volume aqueous phase. These factors may have contributed to 
fairly low yield obtained. The optical rotation of the product was -46.6° (c, 1.0, 
dichloromethane). This is a novel compound and therefore the absolute 
stereochemistry cannot be known from this measurement. However by 
comparison with several compounds in this series,180 it is highly likely that the (-) 
enantiomer is the /^-enantiomer.
A method was also needed to prepare the other enantiomer, the (5)-diol 18. 
Kometani182 reported a method by which the (S)-diol is obtained, from the 
corresponding racemic diol, using baker's yeast. (Scheme 13).
OH Baker's yeast O H OH
X  /O H  ** J L  .OH + .OHR 02 R — R
(R, S)-1,2-Alkanediol (5)-1,2-Alkanediol
Scheme 13182
It is proposed that the (/?)-diol, is selectively oxidised by an oxidoreductase with 
an accompanying reduction of NAD+ to NADH. The NADH is then reconverted 
to NAD+ in the respiratory chain within the cells. The (S)-diol remains and is 
easily separated from the ketone. Unfortunately this method only appears to work 
for alkyl diols and not aromatic compounds.
The baker's yeast-mediated reduction of 14 and 17 follows Prelog's rule for the 
stereochemical outcome for bioreductions.183 Prelog noted that the 
stereochemistry of the products of many bioreductions followed a pattern and
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could be predicted according to the scheme shown in Figure 24. The substituents 
on the carbonyl carbon are designated large (L) and small (S) and the rule 




Figure 25: Prelog's Rule. (S and L represent "small" and "large" substituents, 
respectively._______________________________________________________
Most bioreductions with alcohol dehydrogenases follow Prelog's rule but there 
are some exceptions that are anti-Prelog in their specificity. These can be partly 
explained by the ambiguities involved in determining which groups are "large" 
and "small" in a molecule. Also, in the case of baker's yeast, it is now recognised 
that several oxidoreductases are present in Saccharomyces cerevisiae; Prelog's 
rule is based on one enzyme carrying out the reduction. The enzymes present 
might reduce the same substrate with opposite stereochemistry. Some substrates 
have been reported to be reduced by baker's yeast giving the opposite product to 
that predicted by the rule. These include a few aliphatic ketones, an example 
being 1-hydroxyacetone, which gave the {-)-R-diol, 1,2-propanediol.184
It has also been found that protection of the hydroxyl group of aromatic a- 
hydroxyketones can, in some cases, result in anti-Prelog bioreduction.179’180 
Manzocchi et alm  carried out baker's yeast reductions on various analogues of
2-hydroxyacetophenone 14 in which the hydroxy group was protected by esters. 
The best protecting group was found to be acetyl (19); larger groups led to a loss 
of yield and enantiomeric selectivity. The formate ester was too vulnerable to
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hydrolysis. The reduction of 19 was reported to give the acetoxy-protected (+)- 









Another study found that the enantiomeric excesses were reduced when the 
aromatic ring was substituted. The para-methoxy derivative 21 and para-bromo 





yield 25%; e.e. 82% 
yield 34%; e.e.84%
Scheme i s 180185
It is interesting to note that when a methyl ether is used to protect the hydroxy 
group as in 23, the same enantiomer is produced as in reduction of the 
unprotected hydroxyketone 14.180 This system, unlike the acetoxy-protected 
system, follows Prelog's rule (Scheme 16).
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Scheme 16180
For the purposes of this project, synthesis of the acetoxy-protected analogue of 
a-hydroxyketone 17 and its bioreduction provided a convenient route to the (S)- 
diol 18. Scheme 17 shows the synthesis of the protected a-hydroxyketone 24. 
Introduction of the acetoxy group into the acetophenone 9 was carried out in a 
two step process via the a-bromoketone 25.
CN


















Ketones can be a-brominated in the presence of either acid or base. The purpose 
of the acid/base catalyst is to catalyse the formation of either the enol, in the case 
of an acid, or the enolate ion, in the case of the base. For monobromination,
acidic conditions are required. In basic conditions it is not possible to isolate the 
monobrominated product because the electronegativity of the first halogen 
increases the acidity of the remaining hydrogens and the enolate ion forms even 
more readily. In the case of methyl ketones, the haloform reaction takes place in 
basic conditions. In this reaction methyl ketones are cleaved by treatment with 
halogen and a base. Two reactions take place: The methyl group is firstly 
trihalogenated. The intermediate trihalo ketone is attacked by the hydroxide ion, 











Br3C +  RCOOH
Scheme 18
Br3CH +  RCOO
Acidic conditions should limit the substitution to monobromination; there is slow 
formation of the enol form of the ketone, followed by electrophilic attack by 
bromine and substitution of one of the methyl protons with a bromine atom 
(Scheme 19). The dibrominated ketone can be produced if there is an excess of 
bromine present.
Electrophilic substitution by bromine can also take place on aromatic rings. 
However, in the case of compound 9, this is not a problem since the ring is 
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When acetic acid was used as the solvent at room temperature, the reaction gave 
a low yield (32%) of the monobromoketone 25 and a 6% yield of the dibromo 
product 26. The yield of the desired product 25 was greatly improved (78%) by 
carrying out the addition of bromine at 0°C and using chloroform as the 
solvent.186 The yield of dibrominated product, 26, was only increased by 2%. The 
solvent in this case is only very slightly acidic but there are enough H+ ions 
present to catalyse the formation of the enol.
3-(Bromoacetyl)benzonitrile 25 was treated with potassium acetate and a 
catalytic amount of sodium iodide, according to the general method of Kaufmann 
and Muller,187 to give the acetoxy-protected hydroxyketone 24 in good yield 
(64%). Two other products were recovered and characterised; the methyl ketone 
9 and a third minor but unexpected product, 3-(diethoxyacetyl)benzonitrile 27. 
The sodium iodide is present as a nucleophilic catalyst and in the main reaction 
there is firstly a nucleophilic substitution to form the iodoketone. The iodide is a 
better leaving group than the bromide ion and therefore catalyses the nucleophilic 
substitution by the acetate group. The sodium iodide can also act as a reducing 










A possible mechanism for the formation of the acetal 27 relies on the formation 
of an a-disubstituted ketone species as shown in structure 28 (Scheme 21). There 
is substitution of one iodo group by an acetoxy group. This group is then attacked 
by the solvent ethanol to give the aldehyde 29. Ethanol will then attack the more 


















The ^  NMR spectrum for this compound is interesting because the methylene 
groups in the two ethoxy moieties act like pro-chiral methylenes. There is not a 
tme chiral centre but each methylene group "sees" the centre marked by * below 




The protons within each methylene group are not magnetically equivalent, there 
is, therefore, geminal as well as vicinal coupling. The ethoxy groups are however 
equivalent to each other and their signals coincide. This results in the methylene 
signals appearing in the spectrum as two double quartets. (Figure 26)
Figure 26: The methylene region o f the JH NMR spectrum o f 21 (270.05 MHz, 
CDCI3).
The protected a-hydroxyketone 24 was reduced to (+)-3-(2-acetoxy-l- 
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Scheme 22
A method similar to that used by Manzocchi et alm  was used. The conditions 
differ from those used for the reduction of the a-hydroxyketone in that; more 
concentrated solutions were used; the reaction vessel was kept at room 
temperature and the reaction was complete within eight hours. A small amount of 
the diol 3-(l,2-dihydroxyethyl)benzonitrile was also present in the crude product. 
This is could have been formed in two ways; either by the reduction of 
hydrolysed starting material, i.e. unprotected a-hydroxyketone [(-)-(/?)-diol]; or 
by the hydrolysis of the product [(+)-(S)-diol], Unfortunately the sample was too 
small to get an optical activity measurement.
The optical activity of 30 was found to be +34.9° (c, 2.9, dichloromethane). By 
comparison with similar compounds,179 the (+) isomer is likely to be the (S) 
isomer. The optical rotation measurements for both the products of the yeast 
reductions did not provide any information as to the absolute stereochemistry or 
the proportion of enantiomers present, as these are novel compounds and there 
are no reference values. The optical purity of both of the products 16 and 30 had 
to be determined by some other method.
There are a number of ways to determine optical purity of a chiral compound.
a) Chiral Derivatising Agents:188,189 The mixture of enantiomers to be 
determined is derivatised with an optically pure compound. The diastereomers 
produced will often have non-equivalent chemical shifts in their NMR spectra. 
The ratio of the integrations of a pair of inequivalent diastereomeric signals
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gives a measure of the optical purity. Several chiral compounds have been 
used as chiral derivatising agents, some examples are shown in Figure 27. 
These compounds will often have a fluorine group, e.g. Mosher's acid 
(MPTA),190or a phosphorus group, e.g. l,l'-binaphthyl-2,2-diyl phosphoryl 
chloride 31.191 This allows 19F and 31P NMR analysis as well as NMR to 
be used. For this method to be accurate: the derivatising agent must be 
enantiomerically pure; the derivatisation reaction must occur under conditions 
which exclude the possibility of racemisation or of kinetic resolution due to 
the enantiomers reacting at different rates with the agent and any purification 
of the diastereomers must not allow enrichment of one diastereomer.
Figure 27: Examples of chiral derivatising agents for NMR analysis.
b) Chiral Lanthanide Shift Reagents:189,193 Lanthanide shift reagents can form 
weak addition complexes with a wide range of organic compounds. This 
causes a change in the magnetic field around nuclei in the compound and this 
in turn causes a shift of signals in the NMR spectra to a higher or lower 
frequency. When the shift reagent contains a chiral group, such as a camphor 
derivative in its optically pure form, it can form diastereomeric complexes 
with a mixture of enantiomers. These diastereomeric complexes may have 
non-equivalent NMR spectra allowing determination of optical purity. 
Europium shift reagents cause a downfield shift, whereas praeseodymium 




europium tris [3-heptafluoropropylhydroxymethylene)-(+)-camphorate], 
[Eu(hfc)3] and praseodymium tris[3-heptafluoropropylhydroxymethylene)-(+)- 
camphorate], [Pr(hfc)3].194
c) Cyclodextrins: Cyclodextrins195 have a central cavity into which (usually 
aromatic) organic molecules can enter to form inclusion complexes. This can 
alter the chemical shift of the protons located in the cavity.196 Since 
cyclodextrins are chiral molecules, enantiomeric mixtures can form 
diastereomeric inclusion complexes which may in some cases have different 
NMR spectra, allowing determination of optical purity. This has been
107demonstrated very successfully with the drug propanolol hydrochloride.
d) Chiral HPLC:198 HPLC can be manipulated to allow the separation of 
enantiomers. This can be done indirectly by making diastereomeric 
derivatives using an enantiomerically pure chiral reagent and then separating 
the diastereomers by HPLC. Alternatively diastereomeric complexes can be 
formed either by having a chiral stationary phase or a chiral mobile phase, 
with the aim of altering the retention time of each enantiomer in the system 
and allowing their separation.
One of the mostly widely used methods for determining the optical purity of 
alcohols, such as 16 and 30, is to use the chiral derivatising agent a-methoxy-a- 
trifluoromethyl)phenylacetic acid (MTPA). MTPA was introduced by Mosher190 
in 1969 and both enantiomers of the acid are commercially available. The 
optically pure MTPA is converted to the corresponding acid chloride and then 
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Scheme 23
This method was used to determine the optical purity of 30. As a comparison, a 
racemic sample of the alcohol was also needed, so that it could be derivatised 
and both diastereomeric sets of signals could be identified. The protected a- 
hydroxyketone 24 was reduced using sodium borohydride in propan-2-ol with 
only a trace amount of water to minimise hydrolysis of the acetoxy group to the 
diol 32. As shown in Scheme 24, the product consisted mainly of the desired 
protected diol 33. However 13% yields of the racemic diol 32 and 3-(l-acetoxy- 
2-hydroxyethyl)benzonitrile 34 were obtained. This second by-product is formed 
by the migration of the acetoxy group to the benzylic hydroxy group formed in 
the reduction. The reaction therefore has to be followed carefully and stopped as 











It was not possible to isolate the desired product by chromatography; attempts to 
do so resulted in the product being lost. However in the NMR spectrum of the
mixture the signals for the aliphatic protons were distinct and easily 
distinguishable, therefore the mixture was treated with MTPA-C1 without further 
purification. Alternatively, using racemic MTPA-C1 with the asymmetrically 
prepared alcohol gives the same result since the diastereomers produced here will 
be the enantiomers of those produced by using the racemic alcohol.
The asymmetrically prepared acetoxy-protected diol 30 and the racemic analogue 
33 were treated with GR)-MTPA-C1, as in Scheme 23. Unfortunately the MTPA 
derivatisation reactions did not go to completion and about 40% of underivatised 
alcohols 30/33 remained. This may be because the hydroxyl group is a secondary 
alcohol with bulky groups on either side and is hindered. For a completely 
accurate determination of enantiomeric excess, the reaction should go to 
completion in quantitative yield to show that, in the racemic sample, equal 
amounts of each diastereomer are formed. This shows that there is no kinetic 
enhancement. However, the use of MTPA as a chiral derivative is very well 
known, with very few reports of any kinetic resolution. 189 Therefore calculation 
of enantiomeric purity from the results obtained are likely to be a good estimate 
of the true picture.
In the !H NMR spectrum of the sample derived from the racemic alcohol there 
are two sets of signals of approximately equal integral. The CH3 protons of the 
acetoxy group gave clearly separated signals. The starting material CH3 group 
protons resonate at 5 2 .1 1 , whereas in the two diastereomeric esters the signals 
are at 8  2.00 and 5 2.07. (Figure 28). An enantiomeric excess of 96% was 
calculated using the integrations of these two signals for the asymmetrically 
prepared sample.
On a second occasion when the experiment was carried out using racemic MTPA 
as the control rather than racemic alcohol, the same value of 96% was calculated
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using the CF3 signal in the 19F NMR spectra. The diastereomers gave signals at 8 
-71.5 and 8 -71.9 ppm (Figure 29).
Figure 28: lH NMR (CDCI3 , 270 MHz) o f the products o f the MTPA 
derivatisation o f (i) (+)-2-acetoxy-1 -(hydroxyethyl)benzonitrile 30 and(ii) (±)-2- 
acetoxy-1 -hydroxyethyl)benzonitrile 33.
Key to Assignments:
U : unreacted 30/33 CH3  protons 
I ; diastereomer I CH3  protons 
I I : diastereomer II CH3 protons 
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Figure 29: 19F NMR spectra for the products o f MTPA derivatisation o f (+)-2- 
acetoxy-1-(hydroxyethyl)benzonitrile 30 (a) Using (R)-MTPA. (b) Using racemic 
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Determination of the optical purity of the (-)-diol 16 was less straightforward. 
The racemic diol 32, was obtained by treating the a-hydroxyketone 17 with 
sodium borohydride in ethanol. The mono-MTPA esters of both the racemic and 
asymmetrically prepared diols 32 and 16 were synthesised and their and 19F 
NMR spectra examined. Unfortunately the signals for the two diastereomers 
were too similar for any calculation of enantiomeric excess to be made. The 
diesters were also prepared using a method described by Dale and Mosher.199 
The reaction mixture was heated to 45°C to encourage derivatisation of both 
hydroxyl groups. However, there was not sufficient separation of the 
diastereomeric signals to allow calculation of the enantiomeric excess.
A second chiral derivatising agent was then tried. The synthesis of the 
biscamphanate of the diol 35 was attempted as shown in Scheme 25. 
Unfortunately, this was not helpful as even after several days stirring the starting 
diol 16 remained and the main product was the mono-camphanate with a much 
smaller amount of the bis-camphanate 35 present. There was no sign of 








Another approach taken towards determining the enantiomeric purity of the diol 
15 was to use lanthanide chiral shift agents. Both [Eu(hfc)3] and [Pr(hfc)3] were 
added to NMR samples of the racemic diol to see if there was any separation of
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the enantiomers. The only effect seen was a general line broadening of the NMR 
spectra in both cases.
Finally an estimate of optical purity was made from the optical rotation readings 
of the (-)-diol 16 and the (+)-diol 18. (+)-3-(l,2-Dihydroxyethyl)benzonitrile 18 
was synthesised by hydrolysis of the asymmetrically prepared acetoxy-protected 
diol 30. The enantiomeric purity of 30 had already been determined and the 
hydrolysis using ammonia in aqueous methanol (Scheme 26) should not have 
affected this. The optical rotation of the (+)-diol 18 obtained was +46.6° (c 2.0, 
dichloromethane). Since the (-)-diol 16 was found to have an optical rotation of 
-46.6° (c 1.0, dichloromethane); this would suggest strongly that the enantiomeric 
excess of the (-)-diol synthesised is approximately 96%. Subsequent 
preparations of both enantiomers gave similar results.
.CN .CN
NH3, aq.MeOH







Therefore, both baker's yeast reductions of the protected and unprotected a- 
hydroxyketones proceeded well in terms of enantiomeric excess. This indicates 
that substitution by a cyano group in the 3-position of the aromatic ring does not 
affect the efficiency or selectivity of the reactions. This is in contrast to the para- 
disubstituted derivatives in the acetoxy-protected series mentioned earlier 
(Scheme 15).180’185
As shown in Scheme 26, the acetoxy-protected diol 30 was deprotected to give 
the (+)-diol 6. This procedure was also carried out on the racemic compound 33
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to give 32. Initially, potassium methoxide was used as the nucleophile to carry 
out this transesterification reaction. This resulted in a mixture of compounds that 
were difficult to separate by chromatography. Use of ammonia in methanol 
proved to be a much more clean, efficient procedure, not requiring 
chromatography.
The nitriles 16, 18 and 32 were treated with hydrogen peroxide and sodium 
hydroxide to give the corresponding amides (-)-3-(l,2-dihydroxyethyl)benzamide 
36, (+)-3-(l,2-dihydroxyethyl)benzamide 6 and (±)-3-(l,2-dihydroxyethyl)- 
benzamide 37. Scheme 26 shows this step for the (+) isomer. The amides are 
very hygroscopic gums and are not soluble in most organic solvents. They could 
not be extracted using organic solvents in the usual way and were freeze-dried 
immediately prior to use in subsequent steps.
The properties of cyclic sulphates made benzamide 3 an ideal target compound 
for the synthesis of irreversible inhibitors of PARP.
3
Cyclic sulphates are very good electrophiles and have a high reactivity towards 
various nucleophiles.200 Nucleophiles generally attack the less hindered carbon in 
the ring and the P-sulphate is formed. The SC>3~ group is then removed by 
hydrolysis (Scheme 27). However, the mechanism of PARP may favour attack of 
the nucleophile at the benzylic position.
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Scheme 27
Optically active cyclic sulphates are prepared from the corresponding 
enantiomerically pure diol via the cyclic sulphite. Cyclic sulphites are usually 
synthesised by the treatment of the diol with thionyl chloride or sulphur 
tetrafluoride.200 The reaction is carried out in anhydrous conditions to prevent 
hydrolysis of the reagent or the sulphite product. If the substrate diol contains 
acid-labile groups, pyridine or triethylamine is added to scavenge the hydrogen 
chloride which is produced in the reaction.
Ri Ri Ri
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Scheme 28
The oxidation of the sulphite to the sulphate has been carried out in the past 
using potassium permanganate201 which tends to give fairly low yields, or 
stoichiometric amounts of ruthenium tetroxide which is expensive.202 More 
recently, however, a system was described by Gao and Sharpless,203 in which 
ruthenium tetroxide is present in catalytic amounts. Ruthenium trichloride and 
sodium periodate are used to create the ruthenium tetroxide in situ. This method 
has since proved to be the most general method for the synthesis of cyclic 
sulphates in good yields. The reaction is fairly versatile and can be carried out in 
the presence of acid or base labile groups but does not work in the presence of 
groups that can bind the ruthenium tetroxide and stop catalytic turnover. Some 
cyclic sulphites with amide functionalities have presented this problem; here the
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amide functionality was adjacent to the sulphite group,204 other sulphites with 
amides elsewhere in the molecule were oxidised using this system.200
This method of synthesising the cyclic sulphite and sulphate was firstly tried on 
the nitrile 18 rather than the amide (Scheme 29). The formation of the cyclic 
sulphate, however has to be carried out on the benzamide rather than the 
benzonitrile because of the instability of the cyclic sulphate to nucleophiles. The 
cyclic sulphite was formed and used immediately as it is likely to be unstable to 
storage.







NMR analysis of the intermediate showed that the cyclic sulphite 38 was formed 
and that two geometrical isomers were present in approximately equal 
proportions. These occur because the sulphur has a lone pair of electrons that can 
be either cis or trans to the aromatic substituent with respect to the cyclic 
sulphite ring.
.CN X Nf Y iTY
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Figure 30: Geometrical isomers of the cyclic sulphite 4(S)-4-(3-cyanophenyl)- 
l,3,2-dioxathiolane-2-oxide (38).
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Attempted oxidation of the cyclic sulphite 38 to sulphate 39 gave only the diol 
18, indicating that cleavage of the cyclic sulphite/sulphate had occurred.
The amide 6 is not soluble in organic solvents such as carbon tetrachloride and is 
very hygroscopic. These properties would not favour the synthesis of the cyclic 
sulphate 3. Therefore this was not considered as a feasible substrate.
In an attempt to confirm the absolute stereochemistry of the series of diols, the 
reaction of the methyl ester of (5)-proline with the cyclic sulphite was studied, as 
shown in Scheme 30. In the cyclic product 40, the positions of the two chiral 
centres are fixed in relation to each other. Although the cyclic sulphite is a 
mixture of epimers, this is irrelevant since the sulphur is discarded in the 
reaction. The stereochemistry of the proline centre is known; comparison of the 
positions of the groups around the second chiral centre in relation to the proline 
can be used to determine whether the benzylic centre is R or S. This could be 
done using NMR analysis and NOE (nuclear Overhauser effect) experiments to 
determine which protons are close in space. Alternatively a crystalline sample 
would enable X-ray crystallography to be carried out and the stereochemical 
arrangement determined in this way. Unfortunately, the reaction did not proceed. 








The second target compound shown in Figure 24, (+)-3-(2,2-dimethyl-1,3- 
dioxolan-4-yl)benzamide 4, was synthesised from 6 in a transketalisation as 
shown in Scheme 31. The diol 6 was treated with 2,2-dimethoxypropane in 
acidic conditions to give the dioxolane 4 in good yield. The enantiomer 36 is 
treated in the same way to give (-)-3-(2,2-dimethyl-l,3-dioxolan-4-yl)benzamide
Following on from the successful synthesis of 4, the synthesis of the 
thiocarbonate 42 was attempted. The thiocarbonate group is electrophilic unlike 
the dioxolane group in 4, and 42 would be a potential irreversible inhibitor. 
Thiophosgene (CSCI2) is the obvious reagent to use for this nucleophilic 
substitution reaction, but since it is very toxic, a safer alternative, 1,1- 















The product from the reaction was a mixture of compounds and could not be 
separated due to lack of solubility in almost all solvents. There were no signals in 
the region of the *H NMR spectrum corresponding to the predicted shifts of the 
methylene protons in the desired product. These protons would be expected to 
resonate in the same region as the methylene protons in the acetoxy-protected 
diol 30. This work was taken no further.
Another desirable target compound was the epoxide 5. This has the 
characteristics required for potential irreversible inhibition of PARP. Like the 
cyclic sulphate, the epoxide is susceptible to nucleophilic attack and has the 
potential to become irreversibly bound to the nucleophilic site on the acceptor 
protein.
5
Three main methods used to synthesise epoxides are:-
a) Epoxidation of alkenes; Sharpless asymmetric epoxidation methodology can 
be used to produce epoxides with high enantioselectivity.205
b) Intramolecular cyclisation of alcohols bearing a leaving group on the adjacent 
carbon.
c) Nucleophilic alkylation of carbonyl compounds, e.g. Darzens condensation
The racemic epoxide 43 was prepared in the first instance using a method of the 
type (b) above. Scheme 33 shows the steps involved in the synthesis. The a- 
bromoketone 44 was prepared by bromination of the methylketone 11. This 
method was used earlier for the preparation of the benzonitrile analogue 25. The 
reduction of 44 with sodium borohydride gave the bromohydrin 45 (not isolated) 
which then undergoes an intramolecular SN2 reaction to form the epoxide 43.
99


















Both the bromoketone 44 and the epoxide 43 were evaluated as PARP inhibitors.
The enantiomerically pure epoxide 5 would be obtained if the reduction of the 
bromoketone to the bromohydrin is carried out asymmetrically. As a continuation 
of the work on baker's yeast, the reduction of 44 and subsequent cyclisation by 
treatment with sodium hydroxide was attempted. The baker's yeast seemed to be 
unable to reduce this substrate. It may be that this analogue of NAD+ binds 
irreversibly to the NAD+ site of the alcohol dehydrogenase inhibiting the 
enzyme.
Another approach to the preparation of the enantiomerically pure epoxide 5 is to 
use the asymmetrically prepared diol 6 and derivatise the primary alcohol to give 
a good leaving group while not affecting the chiral centre. For example, the 
2,4,6-trimethylbenzenesulphonate ester could be made. Cyclisation would then 
follow, by treatment with base, as for the bromohydrin above. For the 
stereochemistry to be retained, activation must take place exclusively at the 
primary hydroxyl group.
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An example of a method of a similar type is to form the bromoalkyl acetate from 
the diol as shown in Scheme 34. This method207 is reported to be superior to 
methods in which the 1-O-sulphonate ester is made in terms of retention of 
optical purity.208 When this method was used for the preparation of (.R)- and (S)- 
methyloxirane the optical purity of the starting materials was retained through the 
synthesis to the epoxides.209 However in the case of (-)-(R)-phenylethane-l,2- 
diol 15 when this method was used to form the corresponding epoxide, the 
optical purity was reduced to 88% (i.e. 76%).207 An aromatic group as a 
substituent on the secondary alcohol leads to the bromine attacking the carbon 
here rather than at the primary position, as in Scheme 34. This is due to the 
stabilisation of a carbocation at the benzylic position. This makes this method 
unsuitable for the preparation of 5.
0H  HBr ? Ac C5 HnO’K+ °




Diaryldialkoxysulphuranes (Figure 31) can also be used to make epoxides from 
diols. Martin et al210 described the formation of epoxides from the corresponding 
diols in excellent yields, in mild conditions using this reagent. However this 






210Figure 31: Structure of a diaryldialkoxysulphurane
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The preparation of further analogues from the amide 6 was fraught with 
difficulties due to its hygroscopic nature and insolubility in any solvents other 
than water and ethanol.
The final compound to be discussed in the benzamide series is the aziridine 46. 
In common with the other cyclic derivatives mentioned above, aziridines undergo 
ring opening reactions with nucleophiles. However, in the case of aziridines this 
only occurs in acidic conditions. It is likely that a residue in the enzyme active 
site would provide an H+. It is also likely that the active site would provide an 
environment in which cations are stable in this region of space, since the likely 
mechanism for the cleavage of NAD+ by PARP involves the formation of an 
oxonium ion. The site for nucleophilic attack is fairly close in space to the 
equivalent position in NAD+. The aziridine should therefore bind covalently to 
and irreversibly inhibit PARP.
Many of the preparative routes to aziridines involve the internal cyclisation of an 
amino group in an intramolecular displacement reaction. The best known and
.CONH2
46
oldest of these procedures are the Gabriel212,213 and Wenker212'214 syntheses of 
aziridines. (Scheme 35).




X = Br, Cl, I (Gabriel) 
X = 0 S 0 3' (Wenker)
Scheme 35
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The Wenker synthesis involves the conversion of an amino alcohol to an 
aziridine whereas the Gabriel synthesis uses an p-haloamine. Many methods 
developed since involve the treatment of an amino alcohol to convert the OH to a 
good leaving group and subsequent cyclisation. A useful starting material for the 
synthesis of the aziridine 46 might be the amino alcohol 47 or its nitrile analogue 
48 (Schemes 36 and 37). Both of these amino alcohols were made by treating 
either the chloromethyl (1) or the bromomethyl (49) derivative with 
ethanolamine in ethanol.





The amide 47 was, in common with other compounds in this series, insoluble in 
many solvents and difficult to manipulate. Therefore the nitrile 48 was the amino 
alcohol used to attempt aziridine preparation.
Scheme 37
Aziridines are unstable to acids because protonation at nitrogen increases the 
susceptibility to ring opening. In acidic conditions hydrolysis occurs rapidly, as 
shown in Scheme 38. However, unlike epoxides and cyclic sulphates, aziridines 
are much more stable in alkaline conditions. Therefore, partial hydrolysis of the
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cyano group to the amide using hydrogen peroxide and sodium hydroxide, should 
be possible without affecting the aziridine.
The Wenker procedure for the conversion of amino alcohols to aziridines 
originally involved boiling the amino alcohol with concentrated sulphuric acid to
method requires addition to hot concentrated sodium/potassium hydroxide to 
effect the cyclisation, which tends to occur with yields less than 40%. These low 
yields and harsh conditions make these methods undesirable.
The first method tried in the attempted preparation of the aziridine 50 was of the 
Gabriel type (Scheme 35). The amino alcohol 48 was boiled with thionyl 
chloride in an attempt to form the 2-chloroethylamine intermediate, 51, which 
would then undergo cyclisation by treatment with potassium terf-butoxide 
(Scheme 39). A complex mixture of products was obtained which, by NMR 
analysis did not contain the aziridine.
Scheme 38
produce the hydrogen sulphate ester.214 A variation which has been used in more 
sensitive systems is the use of chlorosulphonic acid at room temperature.215 This
(CH3)3CO K
reflux MeOH




More recently there have been several reports of the one-step preparation of 
aziridines from (3-amino alcohols.216*219 These have largely utilised reagents 
formed from triphenylphosphine (PI13P) and chlorine, bromine or carbon 
tetrachloride, in basic conditions. It is suggested that the triphenylphosphine 
forms a complex with the halogen which then undergoes nucleophilic attack by 
the OH group of the amino alcohol, the OPPh3+ group formed is a good leaving 
group and drives the intramolecular cyclisation. This general mechanism is 
depicted in Scheme 40.
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Three methods of this type were used in the attempted preparation of the 
aziridine 50. The first of these was based on a method reported by Okada et al217 
for the preparation of aziridines and by Freeman and Mondron216 for the 
preparation of azetidines. In this procedure, the reagent is triphenylphosphine 
dibromide with triethylamine as the base. Okada et al210 made several different 
substituted aziridines in reasonable yields. However, in the case of 1-substituted 
aziridines the only product isolated was the corresponding piperazine. The 
piperazine is formed by a bimolecular reaction, rather than an intramolecular 
reaction, occurring at the intermediate stage shown in Scheme 40. A nitrogen 
from a second molecule attacks the carbon of the C-O bond to join the two 
molecules. An equivalent reaction occurs to complete the piperazine ring. This 
intermolecular reaction occurs more readily in the amino alcohols that have no 
substituents on the carbon adjacent to the hydroxyl group, i.e. in Scheme 40, R2
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is H. This is because it is easier for the second molecule to approach and react 
before the intramolecular cyclisation has taken place. When there is a substituent 
at this position, there is more steric hindrance to prevent the intermolecular 
reaction. In the attempted synthesis of the analogue of 49; 1-
phenylmethylaziridine 52, the only product reported to be isolated was the 




The amino alcohol 48 was treated with triphenylphosphine dibromide in basic 
conditions. In agreement with the results of Okada et al,217 the only product 




Similarly, treatment of 48 with the analogous triphenylphosphine diiodide 











The most successful method of this type was one in which the amino alcohol 48 
was treated with carbon tetrachloride and triphenylphosphine in basic conditions. 
This procedure was first reported by Appel and Kleinstuck.218 Among other 
examples, these workers reported a yield of 6 6 % of 1-phenylmethylaziridine (52) 
and only 12% of the corresponding piperazine 53. In this system the carbon 
tetrachloride is thought to form a complex, 55, with the triphenylphosphine.
Ph3P—CI--CCI3 
55
As shown in Scheme 43, a mixture of the aziridine 50 and the piperazine 54 was 
obtained; some starting material was also present in the mixture. This was 
determined by NMR analysis. The aziridine ring protons resonate upfield of the 
other signals in the spectrum at 1.30 ppm and 1.69 ppm. These two signals 
correspond to the trans and cis protons, respectively. Those protons on the same 
side of the ring as the aromatic substituent (cis) are magnetically equivalent so 
resonate at the same chemical shift. The trans protons on the opposite side of the 
ring to the aziridine are also equivalent to each other and give the second signal. 










More recently Pfister219 reported a procedure for the "one-pot" synthesis of 
aziridines from amino alcohols. Again triphenylphosphine was used as the 
reagent, but in this case diethyl azodicarboxylate 56 forms a complex with the 
triphenylphosphine, rather than a halogen. As with other triphenylphosphine 
methods, although yields for other more substituted examples were high, 1-
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phenylmethylaziridine 52 was obtained in a yield of only 18%. Nevertheless this 









In this case only a trace amount of the piperazine 54 and no aziridine 50 was 
recovered. The main product recovered following chromatography was a mixture 
consisting of triphenylphosphine oxide and dicarbethoxyhydrazine, 57. This was 
confirmed by NMR and mass spectroscopy.
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Finally the amino alcohol was treated with N-bromosuccinimide and 
triphenylphosphine. This method was used by Ponpipom and Hanessian to 
brominate primary alcohols selectively.221 It was the intention that treatment of 
the resulting reaction mixture with base would cause the cyclisation of the 
bromoamine 58 to the required aziridine 50 (Scheme 45). Once again the only 















A suitable method for the preparation of the aziridine 50 has yet to be found. In 
the one case where the compound was shown to be present in the crude product, 
it was not recovered on purification. The majority of the methods tried involved 
the use of triphenylphosphine as a reagent. This gives rise to the problem of 
having to separate the aziridine product from the triphenylphosphine oxide 
produced. The formation of piperazine 54, in these conditions at least, seems to 
be more favourable than the formation of the aziridine 50. This seems to be the 
major reason for failure of these methods.
The crude mixture produced by the reaction shown in Scheme 43 was treated 
with hydrogen peroxide and sodium hydroxide solution to convert the cyano 
groups present to the corresponding amide groups. It was hoped that 3-(aziridin- 
l-ylmethyl)benzamide 47 might be easier to separate from the mixture than 50. 





In this series of compounds, the initial aim was to synthesise isoquinolin-l-one 
analogues of NAD+ with electrophilic groups at the 5-position (corresponding to 
the 3-position in benzamides, Figure 23). The isoquinolin-l-ones have the 
benzamide core in their structure, but with the amide group as part of a 
heterocyclic fused ring. By conformationally restricting the amide group in this 
way, the activity of these compounds as inhibitors of PARP is greatly increased.
An early target was 5-cyanoisoquinolin-l-one 59. From this analogue, it was 
intended that several electrophilic-side chains could be developed. For example, 
the Pinner reaction could be used to furnish the methyl ester 60, which in turn 
could be used to prepare the chloromethyl analogue 61 (Figure 32).
Figure 32: Isoquinolin-l-one targets; (a) Intermediate synthetic targets; (b) 






Following several approaches to the synthesis of 59, it was found that, due to 
lack of solubility and reactivity, this compound was not a suitable intermediate in 
the synthesis of a series of isoquinolinones. Efforts were then directed towards 
derivatising isoquinolinones via the C-metallated isoquinolinones. This approach 
involved the preparation of halogenated isoquinolin-l-ones 62 and 63.
In addition to electrophilic side-chains, groups mimicking the ribose moiety in 
NAD+ were also considered. Steps towards the synthesis of the isoquinolinone 
riboside 64 were also taken.
The first target compound was 5-aminoisoquinolin-l-one 65. This compound is 
known to be a potent PARP inhibitor.158 A method of extracting PARP from 
nuclear extracts using magnetic beads has been under development.222 The 
principle behind this method is that the magnetic beads, when added to the 
nuclear extract, bind PARP and are then separated magnetically. The enzyme is 
then eluted from the beads. Various methods of binding PARP to the surface of 
the beads are under investigation. One method of binding PARP to the beads 
would be to attach a PARP inhibitor via a "spacer" or "linker" to the surface of 
the beads. Isoquinolinones are potent inhibitors and should provide a strong 
binding interaction with PARP. 5-Aminoisoquinolinone 65 has an amino group 
which can be easily linked to a "spacer" group. Therefore, a protected "spacer" 
with the isoquinolinone moiety attached was synthesised for this purpose.
5-Aminoisoquinolin-l-one, 65, was prepared by a method similar to that 
described by Wenkert et al,223 shown in Scheme 46. 5-Nitroisoquinoline 66 was 
treated with hydrogen peroxide and acetic acid to give the V-oxide 67. 
Rearrangement of the V-oxide 67 by heating with acetic anhydride gave 5- 
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The rearrangement of the //-oxide 67 was a fairly low yielding step, largely 
because of the lengthy and inefficient extraction and purification processes 
involved (the yields in Scheme 46 are the best yields obtained in a number of 
runs). Attempts to carry through the crude product, which consisted, 
nevertheless, mainly of 68, resulted in a large reduction in the yield of 
hydrogenation product 65.
5-Aminoisoquinolinone 65 was coupled to Cbz-protected 6-aminohexanoyl 
chloride 69 to form the amide 70, as shown in Scheme 47. The derivatised 
inhibitor 70 can be deprotected and coupled to biotin, for example, via an amide 
linkage.224 In this example, the biotinylated linker would bind strongly to 
streptavidin-coated beads.
A possible method of preparation of 5-cyanoisoquinolinone 59, is to diazotise the 
amine 65 and treat the diazonium salt with copper (I) cyanide (the Sandmeyer 
reaction, discussed in Chapter 5). However, large quantities of 5- 
cyanoisoquinolinone 59 were required, as this was to be a starting material for 
the preparation of several target compounds. The diazotisation step is likely to be
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fairly low yielding; it was therefore decided to use a less lengthy and higher 









One method for the preparation of 5-cyanoisoquinolin-l-one 59, is reported in 
the literature by Wenkert et al.223 2,6-Dicyanotoluene 71 was treated with ethyl 
formate under basic conditions, followed by acid hydrolysis. The reported yield 
of 59 was 20%.223 This procedure was repeated and both the isoquinolinone 59, 
and 5-cyanoisocoumarin, 72, were isolated from the complex mixture of products 
(Scheme 49). These two products have similar structures and similar NMR 
spectra. However, on closer inspection, a clear distinguishing feature is the 
coupling constant of the protons at positions 3 and 4. In the isoquinolinone, with
113
nitrogen in the ring, J^a is 7.0 Hz; whereas in the oxygen heterocycle 73)4 is 5.7 
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Mechanisms for the formation of these products are proposed in Scheme 48. The 
base abstracts a proton from the methyl group and the carbanion formed attacks
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the ethyl formate. This leads to the formation of the intermediate aldehyde 73. 
Cyclisation occurs and the imino lactone (imidate) 74 is formed. From this 
intermediate 74, the isocoumarin 72 can be formed by hydrolysis. The 
isoquinolinone is formed possibly as a result of the attack of 74 by an ethoxide 
ion and ring opening. Rearrangement, cyclisation and, finally, hydrolysis follow 
to give 59.
The yield of 59 was low using this method. The isocoumarin 72 could be 
manipulated to give further amounts of 59; syntheses of some isoquinolinones 
from the corresponding isocoumarins, by treatment with ammonia in ethanol at 
increased pressure, have been described.225 However, the yield of 72 was also 
low. Therefore, other methods of synthesis of 5-cyanoisoquinolinone and its 
analogues were investigated. These approaches are summarised in Scheme 49.
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Sakamoto et a/226,227 reported the synthesis of various unsubstituted, 6,7- 
disubstituted and 6,7,8-trisubstituted isoquinolin-l-ones. These procedures 














R = OMe (78%)
R = H (82%)
Scheme 50226’227
In the position ortho to the amide group is a substituent with two-carbon chain 
and with a potential leaving group attached. On heating in the presence of acid, 
these benzamides 75 and 76 cyclise to form the isoquinolin-l-ones 77 and
y g  226,227
A similar strategy was investigated for the synthesis of the 5-cyano derivative. 
The intended pathway is shown retrosynthetically in Scheme 51. The aim was to 
derivatise the methyl group of 2,6-dicyanotoluene 71 with an ethenyl group with 
a leaving group attached (79). One of the cyano groups is hydrolysed to an amide 












The dimethylamino group (X = NMe2) was one of the leaving groups employed. 
Treatment of substituted toluenes, such as 71, with dimethylformamide dimethyl 
acetal (DMFDMA) gives the corresponding enamine.228 As in 2,6- 
dicyanotoluene 71, the other substituents on the ring should be electron- 
withdrawing so as to encourage the loss of a proton from the methyl group to 
form the CH2- anion. This method was used to prepare the enamine 81 in good 
yield (Scheme 49). Attempts to convert one of the cyano groups to give the 
corresponding amide 82 were not successful. Therefore, selective hydrolysis of 
the cyano group was carried out on the toluene derivative 71. This step was 
successful; the only product isolated was that in which only one of the cyano 
groups had been converted (83). This can be seen clearly in the infra-red 
spectrum, a band at vmax 2218 cm'1, corresponding to the cyano group and the 
characteristic amide bands at vmax 1625 and 1680 cm'1 are present.
Treatment of 83 with DMFDMA did not result in enamine formation at the 
methyl group. In this case the amide nitrogen, rather than the methyl carbanion 
attacked the acetal and the formamidine 84 was formed. Attempts to cyclise the
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product 84 by heating in acidic conditions resulted in the formation of the 
"dimer" diacyl formamidine 85 rather than the required isoquinolinone 59.
A slightly different approach was then studied. The amide 83 was heated with 
triethyl orthoformate in an attempt to form 86, where an ethoxymethylene group 
is condensed onto the amide group. The ethoxy group acts as a leaving group in 
this case. This product did not form and, when DMF was added as a co-solvent, 
only the dimethylformamidine derivative 84 was obtained.
The next approach was to take the enamine 81 and convert one or both of the 
cyano groups to methyl esters using the Pinner reaction.229 Cyclisation of this 
product would give the isocoumarin, which could then be converted to the 
corresponding isoquinolinone by treatment with ammonia at reduced pressure.225 
Theoretically, two products are possible from the two-step process; 5- 
cyanoisoquinolinone 59 formed if only one of the cyano groups is converted to 
the methyl ester; and 60, if the diester is formed. However, when the enamine 81 
was treated with dry HC1 and methanol, the product isolated was found to be 5- 
cyanoisoquinolinone, 59. A possible mechanism for the formation of 59 is shown 
in Scheme 52. In the first step one of the cyano groups of the enamine 81 is 
converted to the corresponding imino ester (82). Protonation occurs followed by 
rearrangement to form the dimethyliminium ion 87. Cyclisation followed by 
hydrolysis gives 59. Evidence that the methyl ester did not form as was intended, 
was seen when the Pinner synthesis of ester 88, from 2,6-dicyanotoluene 71, was 
unsuccessfully attempted.
This method of cyclisation of the enamine 81 produced a 55% yield of 
isoquinolinone 59, with an overall yield of 39% for the two steps from 2,6- 
dicyanotoluene. This procedure is more than adequate for the preparation of large 
quantities of 5-cyanoisoquinolinone 59. However this compound proved to be 
insoluble in most solvents and very difficult to handle. Attempts to make the
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methyl ester by treatment with HC1 and methanol were unsuccessful. The 
compound could not be assessed as a PARP inhibitor due to lack of solubility in 
the aqueous buffer used. It was possible to hydrolyse the cyano group to give the 



















Following the difficulties with 59, a new strategy was required. It was proposed 
that, rather than introduce the benzylic carbon using the cyano group, the carbon- 
carbon bond could be introduced through the formation of a C-metallated 
isoquinolinone. The reaction of C-metallated isoquinolinones with electrophiles 
should afford C-substituted products. Organolithium compounds can be prepared 
from the corresponding halide using butyllithium. In the isoquinoline series, 
various haloisoquinolines have also been coupled to form C-substituted products
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using palladium230,231 and nickel232,233 reagents. Two of these three examples of 
C-metallation were investigated.
There are a few reports of the preparation of 1- and 4-lithioisoquinolines by 
halogen-lithium exchange from 1-bromo234 and 4-bromoisoquinolines.234'236 
These lithioisoquinolinones undergo subsequent reactions with electrophiles to 
generate C-substituted products. The lithiation of 5-bromoisoquinoline 90 was 
therefore investigated, with a view to converting the derivatised isoquinoline 
product to the required isoquinolinone via the rearrangement of the N-oxide as 
was carried out in the synthesis of the nitro derivative 68.
5-Bromoisoquinoline 90 was prepared from 5-aminoisoquinoline 91 by forming 
the diazonium salt and treating it with cuprous bromide. This is the Sandmeyer 
reaction; a variation of this reaction was also used in the preparation of 3- 
acetylbenzonitrile 9, in the benzamide series. The lithiation of 90 was carried out 
at -100°C using 1.1 equivalents of butyllithium. These conditions are analogous 
to those used in the lithiation of 3-bromopyridine.237 In this initial experiment, 
the lithioisoquinoline 92 was treated with benzaldehyde as the electrophile. The 
desired product 93 was formed in modest yield (Scheme 53). The other products 
isolated from the reaction were the starting material 90 (13%) and isoquinoline 
94 which is formed when the lithioisoquinoline 92 is quenched with water before 
reacting with the benzaldehyde. It was confirmed, using NMR techniques, that 
the 1-phenyl-1-hydroxymethyl group was attached to the ring at position 5. A 
NOESY spectrum (NOE correlation spectroscopy) of 93 was obtained and the 
cross peaks for the benzylic proton were studied. The benzylic proton showed 
cross peaks with the protons at positions 4 and 6 of the isoquinolinone ring; a 
cross peak indicates that the two protons are close in space. This model 
experiment demonstrates, for the first time, successful lithiation of isoquinoline 
at the 5'-position and reaction with a carbonyl electrophile.
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The successful lithiation of 90 would allow the synthesis of several 
isoquinolinone derivatives, including the isoquinolinone riboside 64. The 
riboside 64 would be an interesting compound to test for activity as a PARP 
inhibitor. An analogue of this compound 64, benzamide-p-D-riboside was found 
to be very toxic to cells162 (see Chapter Three). This toxicity prevented 
evaluation of PARP inhibition and is probably due to interference with NAD+- 
dependent cellular processes. The majority of compounds tested for PARP
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activity have mimicked the nicotinamide moiety of NAD+. More information 
about the binding interactions in the ribose region of the NAD+ site might be 
gained from compounds with a ribose-like group in the equivalent position.
The reported synthesis of benzamide-p-Z)-riboside involved lithiation of 
carboxamide-protected bromobenzamide and treatment of the lithiobenzamide 
with the ribonolactone 95 to form the C-riboside.162 A similar strategy was used 
here in the attempted preparation of the isoquinoline riboside 64 (Scheme 53).
The ribonolactone 95 was prepared as shown in Scheme 54. The synthesis of the 
2,3,5-benzylated ribose 96 was reported in the literature by Barker and 
Fletcher.238 Treatment of p-D-ribose 97 with methanolic sulphuric acid gave a 
mixture of a  and p methyl-Z)-ribofuranosides 98. The free OH groups were then 
protected in one step, using benzyl chloride and powdered potassium hydroxide 
in tetrahydrofuran. At this stage the a  and P anomers, 99 and 100, were separated 
by chromatography. The signal corresponding to the anomeric proton in the !H 
NMR spectrum is a doublet, due to coupling with the proton at C-2. The 
coupling constant for this doublet is different in 99 and 100, due to the different 
angles between the anomeric protons and the adjacent proton as explained by the 
Karplus equation. The coupling constant for the a  anomer 99 is very small (<1 
Hz) and the signal appears as a broad singlet, whereas the p anomer 100 gives a 
doublet with coupling constant of ca 4 Hz.239 Although these diastereomers were 
separated in the course of the synthesis, this was not necessary to the overall 
preparation since the key intermediate 95 is trigonal at C-l. The next step 
involved the hydrolysis of the acetal group by boiling with dilute acid, which 
resulted in a mixture of both a  and p 2,3,5-tri-O-benzyl-D-ribose 96. The 
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All attempts to couple the ribonolactone 95 to the lithioisoquinoline 92 were 
unsuccessful. A complex mixture was obtained in each case. Extensive 
chromatography failed to furnish the desired product 101 (Scheme 53). 
5-Bromoisoquinoline 90 was isolated, as was 5-H isoquinoline. The 
ribonolactone 95 was not recovered indicating that maybe this reagent was 
degraded before electrophilic reaction with the lithiated isoquinoline could occur. 
It might be that the anion is too basic and facilitated the removal of the lactone 
2'-H (there is no equivalent a- proton in benzaldehyde). In one case, no attempt 
was made to isolate the alcohol 101 and the crude product was treated with boron 
trifluoride etherate and triethylsilane which would reduce the alcohol to give 102. 
No such product was isolated. This method was not suitable for the preparation 
of the isoquinolinone riboside 64.
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The preparation of 5-substituted isoquinolinones via the lithioisoquinoline 92 
requires the conversion of the derivatised isoquinoline to the corresponding 
isoquinolinone. The intention was that this conversion would be carried out, as in 
the synthesis of 5-nitroisoquinolinone 68 (Scheme 46); via the N-oxide 67. The 
preparation of 5-bromoisoquinolinone 62 was attempted using this method. The 
TV-oxide 103 was formed in quantitative yield, although the reaction was slow. 
The rearrangement to form 62 was not successful, however, with a complex 
mixture of products being produced. It was decided that this route would not be 
convenient for the production of 5-substituted isoquinolinones. The last steps to 
convert the isoquinoline into the isoquinolinone are likely to be low yielding and 
involve harsh conditions which might interfere with the substituent which has 
been introduced.
An alternative pathway was considered in which a protected form of the 
isoquinolinone is lithiated. It is not possible to lithiate the unprotected 
isoquinolinone at carbon. The acidic NH proton and electrophilic carbonyl group 
present lead to the butyllithium reacting at these positions in the molecule rather 
than carrying out the halogen-lithium exchange. A possible pathway to 
substituted isoquinolinones via halogen-lithium exchange might be to prepare the 
halo-isoquinolinone protected at preferably the 1-, or alternatively, the 2- 
position.
Only a few simple examples of 1-alkoxyisoquinolines have been reported. The 
method used to prepare these compounds, which include 1-methoxy and 1- 
ethoxy isoquinolinones, is treatment of the corresponding 1-chloroisoquinoline 
with sodium alkoxides under vigorous conditions.241-244 For our purposes, 
protection of the isoquinolinone with a benzyl group was desirable. Such a 
protecting group is removed using hydrogenolysis or with hydrogen bromide. 
Given the vigorous conditions required for the substitution of 1-
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chloroisoquinolinones and the lack of examples using larger alkoxy groups, the 
direct alkylation of 5-bromoisoquinolinone 62 was carried out.
The synthesis of 5-bromoisoquinoline 62 has not been reported in the literature. 
A preparation of the 5-chloro derivative is, however, described by Eloy and 
Deryckere.245 This group synthesised several substituted isoquinolin-l-ones 
using a "one-pot" process which involves Curtius rearrangement of cinnamyl 
azides and subsequent thermal cyclisation. The method is only suitable for the 
preparation of isoquinolinones which do not have electron-withdrawing 
substituents. The 5-bromo derivative 62 was prepared using this general method 
(Scheme 55). The bromocinnamic acid 104 was prepared by two methods. The 
first required the formation of the diethyl acetal 105 from the corresponding 
aldehyde 106. The acetal 105 was then condensed with malonic acid under 
Knoevenagel-Doebner conditions.246 A more convenient method is described by 
Plevyak et al.247 2-Bromoiodobenzene 107 is converted, in one step to the 
desired cinnamic acid 104 using an iodine-selective Heck reaction. The Heck 
reaction involves the palladium-catalysed vinylation of organic halides.248,249 The 
catalyst required depends upon the halide present; aryl iodides require only 
palladium acetate, whereas aryl bromides also require triphenylphosphine to be 
present as a ligand for palladium. Therefore, only the iodo group in 107 reacts 
with the acrylic acid to form 104. The method of Plevyak et al247 was adapted in 
that a different solvent was used. It was found that the use of boiling propionitrile 
was a good alternative to acetonitrile in conducting the reaction at 100°C; the 
latter necessitated heating the reaction mixture in a sealed tube. This method was 
successfully used in the preparation of large quantities of 104 (Scheme 55).
The cinnamic acid 104 was firstly converted to the mixed anhydride 108 by 
treatment with ethyl chloroformate. Subsequent addition of sodium azide 
furnished the acyl azide 109. This was confirmed by analysing a small sample 
using infra-red spectroscopy. A characteristic azide band, a strong band at vmax
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2150 cm'1, was detected. The acid azide was cyclised by addition to boiling 
diphenyl ether. There is initially thermal rearrangement of the azide 109 to the 
isocyanate 110, believed to occur at around 60-80°C.245 This is followed by 
cyclisation at approximately 240°C245 (Scheme 55)
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The yield of 62 was moderate; several compounds were present in the crude 
product and recovery of the desired isoquinolinone 62 was difficult. However, 
following several stages of chromatography and recrystallisation, pure 62 was 
obtained and a sample was evaluated for PARP inhibition.
Alkylation of 5-bromoisoquinolin-l-one 62 was carried out by deprotonation 
with the non-nucleophilic base lithium bis(trimethylsilyl)amide followed by 4- 
methoxybenzyl chloride. The alkylation was found to occur exclusively at the 
nitrogen, rather than the oxygen, to give 111 in excellent yield. Assignment of 
the structure of 111 as being the A^-(arylmethyl)isoquinolin-1 -one rather than the 
l-(arylmethoxy)isoquinoline was carried out by analogy with the protected 
iodoisoquinolinone 112 (Scheme 56), which is described below. Examination of 
the literature for reports of alkylation of other isoquinolinones revealed that, in 
the relatively few examples described, alkylation occurs predominately at 
nitrogen of the conjugate anion, under various conditions using simple 
haloalkanes.250'252 Although protection at the 1-position would have been 
preferable, the N-alkylated isoquinolinone 111 should undergo lithium-halogen 
exchange by butyllithium.
5-Iodoisoquinolinone 64 was prepared in a similar way to the bromo derivative 
62, but was obtained in much better yields. It was consequently a more 
convenient aryl halide for metal-halogen exchange. As shown in Scheme 56, 2- 
iodobenzyl alcohol 113 was oxidised to the corresponding aldehyde 114 with 
pyridinium dichromate253,254 and a direct Doebner-Knoevenagel condensation 
with malonic acid afforded the cinnamic acid 115. In this case, the corresponding 
acyl azide 116 was prepared by the treatment of the acid chloride 117, rather than 
the mixed anhydride, with sodium azide. A further modification of the process 
was to use boiling tetraglyme as the solvent for the Curtius rearrangement and 
cyclisation of 116 to give 63. This allowed the isolation of the isoquinolinone 
product 63 by precipitation with water. In general, recovery of the
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isoquinolinones prepared was poor. This is largely due to very poor solubility in 
the non-polar organic solvents which are used in normal phase chromatography. 
Using tetraglyme as opposed to diphenyl ether apparently increased the yield of 
63; yields ranged from 28 to 42% when tetraglyme was used, compared to 11 to 
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The anion of 5-iodoisoquinolinone 63 was formed and benzylated in high yield, 
using lithium bis(trimethylsilyl)amide followed by benzyl chloride, to give 112. 
Assignment of the structure of 112 as being the N-(arylmethyl)isoquinolinone 
rather than the l-(arylmethoxy)isoquinoline was made by both 13C NMR and IR. 
The benzyl CH2 carbon resonates at 6 51.9 ppm. Using published tables to
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calculate predicted shifts for this carbon when the 1-position of the 
isoquinolinone is alkylated (giving PhCI^O), the predicted shift is 8 69 ppm, 
compared to 8 48 ppm when the 2-position is alkylated (giving PhCH2N). This 
confirms structure 112. This was further substantiated by the JR spectrum which 



















Both protected isoquinolinones 111 and 112 were treated with butyl lithium, to 
form lithio derivatives 118 and 119, followed by one of three simple 















DMF was chosen as an electrophilic formylating agent in these preliminary 
experiments as it has been used to prepare the corresponding aldehydes of 
various lithioisoquinolines.235,236 Preparation of the aldehydes 120 and 121 
would allow further extension of the side-chain and development of additional 
isoquinolinone derivatives. JV-Methylformanilide was used as an alternative to 
DMF. This reagent has a chromophore and it was hoped that this would allow 
improved monitoring of the reaction by TLC. Benzaldehyde was also used as a 
model in these investigations. This electrophile was successfully coupled to 5- 
lithioisoquinoline 92 to give 93, as described earlier. The 1-methoxybenzyl 
derivative 122 was not formed. Several experiments with various reaction 
conditions were carried out; temperatures of -100°C and -78°C were 
investigated. The outcome was similar in all cases (a typical example is given in
131
the experimental section). In addition to unreacted starting material, the main 
products of these reactions were the protected isoquinolinones 123 and 124, 
recovered in ca. 20% yields. These results indicate that a proportion of the aryl 
halide was lithiated but then reacted with water rather than the intended 
electrophile. In all cases none of the expected derivatives were isolated.
The second method of coupling haloisoquinolinones investigated was using a 
palladium reagent as the catalyst. This type of reaction was first described, and 
has been extensively investigated, by Heck and his colleagues.248,249 As described 
previously in the preparation of 2-bromocinnamic acid 104, the Heck reaction 
involves the palladium-catalysed vinylation of organic halides. It is a convenient 
method of forming carbon-carbon bonds at unsubstituted vinylic positions, the 
general reaction is shown in Scheme 59.
H. /  „ PCIL2X2 R. /
^ C = C ^  +  RX +  Base -------- ► / C=C\  +  BaseH+x"
X = halogen usually Br or I 
L = ligand
R = aryl, vinylic or heterocyclic
Scheme 59
A limited number of examples of reactions of this type have been reported for the 
isoquinolines. 4-Bromoisoquinoline,230,231 3-bromoisoquinoline231 1- 
chloroisoquinoline231 and 1-iodoisoquinoline231 have been used as substrates for 
this method. However, no isoquinolinones have been prepared. In this case, the 
C-metallation should not be affected by the isoquinolinone amide group. 
Therefore, the unprotected haloisoquinolinone should undergo halogen-vinylic 
substitution.
These reactions, as shown in Scheme 60 and 62 were carried out using 5- 
iodoisoquinolinone 63. Heck reactions using aryl iodides are more
132
straightforward in that triphenylphosphine is not required as a ligand, unlike 
when aryl bromides are used.
In the first example of Heck coupling carried out, aery he acid was coupled to the 
aryl iodide 63, in the preparation of the a,p-unsaturated carboxylic acid 125 
(Scheme 60), in almost quantitative yield. This target compound is a Michael 
acceptor and will undergo nucleophilic attack at the benzylic position. It is 
therefore a potential irreversible inhibitor of PARP. This compound was 
evaluated for PARP inhibition but was found to be less active than the other 
isoquinolinones that have been tested, with activity corresponding more with the 
benzamides. This may be due to the electron-withdrawing properties of the side 
chain, which, it has been noted (see Chapter 3), can result in a diminution in 
activity.
The successful coupling of acrylic acid to the isoquinolinone 63 led to other 
larger alkenes being investigated, also shown in Scheme 60. 4-Pentenol gave a 
mixture of four main products; two alcohols 126 and 127, and two aldehydes 128 
and 129. Complete separation was not possible, the two alcohols 126, 127 had 
identical Rf values in all of the mobile phases examined, as did the aldehydes 
128,129. The two isomeric alcohols are produced because there are two possible 
directions for the addition of the organopalladium intermediate to the 
unsymmetrically substituted double bond. This is, in most cases, largely 
sterically controlled. The presence of an electron-withdrawing group at one of the 
carbons of the double bond also directs addition to the other carbon. When allylic 
alcohols are used as the olefinic moiety in Heck reactions, carbonyl compounds 
are usually obtained as significant or exclusive products.255,256 This is due to the 
migration of the double bond along the carbon chain until captured by the alcohol 
to give a carbonyl product. In this example the yield of the two aldehydes 128, 
129 is fairly small.
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4-Butenoic acid was also investigated as a substrate. This example was less 
successful as none of the desired product 130 or any related product could be 
isolated. The crude product was insoluble in all suitable organic solvents. This 
problem led to investigation of the replacement of 63 with its benzyl-protected 
analogue 112 in the reaction, as shown in Scheme 61. The increased solubility of 
the reagent and products allowed a much greater recovery of products from the 
reaction mixture. However, a mixture of isomers was produced and complete 
isolation of the major product was not possible even following several stages of 
chromatography. From *H NMR analysis, the main constituent appeared to be 
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Further investigations towards the synthesis of the riboside 64 were carried out 
using the Heck reaction to form the required C-glycosidic bond. Scheme 62 
shows a suggested retrosynthetic pathway that was considered for the synthesis 
of 64 and also for its deoxyribose analogue 132. This involves the synthesis of 
the pentene derivative 133 with the appropriate stereochemistry at each of the 
chiral centres and the hydroxyl groups at positions 3 and 5 protected. This 
fragment is then coupled to the isoquinolinone 63 to give 134 and cyclised to 
give either 62 or 132 as shown in Scheme 62. A pentenetriol derivative of the 
form of 133 could be prepared from the acetonide protected precursor 135. 
Protection, for example benzylation, of 135 allows selective protection of the 
hydroxyl group at the 3 position. The removal of the acetonide protecting group 
by mild acid treatment followed by selective protection of the primary alcohol, 
for example by benzoylation, affords the 3,5-protected pententriol derivative 

























The aldehyde 136 was prepared by the cleavage of the acetonide-protected 
mannitol derivative 137 according to the method of Dumont and Pfander.258 
Addition of vinylmagnesium bromide in a Grignard reaction afforded the 
protected pententriol 135. This product 135 is a mixture of diastereomers as 
the centre at C-3 is racemic. This was confirmed by NMR spectroscopy. *H 
NMR correlation spectroscopy aided the assignment of most of the signals in the 
complicated !H NMR spectrum, the COSY spectrum for 135 is included in 
Appendix A. Some separation of the signals produced by the two diastereomers 
is seen: The protons at C-l and C-3 resonate at 8 3.78 and 4.27 ppm, 
respectively, in the major isomer, but, in the minor isomer, these protons resonate 
at ca. 5 4.05 ppm - a region of overlapping multiplets. The molar ratio of the two 
isomers is approximately 10:7, although it not possible to assign relative 
stereochemistry from these spectra. The 13C NMR spectrum shows clear 
evidence of two isomers, with most signals present in duplicate. It was hoped 
that benzylation of the free hydroxyl group, to give 138, would allow separation 
of the diastereomers by chromatographic methods. However this was not the 
case. The yield of the protected triol 138 was also fairly low, the method in 
which lithium bis(trimethyl)amide was used as the base was slightly better than 
when sodium hydride was used. NMR analysis of 138, following 
chromatography, showed that two diastereomers were present. A second attempt 
to separate the diastereomers was to deprotect 135 to give 139 and then carry out 
a benzylidene protection to form the 1,3-dioxane derivative 140. This 
diastereomeric mixture was successfully formed but it was not possible to 
separate the components of the mixture. Clearly, further work needs to be done 
to afford the pure diastereomers in order that, once coupled to the isoquinolinone 










































The Heck coupling of the alkene fragment to the isoquinolinone ring was tested 
on the protected triol 135. This reaction afforded a mixture of the desired allylic 
alcohol 141 in poor yield and a significantly greater amount of the ketone 142. 
The assignment of the structure of the ketone 142 was made by *H NMR
138
analysis. The two aliphatic methylene groups resonate at 5 3.00 and 3.20 ppm 
and there are no signals in the alkenic region of the spectrum The structure was 
also confirmed by a band at v  1715 cm'1 in the infra-red spectrum corresponding 
to the ketone C=0 vibration. The allylic alcohol 141 is a mixture of 
diastereomers. This is evident from the !H NMR spectrum. 2-Dimensional 
correlation NMR spectroscopy, which identifies signals directly coupled to each 
other, allowed assignment of the spectrum and confirmation of the structure, The 
COSY spectrum is given in Appendix A. The ketone 142 is formed by the 
migration of the double bond in the presence of palladium. When the double 
bond reaches the alcohol the enol that is formed tautomerises to give the ketone 
142.
The yield of the desired allylic alcohol in this case was quite low in comparison 
to the ketone. This indicates that this pathway will be fairly low yielding, 
however further work and development of this synthetic pathway might furnish 
the deoxyriboside 132 and possibly the riboside 65. These two targets would be 






The inhibitory effects of several benzamides and isoquinolinones on PARP 
activity were examined using an assay system in vitro. The enzyme was extracted 
from nuclei isolated from L929 cells (mouse areolar and adipose tissue cells). 
PARP activity was estimated by the rate of incorporation of radioactivity from 
adenosine [3H]NAD into acid-insoluble material.
The effect on PARP activity was measured in the presence of the potential 
inhibitors at concentrations ca. 10 pM over a time-course of 4 minutes. These 
initial assays were used to compare the test compounds in terms of their activity 
as PARP inhibitors at a particular concentration. The results were also used as a 
feedback into the design of new compounds. Some of the most active compounds 
of those assessed earlier in the project were tested at a range of concentrations. 
This allowed an approximate estimate to be made of the IC50 values for these 
compounds. Finally, for three potentially irreversible inhibitors, the effect of pre­
incubating the inhibitor with the enzyme for one of three time intervals before 
the addition of the radiolabelled NAD was measured.
7.2 Initial PARP Activity Assays
PARP activity was measured over a 4 minute time-course in the presence of 
approximately 10 pM test compound. A summary of the percentage inhibition 
values calculated from the results is given in Table 6, later in the chapter.
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7.2.1 Benzamides
3-Chloromethylbenzamide 2 was one of the first compounds tested for its effect 
on PARP activity. This target compound was synthesised as a potentially 
irreversible inhibitor of PARP with an electrophilic group in the 3-position. 
Figure 33 shows a graph of PARP activity, estimated as the rate of incorporation 
of radioactivity from adenosine [3H] NAD into acid-insoluble material, against 
time, for the 4 minute time-course. Data are plotted for the control system, with 
no inhibitor present, and for the system with the addition of 10.5 |iM benzamide 
2 .
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The percentage inhibition is calculated by comparison of PARP activity with and 
without the inhibitor present. At the 2 minute time-point, the value calculated for 
this benzamide 2 is 62 %. This value is in the same order as other benzamides 
that have been assessed. An IC50 value of 9.0 (JM for 3AB was reported by Suto 
et a/;158 Pemberton et al260 reported 36% and 37 % inhibition at 10 |iM for 3AB 
and 3-hydroxybenzamide, respectively. This compound is therefore of potency 
similar to that of 3AB.
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3-Acetylbenzamide 9 was not a specific target compound but was synthesised as 
an intermediate as part of the synthetic investigations into other inhibitors. 
However, this compound proved to be a good inhibitor as is shown in Figure 34.
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The inhibition calculated for this compound 9 was 83% at 11.0 |iM; showing it 
to be a highly potent benzamide inhibitor. This result led to the investigation of 
the analogous bromomethylketone 44 (Figure 35). This compound is similar in 
that it has a carbonyl group adjacent to the benzene ring. This compound had 
very similar activity; 84% inhibition of PARP activity was achieved at 10.7 |liM . 
These values are more in line with the inhibition seen for the isoquinolinones 
(see Table 6).
The epoxide 43 was designed as a potentially irreversible inhibitor of PARP. In 
the 5-enantiomer, the location of the oxiranyl oxygen, relative to the aromatic 
ring, is approximately equivalent to that of the ribose oxygen in NAD+. As 
explained in Chapter 5, the epoxide 43 will undergo nucleophilic attack and may 
become covalently bound to the active site, thus irreversibly inhibiting the 
enzyme. Racemic compound 43 proved to the most potent PARP inhibitor of the
142
benzamides tested, with an inhibition of 88% at 9.2 pM. The time course is 
shown in Figure 36.
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This is more potent than any of the benzamides reported in the literature. It is 
also freely soluble in the aqueous buffer in which the assay is carried out, at the 
concentrations required. This is a desirable property for a good inhibitor; poor
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solubility is a problem with many of the isoquinolinones. The epoxide 43 tested 
is racemic, it would therefore be interesting to investigate the relative potencies 
of the two pure enantiomers. These results might give important information 
about the interactions that take place with the residues of the PARP active site in 
this region of the inhibitor molecule. It may be that the enantiomer with an 
equivalent spatial arrangement of groups around its chiral centre as in NAD+, is 
more active. Alternatively, the interaction of the epoxide group may be non­
specific.
Two further compounds tested also have an oxygen atom bonded to the benzylic 
carbon. These are the (+) and (-) diols 6 and 36. The PARP assay results for these 
compounds are shown in Figures 37 and 38. These compounds are intermediates 
in the synthesis of asymmetric benzamides. Both enantiomers were tested to 
investigate whether one enantiomer binds preferentially and so is a more potent 
PARP inhibitor. The (+)-(S)-isomer 6 represents the same arrangement of groups 
at the chiral centre as in the equivalent position in NAX>+. Neither of these 
benzamides 6 and 36 were very potent inhibitors, with inhibitions of 44% and 
32% at 9.4 pM and 9.3 pM, respectively. These are less potent PARP inhibitors 
than 3AB. The (+)-diol 6 is slightly more potent than the opposite enantiomer 36, 
although this difference may not be significant. These compounds might have 
been expected to have been better inhibitors than was apparent from these 
experiments. One problem with these compounds is that they are hygroscopic 
gums and, consequently, accurate measurement of dry mass is very difficult. The 
samples used in the PARP assays were prepared by freeze-drying. The actual 
concentration of test compound in the assay mixture may have been less than 
calculated due to the presence of residual water.
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Figure 37: PARP activity in the presence of (+)-S-3-( 1,2-dihydroxyethyl)- 
benzamide 6 at 9.4 \\M.

















Figure 38: PARP activity in the presence of (—)-R-3-( 1,2-dihydroxyethyl)- 
benzamide 36 at 9.3 jjlM.
The final benzamide tested was the dioxolane derivative 4. This has an oxygen 
containing cyclic group, in common with the epoxide 43, but does not undergo 
nucleophilic attack in the same way and was not, therefore, designed as a 
potentially irreversible inhibitor. This compound was asymmetrically prepared 
and this enantiomeric form resembles the arrangement of groups at the anomeric 









slightly less potent than 3AB. A 54% inhibition of PARP activity was achieved 
at a concentration of 10.0 |iM (Figure 39).
Figure 39: PARP activity in the presence of (+)-S-3-(2,2-dimethyl-1,3-dioxolan- 
4-yl)benzamide 4 at 10.0 \lM.
7.2.2 Isoquinolinones
5-Bromoisoquinolinone 62 was one of the first compounds tested. Although not 
designed as a potential irreversible PARP inhibitor, this compound is a novel 
isoquinolinone derivative, and as a member of the series of compounds in which 
the amide group is conformationally restricted (see Figure 17), should be a potent 
PARP inhibitor. Indeed, the assay results shown in Figure 40 below confirm this 
prediction. At 11.2 |iM, PARP activity was virtually abolished with an inhibition 
of 95% calculated at the 2 minute time-point. The lack of solubility of the 
isoquinolinones is a problem that restricts their use as PARP inhibitors. The 
bromo derivative 62 is slightly more soluble than some of the other 
isoquinolinone derivatives handled in this work; 5-cyanoisoquinolinone 59, for 
example, would not dissolve to any extent and could not, therefore, be tested.
























5-Iodoisoquinolinone 63 is a synthetically useful intermediate and a very potent 
PARP inhibitor as is shown in Figure 41. This isoquinolinone has a similar effect 
on PARP activity as has the bromo derivative 62, in that 96% inhibition is 
achieved at a concentration of 8.0 |iM. These results indicate that a moderately 
bulky substituent at the 5-position in the isoquinolinone series is tolerated in the 
active site of the enzyme and halides appear to be effective inhibitors.
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Figure 41: PARP activity in the presence of 5-iodoisoquinolinone 63 at a







The isoquinolinone-5-carboxylic acid 89 was also tested. This compound has the 
advantage that it is soluble in the assay reaction mixture, since it is buffered to 
pH 8. This isoquinolinone was a potent inhibitor, although not as potent as some 
of the other isoquinolinones (Figure 42). This is to be expected as the carboxylic 
acid is an electron withdrawing group; a structural feature that tends to result in 
lower activity in both the benzamide and isoquinolinone series.
Figure 42: PARP activity in the presence of l-oxoisoquinoline-5-carboxylic 



















The final isoquinolinone tested was the a, p-unsaturated carboxylic acid 125. 
This isoquinolinone has a soft electrophilic group in the 5-position and may, 
therefore, be an irreversible inhibitor. Initial studies show that, in common with 
the isoquinolinone carboxylic acid 89, this isoquinolinone is not as potent as the 
bromo- and iodo- derivatives 62 and 63, in terms of PARP inhibition. This is 
probably due to the electron-withdrawing nature of the side-chain. Nevertheless, 
at 11.6 pM, compound 125 inhibited PARP activity by 81% in comparison to the 
control system (Figure 43). This inhibition is greater than that measured for the 
majority of benzamides at similar concentrations.
Figure 43: PARP activity in the presence of 3-(l~oxoisoquinolin-5-yl)propenoic 











Table 6 gives a summary of the results of the PARP activity assays with 
inhibitors at concentrations ca. 10 |iM. All the compounds tested were good 
inhibitors of PARP. Particularly promising results were obtained from the 
epoxide 43 and the acetyl and bromoacetyl derivatives of benzamide, 9 and 44. 
These results suggest that a side chain containing an oxygen bonded to the 
benzylic carbon, which is not part of a hydroxyl group, might be favoured for 
activity. Compounds of this type are closer analogues of NAD+.
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Table 6: Comparison of PARP Inhibitors: Percentage inhibition values at 2 min.
Compound Number Structure Concentration (pM) % Inhibition
Benzamides
,CONH2
.c o n h 2
.CONH-
,CONH2
.c o n h 2




7.3 PARP Assays at Various Inhibitor Concentrations
For some of the earlier, most active, PARP inhibitors tested, experiments were 
carried out in which a range of five different concentrations of inhibitor were 
used. These concentrations were estimated so that 50% inhibition would be 
achieved at, or in the region of, one of the values in the range. The purpose of 
these studies was to estimate an IC50 value for the inhibitor, i.e. the concentration 
at which 50% inhibition is achieved. The IC50 value is the most suitable value by 
which to compare inhibitors, as most reported inhibitor potencies are expressed 
in this way.
The results for the five assays carried out using varying concentrations of 
chloromethylbenzamide 2 are shown in Figure 44. For this compound, the time- 
course graphs for all five concentrations are shown in the first part of the figure. 
In the second part of the figure the percentage inhibition achieved at the 2 minute 
time point in each assay is plotted against the concentration to show how 
concentration affects the inhibition achieved. From this graph, the concentration 
that would give 50% inhibition can be estimated as 5 jiM.
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These assays were also carried out for 3-acetylbenzamide 9, one of the more 
potent benzamides. Figure 45 shows inhibition versus concentration of inhibitor. 
As the graph shows, the concentration range was not well chosen in this case. 
Assays with lower inhibitor concentrations need to be carried out. These results 
tend to suggest an I C 5 0  in the region of between 0.6 and 1.0 jiM, demonstrating 
that this is a particularly potent benzamide inhibitor.
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Figure 45: PARP inhibition in the presence of 3-acetylbenzamide 9 as a function
of concentration.
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Of the isoquinolinone inhibitors, three have been assessed at different 
concentrations. Figure 46 shows the results for 5-iodoisoquinolinone 63.
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This graph does not easily allow an estimate of the concentration that would give 
50% inhibition as the second two points of the series are do not follow the 
general trend. Further data points would confirm the shape of the curve. The
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results suggest that the IC50 value is below 1 juM, which is in line with other 
isoquinolinones. The results obtained for the bromo derivative 62 are out of the 
required range of inhibition. The inhibition obtained for the lowest concentration 
tested (0.27 juM) was 69 %. This implies that the IC50 value is less than 0.27 |iM, 
making one of the most potent PARP inhibitors known. The results are shown in 
Figure 47.
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The final isoquinolinone tested in this way was the carboxylic acid derivative 89. 
This was a less potent isoquinolinone PARP inhibitor. This is reflected in the 
assay results shown in Figure 48. The estimated concentration of 89 that would 
give 50% inhibition of PARP is approximately 5 jiM.
These assays require further development to be very useful. For our initial 
purpose of assessing whether or not a compound is a good PARP inhibitor, the 
PARP assays in the presence of a 10 pM concentration of the test compound are 
sufficient. Determination of accurate IC50 values require several more 
experiments.
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Figure 48: PARP inhibition in the presence of 1-oxoisoquinoline-5-carboxylic
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7.4 Assays involving pre-incubation of the inhibitor with the enzyme
Three of the inhibitors tested were designed to be irreversible inhibitors of 
PARP. To fully determine the kinetic properties of an enzyme inhibitor, 
experiments need to be carried out in which the concentration of substrate, in this 
case NAD+, is varied. The effect of a reversible inhibitor is reversed by addition 
of further amounts of substrate, this would not be the case for an irreversible 
inhibitor. These assays are expensive to carry out due to the cost of the 
radiolabelled NAD+. Therefore the properties of these potentially irreversible 
inhibitors were examined by pre-incubating the inhibitor with the enzyme before 
adding the radiolabelled NAD+ and starting the assay. The effect of pre- 
incubating the inhibitors with the enzyme for 1 minute, 15 minutes and 30 
minutes was measured. A control system was incubated for the same time 
interval but with no inhibitor in order that any change in enzyme activity over the 
pre-incubation time period was taken into account. The rationale behind this 
study was that an irreversible inhibitor when incubated with the enzyme 
undergoes nucleophilic attack and becomes covalently bound to the PARP active 
site. If this is the case, the inhibition seen when the radiolabelled NAD+ is added 
should be greater than when the inhibitor is not allowed pre-incubation with the
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enzyme, since the NAD+ cannot displace the already covalently bound inhibitor 
from its binding site. Results are shown below for 3-chloromethylbenzamide 2, 
the epoxide 43 and for the a,p-unsaturated carboxylic acid 125. Graphs of time- 
courses following pre-incubation times of 1 minute, 15 minutes and 30 minutes 
are shown for each compound. Graphs comparing PARP inhibition for each of 
the three assays through the time course are also given.
The results for 3-chloromethylbenzamide 2 are shown in Figure 49. The effect of 
increasing the length of time that the inhibitor is in contact with the enzyme 
before the substrate is added, in this case, seems to cause a general decrease in 
the amount of PARP inhibition seen. This is shown in graph (d) in which PARP 
inhibition is plotted for each assay as a function of time. The experiment 
involving 1 minute pre-incubation gave the highest PARP inhibition. Following 
15 and 30 minutes pre-incubation the inhibition falls markedly after the two 
minutes point in the time-course. There is only a slight decrease, with time, for 
the 1 minute pre-incubation assay.
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Figure 49: PARP activity in the presence of 3.9 \lM 3-chloromethylbenzamide 2.
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Figure 50: PARP activity in the presence of 2.8 \lM  (±)-3-(oxiran-2- 
yl)benzamide 43.
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The results for the assays carried out using the epoxide inhibitor 43 are shown in 
Figure 50. Inhibition of PARP, measured in the presence of this compound, was 
greater following pre-incubation of the inhibitor and the enzyme, at least for the 
first part of the time course. The results for the samples taken at 1 minute, show 
that pre-incubation for 15 and 30 minutes gave inhibition values of 74% and 79% 
in comparison with the 61% inhibition seen following only 1 minute pre­
incubation. The inhibition decreases markedly for the second half of the time 
course. The final 4 minute sample for the 30 minute pre-incubation assay shows 
that PARP activity appears to have recovered to control levels. This apparent 
decrease in inhibition seen with both benzamides 2 and 43 may be due to a 
number of factors. One possibility is that PARG, the enzyme that breaks down 
the poly(ADP-ribose) polymers, is inhibited by the benzamides. Further 
experiments would be required to investigate this phenomenon.
Finally, the results for the isoquinolinone 125 are shown in Figure 51. These 
graphs show that the inhibition was more constant throughout the time course. 
On average 10% more inhibition was achieved following 30 minutes pre- 
incubation as compared to the assay in which only 1 minute pre-incubation was 
allowed.
Clearly these are only preliminary studies and many more experiments need to be 
carried out to investigate these inhibitors fully. The pre-incubation time is one 
variable which should be investigated. Sufficient time must be allowed for the 
chemical reaction to take place, in which the inhibitor becomes covalently bound 
to the enzyme. However, other components of the nuclear extract may be 
affected by the pre-incubation. It would also be useful to ascertain whether the 
inhibitors have any effect on the glycohydrolase enzyme PARG.
159
Figure 51: PARP activity in the presence of 5.1 |iM 3-(l-oxoisoquinolin-5- 
yl)propenoic acid 125









0 1 2 3 4
NH
time (min)








(d) PARP inhibition for each time course
80 -  
© 70 -
32 40 1
------ • — 1 min
------ ■— 15 min
------ ± — 30 min
time (min)
160
These preliminary studies into the effect of the potential inhibitors of PARP on 
enzyme activity gave very promising results. All the compounds tested showed 
inhibition with potencies ranging from moderate to possibly some of the most 
potent PARP inhibitors tested so far. The few studies carried out suggest the 
epoxide 43 and the propenoic acid derivative 125 are possibly irreversible 
inhibitors but more extensive investigation into this concept is required.
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Conclusions
Several novel benzamide derivatives have been synthesised and evaluated for 
their effect on PARP activity. Two benzamides with electrophilic side chains 
have been prepared. The first, 3-chloromethylbenzamide, was at least as potent 
as 3-aminobenzamide as a PARP inhibitor. The second, 3-(oxiran-2- 
yl)benzamide, was a very potent PARP inhibitor; one of the most potent of its 
benzamide class. This compound was also more freely soluble in the aqueous 
buffer used in the assay than were most of the other compounds tested. 
Approaches were made towards the asymmetric synthesis of benzamides with 
chiral substituents. The preparation of chiral alcohols of >95% enantiomeric 
purity was carried out using baker's yeast reduction of the corresponding ketones. 
Several investigations into the synthesis of benzamides with cyclic side chains 
were also carried out.
Various methods of synthesis of isoquinolinones have been investigated and 
several novel isoquinolin-l-one derivatives have been prepared. The successful 
preparation of 5-bromoisoquinolinone and 5-iodoisoquinolinone, by the "one- 
pot" Curtius rearrangement of the corresponding substituted 3-phenylpropenoyl 
azides followed by cyclisation, allowed investigations into the C-metallation of 
isoquinolinones. 5-Bromoisoquinoline was successfully lithiated and treated with 
benzaldehyde to give 5-(a-hydroxyphenylmethyl)isoquinoline. However, an N- 
protected form of the equivalent isoquinolinone was not successfully coupled to 
a selection of electrophiles. 5-Iodoisoquinolinone was coupled to several alkenes 
using the palladium-catalysed Heck reaction. One product of these reactions was 
3-(l-oxoisoquinolin-5-yl)propenoic acid. This has an electrophilic side chain and 
was designed as an irreversible inhibitor. However, it was not as potent as might 
be expected for an isoquinolinone, possibly owing to the electron-withdrawing 
nature of the side chain. The Heck reaction with 5-iodoisoquinolinone should 
prove a very useful method of synthesising many complex isoquinolinone
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derivatives. Several approaches towards the synthesis of l-(l-oxoisoquinolin-5- 
yl)ribose have been made. Development of these ideas and synthesis of this 
compound will be both synthetically challenging and biologically interesting.
Some preliminary studies have been carried out to investigate the effect of 
pre-incubating the inhibitors with PARP before adding the substrate. The initial 
results suggest that the inhibition is increased in two cases, these compounds 





All melting points were determined on a Reichert-Jung Thermo Galen Kofler 
Block and are uncorrected. Kugelrohr distillations were carried out using Biichi 
GKR51 apparatus; the boiling points given correspond to the Kugelrohr oven 
temperature. Optical rotations were determined in an Optical Activity Ltd 
polarimeter type AA-10 in dichloromethane solution at ambient temperature. 
NMR spectra were recorded on a Jeol GX270 spectrometer (270.05 MHz !H; 
67.8 MHz 13C) and a Jeol EX 400 (399.65 MHz 100.4 MHz 13C, 376.05 
MHz 19F). Tetramethylsilane was used as an internal standard for samples 
dissolved in CDCI3 , (CD3)2SO, CD3OD or CD3CO2D. 3- 
(Trimethylsilyl)propanoic-2,2,3,3-d4 acid sodium salt was used for samples 
dissolved in D20. Multiplicities are indicated as follows; s (singlet), bs (broad 
singlet), d (doublet), dd (doublet of doublets), t (triplet), q (quartet), qu (quintet) 
and m (multiplet). IR spectra were recorded on a Perkin-Elmer 782 IR 
spectrometer, either as a liquid film (film) or as a KBr disc (KBr); Vmax values are 
given in cm'1. Mass spectra were obtained by electron impact (El), chemical 
impact (Cl), or fast atom bombardment (FAB) using a VG7070E spectrometer. 
Data are reported in the form m/z (intensity relative to base = 100) for selected 
ions. Analytical thin layer chromatography (TLC) was carried out using Merck 
Keiselgel 60F plates or Polygram Alox N plates (aluminium oxide on polyester), 
visualisation was achieved by UV light, iodine or phosphomolybdic acid. Flash 
chromatography was performed using Merck Silica Gel 60 (0.040-0.063mm) 
flash silica.
Where repetitive experimental procedures were employed, only one description 
is provided. All solutions were aqueous unless otherwise stated. Solvents were 
evaporated under reduced pressure. Solutions in organic solvents were dried 
using anhydrous MgSC>4, unless otherwise noted. Solvents were distilled from
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the indicated drying agents according to standard procedures: Carbon 
tetrachloride, acetonitrile (phosphorus (V) oxide); tetrahydrofuran 
(sodium/benzophenone); triethylamine (potassium hydroxide).
The baker's yeast used in the asymmetric reductions was obtained from Phipps 
Bakery, George Street, Bath.
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c o n h 2
1
3-Chloromethylbenzamide 1
3-Chloromethylbenzoyl chloride 2 (2.85 g, 15.1 mmol) was dissolved in diethyl 
ether (25 ml) and a dried solution of ammonia in diethyl ether (4% w/v, 200 ml) 
was added in small portions. A white precipitate formed. The mixture was stirred 
for 30 min then washed with water. The organic layer was washed twice with 
10% w/v sulphuric acid, with water, then dried and concentrated to give 1 (2.27 
g, 89%) as colourless needles; Rf = 0.38 (ethyl acetate / hexane, 1:1); mp 118- 
120°C (from ethyl acetate / hexane (lit.,261 119-120°C); IR (KBr) 3360, 3190 (N- 
H), 1655 (amide I), 1625 (amide II), 705 (C-Cl); 'H NMR (CDC13, (CD3)2SO) 5
4.64 (2 H, s, CH2C1), 6.34 (1 H, bs, NH), 7.30 (1 H, bs, NH), 7.44 (1 H, t, J  = 7.7 
Hz, 5-H), 7.54 (1 H, d, J  = 7.7 Hz, 4-H), 7.84 (1 H, d, J  = 7.7 Hz, 6-H), 7.94 (1 
H, s, 2-H); MS (El) 169 (M+[3SC1], 58), 171 (M+[37C1], 18).
c o n h 2
4
(+)-3-(2,2-Dimethyl-l,3-dioxolan-4-yI)benzamide 4
Freeze-dried (+)-3-(l,2-dihydroxyethyl)benzamide) 6 (62 mg, 0.34 mmol), 2,2- 
dimethoxypropane (1 ml) and 4-methylbenzenesulphonic acid (1 mg) were 
stirred at room temperature for 3 d. Ethyl acetate (50ml) was added to dissolve 
the white precipitate that had formed and the solution was then washed with 10% 
w/v sodium carbonate solution and saturated sodium chloride solution, dried and 
concentrated to give 4 (55 mg, 82%) as a white solid; Rf = 0.52 (methanol / ethyl 
acetate, 1:19); mp 128-130°C; [a]D20 = +39.2 (c 2.5, dichloromethane); *H NMR 
(CDC13) 8 1.50 (3 H, s, CH3), 1.57 (3 H, s, CH3), 3.70 (1 H, t, J = 8.0 Hz,
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CHaHb), 4.35 (1  H, dd, J  = 8.0, 6.2 Hz, CHaHb), 5.13 (1  H, dd, J  = 8.0, 6 .2  Hz, 
CHcO), 5.71 (1 H, bs, NH), 6.11 (1 H, bs, NH), 7.57 (1 H, t, J  = 7.6 Hz, 5-H), 
7.55 (1 H, dt, J = 7.6,1.5 Hz, 4-H), 7.73 (1 H,dt, J = 7.6, 1.5 Hz, 6 -H), 7.82 (1 H, 
t, J  = 1.5 Hz, 2-H); MS (FAB*) 222.1153 (MH+, 100) C12H15NO3 requires 
222.1130,164(34).
CONH2 
J s .  JOH
6
(+)-3-(l,2-Dihydroxyethyl)benzamide 6
(+)-3-(l,2-Dihydroxyethyl)benzonitrile 18 (330 mg, 2.2 mmol) in ethanol (6.5 
ml), was treated with 0.5 M sodium hydroxide (1.0 ml, 0.52 mmol) and 27.5 % 
w/v hydrogen peroxide solution (0.85 ml, 6 .8  mmol). The reaction mixture was 
heated to 50°C for 1 h, allowed to cool and was neutralised with 2 M 
hydrochloric acid solution. The solvent was removed and the residue dried to 
give 6  (366 mg, 2.2 mmol) as a colourless gum; Rf = 0.1 (methanol / chloroform, 
1:9); *H NMR ((CD3)2SO) 3.45 (2 H, d, J  = 6.4 Hz, CH2), 4.0 (2 H, bs, OH), 
4.57 (1 H, t, J  = 6.4 Hz, CH), 7.32 (1 H, bs, NH), 7.37 (1 H, t, J = 7.7 Hz, 5-H), 
7.48 (1 H ,d ,7 =  7.7 Hz, 4-H), 7.74 (1 H, d, /  = 7.7 Hz, 6 -H), 7.85 (1 H, s, 2-H), 





3-Aminoacetophenone 10 (15.0 g, 0.111 mol) in a mixture of iced water (28 ml) 
and concentrated hydrochloric acid (28 ml) was diazotized by slow addition of 
sodium nitrite (8.0 g, 0.115 mol) in iced water (36 ml). Following neutralisation
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with sodium carbonate, the diazonium salt was added to a solution of copper 
cyanide (12.0 g, 0.134 mol) and potassium cyanide (17.0 g, 0.262 mol) in water 
(45 ml) heated to 60-70°C. The resulting mixture was stirred at 100°C for 15-20 
min. The cooled mixture was extracted twice with ethyl acetate washed twice 
with water, with 10% w/v sulphuric acid and with water. The organic phase was 
dried and concentrated to give an orange-brown solid. Recrystallization from 
hexane provided 3- acetylbenzonitrile 9 (7.54 g, 47%) as pale orange crystals; Rf 
= 0.77, (ethyl acetate / hexane, 1:1); mp 93-94°C (lit.,262 98-100°C); IR (KBr) 
2240 (O N ), 1695 (C=0); !H NMR (CDC13) 6 2.64 (3 H, s, COCH3), 7.62 (1 H, 
t, J=  7.7 Hz, 5-H), 7.85 (1 H, dt, J=  7.7, 1.7 Hz, 6-H), 8.18 (1 H, dt, J=  7.7, 1.7 
Hz, 4-H), 8.24 (1 H, t, J=  1.7 Hz, 2-H).
.c o n h 2
11
3-Acetylbenzamide 11
3-Acetylbenzonitrile 9 (5.0 g, 34.4 mmol) was suspended in ethanol (50 ml) and 
0.5 M sodium hydroxide solution (17 ml, 8.5 mmol) was added. To the stirred 
mixture, 27.5% w/v hydrogen peroxide solution (15 ml, 121 mmol) was added 
dropwise, whilst the temperature of the reaction mixture was not allowed to 
exceed 50°C. On completion of the exothermic reaction, in which oxygen was 
evolved, the reaction mixture was stirred at 50°C for 1 h. Following 
neutralisation with 10 % w/v sulphuric acid, the volume of ethanol was reduced 
in vacuo and the residue taken up into dichloromethane. The organic extract was 
washed with water and brine, then dried and concentrated to give 11 (5.48 g, 
97%) as a white crystalline solid; Rf = 0.17 (ethyl acetate / hexane, 1:1); mp 
125.5-126.5°C; IR (KBr) 3380, 3185 (N-H), 1680 (C=0 acetyl), 1655, 1630 
(C=0, amide); >H NMR (CDC13) 5 2.67 (3 H, s, COCH3), 5.93 (1 H, bs, NH), 
6.30 (1 H, bs, NH), 7.58 (1 H, t, J = 7.8 Hz, 5-H), 8.06 (1 H, dt, J  = 7.8, 1.5 Hz,
168
4-H), 8.12 (1 H, dt, 7=  7.8, 1.5 Hz, 6 -H), 8.40 (1 H, t, J=  1.5 Hz, 2-H); MS (El) 
164.0671 (M+, 7) (13C12C9H9N 0 2 requires 164.0667), 163.0636 (M+, 75) 
(C9H8NO2 requires 163.0633), 148 (100); Anal. Calcd. for C9H9NO2: C, 66.25; 
H, 5.56; N, 8.58. Found C, 66.1; H, 5.55; N, 8.20. [11 is reported in the 




Method A: 3-Acetylbenzonitrile 9 (1.0 g, 6.9 mmol) was dissolved in ethanol 
(30 ml) and a suspension of sodium borohydride (0.8 g, 21.1 mmol) in ethanol 
(10 ml) was added slowly. The mixture was stirred for 1 h. 2 M hydrochloric acid 
was then added dropwise until effervescence ceased. Following concentration, 
ethyl acetate was added and the organic extract was washed twice with water, 
dried and the solvent was removed to give an orange oil, which was crude 12 
(0.96 g, 95%); Rf = 0.4 (methanol / chloroform, 1:19); IR (film) 3400 (O-H), 
2210 (C=N), 1070 (C-O); NMR (CDC13) 5 1.49 (3 H, d, J  = 6.6 Hz, CH3), 2.3 
(1 H, bs, OH), 4.94 (1 H, q, J = 6.6. Hz, CH), 7.45 (1 H, t, J  = 7.7 Hz, 5-H), 7.55 
(1 H, dt, J = 7.7, 1.5 Hz, 4-H), 7.62 (1 H, dt, J=  7.7, 1.5 Hz, 6-H), 7.68 (1 H, t, J 
= 1.5 Hz, 2-H); MS (Cl, iso-butane) 148 (MH+, 100). (Although NMR showed 
that the crude product was mainly (±)-3-(l-hydroxyethyl)benzonitrile, TLC 
showed other spots, however an attempt to purify the product by flash 
chromatography (methanol / chloroform, 1:19) gave only a small percentage of 
the product and it was concluded that degradation occurs on silica.)
Method B: 3-Acetylbenzonitrile 9 (1.0 g, 6.89 mmol) was suspended in ethanol 
(12 ml) at 0°C. Sodium borohydride (156 mg, 4.1 mmol) was added and the 
mixture was stirred at 0°C for 30 min, followed by 1 hour at RT. Procedure
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continued as for Method A, above, to give 12 (1.01 g, 100%) an orange oil, pure 
by NMR analysis; data identical to those above.
(±)-3-(l-Hydroxyethyl)benzamide 13
3-Acetylbenzamide 11 (500 mg, 3.1 mmol) was treated with sodium borohydride 
at 0°C as described in Method B for the corresponding benzonitrile 12 above. 
This yielded 13 (311 mg, 62%) as a white crystalline solid; Rf = 0.57 (acetone / 
hexane, 2:1); mp 127-129°C; IR (KBr) 3360, 3190 (N-H), 1670 (amide I), 1620 
(amide II); *H NMR ((CD3)2SO) 6 1.33 (3 H, d, / =  6.6 Hz, CH3), 4.76 (1 H, ca. 
qu, CH), 5.24 (1 H, d, J = 4.0 Hz, OH), 7.32 (1 H, bs, NH), 7.38 (1 H, t, J  = 7.7 
Hz, 5-H), 7.49 (1 H, d, J  = 7.7 Hz, 4-H), 7.72 (1 H, d, J  = 7.7 Hz, 6-H), 7.86 (1 
H, s, 2-H), 7.95 (1 H, bs, NH); MS (El) 166.0867 (M+, 100) (C9HnN02 requires 
166.0868).
(-)-3-(l,2-Dihydroxyethyl)benzonitrile 16
To a fermenting slurry of bakers' yeast (88 g), water (880 ml) and sucrose (88 g) 
was added 3-(2-hydroxyacetyl)benzonitrile 17 (600 mg, 3.7 mmol). The mixture 
was stirred at 30°C for 7 days. Diethyl ether (100 ml) and Celite® (100 g) were 
added to the mixture and stirring continued for a further 15 min. The slurry was 
then filtered through a sintered funnel and the residue was washed with diethyl 
ether (2 x 50 ml). The aqueous filtrate was extracted with diethyl ether (5 x 
100ml) and the combined organic extracts were dried and concentrated. Flash 
chromatography (ethyl acetate / hexane, 1:1 ->3:2) gave 16 (268 mg, 44%) as a
.c o n h 2
13
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white solid; Rf = 0.13 (ethyl acetate / hexane, 1:1); mp 64-66°C; [a]D20 = -46.6°
(c 1.0, DCM); *H NMR (CDC13) 5 2.33 (2 H, bs, OH), 3.62 (1 H, dd, J  = 11.4,
7.71 (1 H, s, 2-H); MS (Cl) 164 (MET, 100), 146 (32).
The MTPA esters of (+) and (-) 3-(l,2-dihydroxyethyl)benzonitrile gave signals 
in their NMR spectra which were too similar to resolve and no enantiomeric 
excess calculations were possible. Attempts to separate the signals from 
enantiomers using praesodimium [Pr(hfc)3] and europium [Eu(hfc)3] chiral shift 
reagents were unsuccessful. However comparison of optical rotations of 18 and 
16 would suggest an enantiomeric excess of >95% for 16.
3-(2-HydroxyacetyI)benzonitrile 17
3-(2-Hydroxyacetyl)benzonitrile 17 was prepared by the general method 
described by Moriarty et al.m  3-Acetylbenzonitrile 9 (1.0 g, 6.9 mmol) was 
added to a stirred solution of trifluoroacetic acid (1.06 ml, 13.8 mmol), water (8 
ml) and acetonitrile (40 ml). [Bis(trifluoroacetoxy)iodo]-benzene (5.9 g, 13.8 
mmol) was added and the solution heated to reflux for 8 hours. The reaction was 
monitored by TLC. The acetonitrile was removed and the residue was partitioned 
between ethyl acetate and water. The aqueous phase was extracted three times 
with ethyl acetate. The combined organic extracts were washed with saturated 
sodium hydrogen carbonate solution, and were dried and concentrated. Flash 
chromatography (ethyl acetate / hexane, 1:1) gave the starting material 9 (0.05 g, 
5%); mp 93-94°C (lit.262 98-100°C); IR spectrum matched that of an authentic 
sample; and 3-(2-hydroxyacetyl)benzonitrile 17 (0.31 g, 28%) as white crystals;
7.7 Hz, CHaHbOH), 3.81 (1 H, dd, 7 =  11.4, 3.6 Hz, CHaHbOH), 4.87 (1 H, dd, 
J  = 7.7, 3.6 Hz, CHcOH), 7.48 (1 H, t, J  = 7.7 Hz, 5-H), 7.6 (2 H, m, 4,6-H2),
17
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Rf = 0.37 (ethyl acetate / hexane, 1:1); mp 102-105°C; IR (KBr) 3400-3600 (O-
H), 2200 (C=N), 1650-1700 (C=0); W  NMR ((CD3)2SO) 6 3.37 (1 H, bs, OH),
100); MS (El) 161.0471 (M+, 5) (C9H7N 02 requires 161.0432) 130 (100), 102 
(42). [17 is reported in the literature264 but no data are given.]
(+)-3-(l,2-DihydroxyethyI)benzonitrile 18
(+)-3-(2-Acetoxy-l-hydroxyethyl)benzonitrile 30 (0.50 g, 2.4 mmol) was treated 
with ammonia in methanol as described for the synthesis of 32, Method C. This 
gave 18 (0.36 g, 92%) as a white crystals; Rf = 0.3 (methanol / chloroform, 1:9);
[a]D20 +46.6° (c 2.0, dichloromethane); ‘H NMR (CDC13) 8 2.86 (2 H, bs, OH), 
3.60 (1 H, dd, J  = 11.4, 7.9 Hz, CHaHbOH), 3.78 (1 H, dd, J  = 11.4, 3.3 Hz, 
CHaHbOH), 4.84 (1 H, dd, J  = 7.9,3.3 Hz, CHcOH), 7.46 (1 H, t, J  = 7.7 Hz, 5- 
H), 7.60 (2 H, m, 4,6-H2), 7.71 (1 H, s, 2-H); MS (FAB+) 164.0657 (MH+, 100 
%) (C9H9N 02 requires 164.0712).
3-(2-Acetoxyacetyl)benzonitrile 24
3-(Bromoacetyl)benzonitrile 25 (5.50 g, 24.6 mmol) and potassium acetate (2.40
g, 24.5 mmol) were dissolved in ethanol (100 ml). To the stirred solution, 
sodium iodide (0.36 g, 2.4 mmol) was added and the solution was refluxed for 6
h. After removal of ethanol, the residue was extracted with ethyl acetate, washed
4.91 (2 H, s, CH2), 7.68 (1 H, t, /  = 7.7 Hz, 5-H), 7.92 (1 H, d, J = 7.7 Hz, 4-H), 
8.15 (1 H, d, J=  7.7 Hz, 6-H), 8.22 (1 H, s, 2-H); MS (Cl, iso-butane) 162 (MH+
.o c o c h 3 cr CH(OEt)2
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three times with water and dried. Concentration, followed by flash 
chromatography (hexane / ethyl acetate, 4:1) gave the following products: 
3-(Diethoxyacetyl)benzonitrile 27 (160 mg, 3%); a yellow oil; Rf =0.45 (hexane 
/ ethyl acetate, 4:1); IR (KBr) 2240 (O N ), 1705 (C=0); JH NMR (CDC13) 5
1.26 ( 6  H, t, 7 = 7.2 Hz, 2 x CH3 ), 3.65 (2 H, dq, Jgem = 9.5 Hz, 7vic = 7.2 Hz, 2 x 
OCHaHbCH3), 3.81 (2 H, dq, 7gem = 9.5 Hz, 7vic = 7.2 Hz, 2 x OCHAHBCH3), 
7.59 (1 H, t, 7 = 7.7 Hz, 5-H), 7.83 (1 H, dt, 7 = 7.7, 1.5 Hz, 6 -H), 8.39 (1 H, dt, 7 
= 7.7, 1.5 Hz, 4-H), 8.51 (1 H, t, 7 = 1.1 Hz, 2-H); 13C NMR (CDC13) 6  15.00 (2 
x CH3), 64.01 (2 x CH2), 103.68 (CHCO), 112.58 (Cq), 117.92 (Cq), 129.14 (5-
C), 133.71 (2-C), 133.78 (4-C), 134.07 (O N ), 135.97 (6 -C), 192.03 (C=0); MS 
(FAB+) 234.1137 (MH+, 100) (C13H 16NO3 requires 234.1130). 
3-Acetylbenzonitrile 9 (1.15 g, 32%); this fraction was not pure and did contain 
a small amount of 27; Rf = 0.31 (hexane / ethyl acetate, 4:1); mp 83-87°C (lit.262 
98-100°C); lU NMR (CDC13) 6  2.65 (3 H, s, CH3), 7.65 (1 H, t, 7 = 7.7 Hz, 5-H), 
7.86 (1 H, dt, 7 = 7.7, 1.5 Hz, 6 -H), 8.18 (1 H, dt, 7 = 7.7, 1.5 Hz, 4-H), 8.24 (1 
H, t, 7 = 1.5 Hz, 2-H).
3-(2-Acetoxyacetyl)benzonitrile 24 (3.20 g, 64%); white crystals; Rf = 0.21 
(hexane / ethyl acetate, 4:1); mp 70-72°C; IR (KBr) 2240 (O N ), 1755, 1710 
(C=0); m  NMR (CDC13) 6  2.24 (3 H, s, CH3), 5.31 (2 H, s, CH2), 7.66 (1 H, t, 7 
= 7.8 Hz, 5-H), 7.90 (1 H, dt, 7 = 7.8, 1.3 Hz, 6 -H), 8.14 (1H, dt, 7=  7.8, 1.3 Hz,
4-H), 8.20 (1 H, t, J  = 1.3 Hz, 2-H); MS (Cl, iso-butane) 204 (MH+, 100); Anal. 









Method A: To a solution of 9 (0.80 g, 5.5 mmol) in glacial acetic acid (3 ml), 
bromine (0.3 ml, 5.5 mmol) was added slowly. The orange solution was stirred 
for 3 h. The dichloromethane extract was washed three times with sodium 
carbonate solution (10%w/v), with water and dried. Concentration and flash 
chromatography (hexane / ethyl acetate, 9:1), gave two products:
3-(Dibromoacetyl)benzonitrile 26 (0.10 g, 6 %); a white solid; Rf = 0.89 (ethyl 
acetate - hexane, 1:1); mp 84.5-86°C; IR (KBr) 2240 (O N ), 1705 (C=0); >H
Hz, 2-H); MS (Cl, iso-butane) 306 (M[81Br,81Br]H+, 40), 304 (M[79Br,81Br]H+, 
82), 302 (M[79Br,79Br]H+, 42); Anal. Calcd. for C9H5Br2NO: C, 35.68; H, 1.66;
3-(Bromoacetyl)benzonitrile 25 (0.40 g, 32%); white crystalline solid; Rf = 0.82 
(ethyl acetate / hexane, 1:1); mp 65-67°C (lit.265 65.5-66.5°C); IR(KBr) 2240 (C=
8.28 (1 H, t, J  = 1.5 Hz, 2-H); MS (Cl, iso-butane) 224 (M[79Br]H+, 100), 226 
(M[81Br]H+, 98).
Method B: 3-Acetylbenzonitrile 9 (3.0 g, 20.7 mmol) was dissolved in 
chloroform (15 ml) and the solution cooled to 0°C. Bromine (1.1 ml, 21.3 mmol) 
was added dropwise to the stirred solution over the course of 30 min. The 
solution was stirred at ambient temperature for 2 h. The solvent was evaporated, 
leaving an orange solid which consisted of two products; these were separated by 
flash chromatography (hexane / ethyl acetate, 9:1) to give:
NMR (CDC13) 8  6.56 (1 H, s, CHBr2), 7.68 (1 H, t, J  =7.9 Hz, 5-H), 7.92 (1 H, 
dt, J  = 7.9, 1.5 Hz, 6 -H), 8.37 (1 H, dt, J = 7.9, 1.5 Hz, 4-H), 8.42 (1 H, t, J  = 1.5
N, 4.62. Found: C, 35.65; H, 1.62; N, 4.58.
N), 1710 (C=0); *H NMR (CDC13) 8  4.43 (2 H, s, CH2Br), 7.67 (1 H, t, /  = 7.9 
Hz, 5-H), 7.90 (1 H, dt, / =  7.9, 1.5 Hz, 6 -H), 8.22 (1 H, dt, J = 7.9, 1.5 Hz, 4-H),
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3-(Dibromoacetyl)benzonitrile 26 (0.50 g, 8 %); a white crystalline solid; mp
84.5-86°C; *H NMR data were identical to those above.
3-(Bromoacetyl)benzonitrile 25 (3.60 g, 78%); white needles; mp 70-71°C 




Bakers’ yeast (7.5 g) was suspended in lukewarm tap water (56 ml) and sucrose 
(11.2 g) was added gradually. To this fermenting slurry, powdered 3-(2- 
acetoxyacetyl)benzonitrile 24 (0.76 g, 3.7 mmol) was added. The mixture was 
stirred at ambient temperature, in a conical flask closed with a cotton wool plug 
for 8  h. The slurry was then filtered through a Celite® pad and was extracted with 
diethyl ether (4 x 30 ml). The extracts were dried and concentrated to give a pale 
yellow oil. Flash chromatography (ethyl acetate / hexane, 2:3) gave two 
colourless oils:
(±)-3-(l,2-DihydroxyethyI)benzonitrile 32 (14 mg, 2%), Rf = 0.21 (ethyl 
acetate / hexane, 1:1); *H NMR (CDC13) 5 2.5 (2 H, bs, OH), 3.62 (1  H, dd, 7 = 
1 1 , 8  Hz, CHaHbOH), 3.80 (1 H, dd, 7=  11 Hz, 3.5 Hz, CHaHbOH), 4.87 (1 H, 
dd, 7 = 8 , 3.5 Hz, CHcOH), 7.48 (1 H, t, 7 = 7.7 Hz, 5-H), 7.6 (2 H, m, 4,6-H2), 
7.71 (1 H, s, 2-H).
3-(2-Acetoxy-l-hydroxyethyl)benzonitrile 30 (0.65 g, 85%); Rf = 0.49 (ethyl 
acetate / hexane, 1:1); [a]D20 +34.9° (c 2.9, dichloromethane); IR (film) 3400-
3500 (OH), 2240 (C=N), 1740 (C=0); lH NMR (CDC13) 8  2.11 (3 H, s, CH3),
3.04 (1 H, bs, OH), 4.12 (1 H, dd, 7=  11.6, 7.9 Hz, CHaHbOAc), 4.30 (1 H, dd, 
7 = 11.6, 3.5 Hz, CHaHbOAc), 5.01 (1 H, dd, 7 = 7.9, 3.5 Hz, CHcOH), 7.49 (1 
H, t, 7 = 7.7 Hz, 5-H), 7.62 (2 H, m, 4,6-H2), 7.73 (1 H, t, 7 = 1.6 Hz, 2-H); MS 
(FAB+) 206.0869 (MH+, 74) (CnHnN03 requires 206.0817), 188 (100).
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A sample of 30 was transformed into the (R)-(+)-a-methoxy-a-(trifluoromethyl)- 
phenylacetic acid (MTPA) ester (see procedure below). An enantiomeric excess 
of 96% was calculated using the integration of the signal of the acetoxy group in 
the 270.05 Mz *H NMR spectrum. The methyl group showed singlets centred at
2.00 and 2.07 ppm (ratio 1:1 and 98:2 for the derivatives from racemic 33 and 
optically active 30 3-(2-acetoxy-l-hydroxyethyl)benzonitrile).
Similarly in the 19F NMR spectrum, the CF3 group showed signals at -71.5 and 
-71.9 ppm. Integration ratios were 1:1 and 98:2 corresponding to the esters of the 
racemic and asymmetrically prepared alcohols, respectively. Again 96% ee was 
calculated.
3-(l,2-Dihydroxyethyl)benzonitrile 32
Method A: 3-(2-Hydroxyacetyl)benzonitrile 17 (80 mg, 0.50 mmol) was 
dissolved in ethanol (3 ml) and sodium borohydride (9.5 mg, 0.25 mmol) was 
added. The solution was stirred and the reaction followed by TLC (methanol / 
chloroform, 1:9). After a period of 30 min a further portion (10 mg) of sodium 
borohydride was added, and this was repeated for a total of 3 h. The ethanol was 
removed and the residue was extracted with ethyl acetate, the extracts were 
washed with water, dried and concentrated to give 32 (70 mg, 8 6 %), as a pale 
yellow viscous liquid; Rf = 0.3 (methanol / chloroform, 1:9); IR (film) 3340- 
3410 (O-H), 2220 (C=N); 1HNMR (CDC13) 8  2.9 (1 H, bs, OH), 3.5 (1 H, bs, 
OH), 3.60 (1 H, dd, J= 11.3, 3.2 Hz, CHAHBOH), 3.78 (1 H, dd, / =  11.3, 8.1 Hz, 
CHaHbOH), 4.85 (1 H, dd, /=  3.2, 8.1 Hz, CHcOH), 7.47 (1 H, t, J = 7.7 Hz, 5- 
H) 7.6 (2 H, m, 4,6-H2), 7.72 (1 H, s, 2-H).
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Method B: A solution of the mixture containing (±)-3-(2-acetoxy-l- 
hydroxy)benzonitrile 30 (250 mg, 1.2 mmol) (see method above) and 
concentrated aqueous ammonia solution (2.5 ml) in methanol (7.5 ml) was stirred 
for 45 min. The solvent was removed and the residue was taken up in anhydrous 
tetrahydrofiiran and again concentrated. This was repeated twice and finally the 
residue was taken up in dichloromethane the solvent was evaporated to give 32 
(183 mg) as a slightly yellow viscous oil; Rf = 0.3 (methanol / chloroform, 1:9); 
IR (film) 3340-3410 (O-H), 2220 (C^N); *H NMR (CDCI3) 8  2.25 (1 H, bs, OH),
2.9 (1 H, bs, OH), 3.62 (1 H, dd, J = 11.3,7.5 Hz, CHaHbOH), 3.80 (1 H, dd, J =
11.3, 3.4 Hz, CHaHb), 4.86 (1  H, dd, J  = 7.5, 3.4 Hz, CHcOH), 7.48 (1 H, t, J =








(±)-3-(2- Acetoxy- l-hydroxyethyI)benzonitrile 33
To 3-(2-acetoxyacetyl)benzonitrile 24 (300 mg, 1.5 mmol) in propan-2-ol (7 ml), 
was added sodium borohydride (95 mg, 2.5 mmol), dissolved in a minimum 
amount of propan-2-ol / water (5:1). The solution immediately became orange in 
colour. After 10 min, sufficient 2 M hydrochloric acid was added to dissipate the 
orange colour. The product was extracted with dichloromethane, washed twice 
with water, dried and concentrated to give a yellow oil (0.27 g). *H NMR 
analysis showed three products to be present:
3-(l,2-Dihydroxyethyl)benzonitrile 32 (32 mg, 13%); !H NMR (CDC13) 8  2.9 
(2 H, bs, OH), 3.62 (1 H, m, CH2) 3.80 (1 H, m, CH2), 4.85 (1 H, m, CH), 7.48 
(1 H, t, J = 7.7 Hz, 5-H), 7.6 (2 H, m, 4,6-H2), 7.7 (1 H, s, 2-H).
3-(l-Acetoxy-2-hydroxyethyl)benzonitrile 34 (40 mg, 13%); !H NMR (CDC13) 
8  2.17 (3 H, s, CH3), 2.9 (1 H, bs, OH), 3.8 (2 H, m, CH2), 5.85 (1 H, m, CH),
7.5 (1 H, t, /  = 7.7 Hz, 5-H), 7.64 (2 H, m, 4,6 -H), 7.7 (1 H, s, 2-H).
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3-(2-Acetoxy-l-hydroxyethyl)benzonitrile 33 (198 mg, 65%); lH NMR
General method for the formation of a-Methoxy-a-(trifluoromethyl)- 
phenylacetic acid (MTPA) esters from racemic alcohols.
MTPA chloride: Oxalyl chloride in dichloromethane (2.0 M, 0.15 ml, 0.3 
mmol) was added to either enantiomerically pure or racemic MTPA (234 mg, 0.1 
mmol) in dichloromethane (0.85 ml) and dimethylformamide (10 pi) was added. 
The mixture was stirred overnight. The solution was then concentrated and the 
residue taken up into dichloromethane. The solvent was evaporated. This was 
repeated three times with dichloromethane and then once with hexane.
MTPA esters: A solution of racemic alcohol (0.1 mmol), pyridine (0.01 ml) and
4-(dimethylamino)pyridine (1 mg) in dichloromethane (1 ml) was added to the 
freshly prepared MTPA chloride. The mixture was stirred overnight and then 
partitioned between dichloromethane (3 x 15ml) and potassium carbonate 
solution (10% w/v, 15ml). The organics were washed with copper sulphate 
solution (5% w/v) dried, concentrated and analysed by and 19F NMR.
(CDC13) 8  2.11 (3 H, s, COCH3), 3.1 (1 H, bs, OH), 4.12 (1 H, dd, J  = 11.5, 3.5 
Hz CHaHbO), 4.29 (d, 1H, / =  11.5, 8.5 Hz CHaHbO), 5.03 (dd, 1H, J=  8.5, 3.5 
Hz CHcOH), 7.5 (t, 1H, 5-H), 7.6 (m, 2H, 4,6-H2), 7.7 (s, 1H, 2-H).
Attempts to separate these components were unsuccessful.
ROOC (S)-MTPA ester COOR (R)-MTPA ester
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(-)-3-(l,2-DihydroxyethyI)benzamide 36
(-)-3-(2-Acetoxy-l-hydroxyethyl)benzonitrile 16 (125 mg, 0.77 mmol) in ethanol 
(2.5 ml) was treated with 0.5 M sodium hydroxide solution (0.35 ml, 0.18 mmol) 
and 27.5% w/v hydrogen peroxide solution (0.3 ml, 2.4 mmol) as described for 
the synthesis of 6  above, to give a white glue, 36 (139 mg, 100%); Rf = 0.1 
(chloroform / methanol, 9:1); !H NMR ((CD3)2SO) 5 identical to that of the 





(±)-3-(l,2-Dihydroxyethyl)benzonitrile 32 (170 mg, 1.0 mmol) in ethanol (5 ml), 
was treated with 0.5 M sodium hydroxide solution (0.5 ml, 3.6 mmol) and 27.5% 
w/v hydrogen peroxide solution as described for the synthesis of 6  above to give 
37 (188 mg, 99%) as a white gum; Rf = 0.08 (methanol / chloroform, 1:9); IR 
(KBr) 3360, 3200 (N-H), 3200-3500 (O-H), 1670 (amide I), 1615 (amide II); 'H 
NMR ((CD3)2SO) 8  3.44 (2 H, d, J  = 5.8 Hz, CH2), 3.5 (2 H, bs, OH), 4.57 (1 H, 
t, J=  5.8 Hz, CH), 7.33 (1 H, bs, NH), 7.37 (1  H, t, J  = 7.7 Hz, 5-H), 7.48 (1 H, 
d, J = 7.7 Hz, 4-H), 7.73 (1 H, d, J  = 7.7 Hz, 6 -H), 7.85 (1 H, s, 2-H), 7.96 (1 H, 





To a solution of (+)-3-(l,2-dihydroxyethyl)benzonitrile 18 (65 mg, 0.40 mmol) in 
dry carbon tetrachloride (1.4 ml), thionyl chloride (0.035 ml, 0.48 mmol) in dry 
carbon tetrachloride (0.4 ml) was added. The mixture was heated to reflux for 30 
min, then allowed to cool. The solvent was evaporated to give a brown oil (85 
mg) which was carried through to the next stage without further purification. The 
crude product was the cyclic sulphite, 38 (85 mg, ca. 100%); Rf = 0.6 (methanol / 
chloroform, 1:19); ’H NMR ((CD3)2SO) 5 4.26 (1  H, dd, 7 = 8 .8 , 6.5 Hz, CHaHb 
[diastereomer I]), 4.45 (1 H, dd, J  = 9.2, 10.3 Hz, CHaHb [diastereomer II]), 4.9 
(1  H, dd, J  = 9.2, 6 .6  Hz, CHaCHb [II]), 5.05 (1  H, dd, J  = 8 .8 , 6.5 Hz, CHaHb 
[I]), 5.51 (1 H, dd, J  = 10.3, 6 .6  Hz, CHcO [II]), 6.0 (1 H, t, J  = 6.5 Hz, CHcO 
[I]), 7.5-7.8 (2 x 4 H, m, Ar-H* [I, II]).
4-(3-Cyanophenyl)-l,3,2-dioxathiolane-2,2-dioxide 39
Attempted synthesis: To an ice-cold solution of the cyclic sulphite 38 (85mg, 
0.41 mmol) in acetonitrile (0.4 ml) and carbon tetrachloride (0.4 ml), sodium 
iodate (0.128 g, 0.60 mmol) was added, followed by ruthenium (El) chloride (1 
mg) and water (0.6 ml). The resulting mixture was stirred for 60 min at ambient 
temperature. After dilution with diethyl ether (4 ml), the organic extract was 
washed successively with water, saturated sodium hydrogen carbonate solution
39
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and saturated sodium chloride solution was dried and concentrated. This gave a 
brown oil which *H NMR analysis showed was mainly the diol 18.
(±)-3-(Oxiran-2-yi)benzamide 43
3-(2-Bromoacetyl)benzamide 43 (0.50 g, 2.1 mmol) was suspended in ethanol ( 6  
ml) and cooled to 0°C. Sodium borohydride (47 mg, 1.2 mmol) was added and 
the mixture was stirred at 0°C for 30 min, then at ambient temperature for 2 h. 
Following the addition of sodium hydroxide solution (1 M 1.5 ml, 1.5 mmol) the 
solution was stirred for 2 0  min at ambient temperature and then for 1 0  min at 
50°C. Water was added and the resulting mixture was extracted three times with 
dichloromethane. The organic extract was washed with brine, dried and 
concentrated to give 43 (331 mg, 98%) as colourless crystals; Rf = 0.38 (hexane / 
acetone, 1:2); mp 95.5-97°C; ‘H NMR ((CD3)2SO) 5 2.89 (1 H, m, oxirane 3-H), 
3.15 (1 H, t, 7 = 4.8 Hz, oxirane 3-H), 3.99 (1 H, m, oxirane 2-H), 7.40 (1 H, bs, 
NH), 7.44 (2 H, m, 4,5-H2), 7.79 (2 H, m, 2,6-H2), 8.01 (1 H, bs, NH); MS 
(FAB+) 164.0736 (MH+, 100) (C9H9N 02 requires 164.0712); Anal Calcd for 
C9H9N 02: C, 66.25; H, 5.56; N, 8.58. Found: C, 66.0; H, 5.67; N, 8.38.
3-(2-Bromoacetyl)benzamide 44
Method A: 3-Acetylbenzamide 11 (2.0 g, 12 mmol) was suspended in 
chloroform (10 ml) and the mixture was cooled to 0°C. Bromine (0.64 ml, 2.0 g, 
12 mmol) in chloroform (5 ml) was added dropwise to the cooled suspension.
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After 2 d, the reaction mixture was heated to 50°C for 1 h. The solvent was 
evaporated. Flash chromatography (methanol /ethyl acetate 1:49) of the solid 
remaining was unsuccessful in separating its components, however, 
recrystallisation of one of the fractions yielded 44 (486 mg, 16%) as colourless 
crystals; Rf = 0.45 (hexane / acetone 1:2); mp 133-135°C (from acetonitrile); lR  
NMR ((CD3)2SO) 5 4.67 (2 H, s, CH2), 6.82 (1 H, bs, NH), 7.59 (1 H, t, J = 7.8 
Hz, 5-H), 8.01 (1 H, bs, NH), 8.12 (1 H, dt, / =  7.8, 1.5 Hz) and 8.21 (1 H, dt, J 
= 7.8, 1.5 Hz) (4,6-H2), 8.57 (1 H, t, J  = 1.5 Hz, 2-H); MS (FAB+) 243.9796 
(([81Br]M+H)+, 100) (C9Hg81BrN02 requires 243.9796), 241.9810
(([79Br]M+H)+, 100) (C9H879BrN0 2 requires 241.9817); Anal. Calcd. for 
CsHgBrNO* C, 44.66; H, 3.33; N, 5.79. Found: C, 44.8; H, 3.33; N, 5.78. 
Method B: 3-Acetylbenzamide 11 (2.0 g, 12 mmol) was added to glacial acetic 
acid (180 ml) warmed to 60°C. Bromine (0.634 ml, 1.966 g, 12 mmol) was added 
to the stirred solution and stirring was continued at ambient temperature for 2.5 
h. The acetic acid was evaporated. Recrystallisation of the residue from 
acetonitrile gave 44 (1.74 g, 48 %) as colourless crystals; data identical to those 





3-Chloromethylbenzamide 1 (0.5 g, 2.9 mmol) in ethanol (1 ml) was added to a 
solution of ethanolamine (0.5 ml, 0.51 g, 8.4 mmol) in ethanol (5 ml) over the 
course of 2 h. The solution was stirred at ambient temperature for 7 d. The 
ethanol was evaporated and the ethanolamine removed on the Kugelrohr 
apparatus to give 47 as a colourless gum; !H NMR ((CD3)2SO) 8  2.83 (2 H, t, /  =
5.5 Hz, CFbCHzOH), 3.58 (2 H, t, J  = 5.5 Hz, CH2OH), 3.83 (2 H, s, PhCH2),
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5.5 (2 H, bs, NH, OH), 7.38 (1 H, bs, NH), 7.41 (1 H, t, / =  8.0 Hz, 5-H), 7.55 (1 
H, d, J  = 8.0 Hz, 6 -H), 7.77 (1 H, d, J = 8.0 Hz, 4-H), 7.90 (1 H, s, 2-H), 8.05 (1 




3-Bromomethylbenzonitrile (5.0 g, 26 mmol) was added in several portions to 
ethanolamine (5.0 ml, 5.1 g, 84 mmol) in ethanol (50 ml). The solution was 
stirred for 7 d. The solvent was evaporated and the residue, in dichloromethane, 
was washed twice with water, dried and concentrated. The product was 
recrystallised from ethyl acetate to give 48 (2.96 g, 6 6 %) as colourless crystals; 
Rf.= 0.23 (ethyl acetate / hexane, 1:1); mp 98-99°C; IR (KBr) 3250 (O-H), 2220 
(CTN); ‘H NMR (CDCI3) 8  2.42 (2 H, bs, NH, OH), 2.78 (2 H, t, J  = 5.1 Hz, 
CH2CH2OH), 3.69 (2 H, t, J = 5.1 Hz, CH2CH2OH), 3.85 (2 H, s, Ar-CH2), 7.44 
(1 H, t, J  = 7.7 Hz, 5-H), 7.55 (2 H, m, 4,6-H2), 7.65 (1  H, s, 2-H); MS (Cl) 
177.1028 (MH+, 100) (Ci0Hi2N2O requires 177.1028), 145 (45); Anal. Calcd. for 
C10H12N2O: C, 68.16; H, 6 .8 6 ; N, 15.90: Found: C, 68.3; H, 6.69; N, 15.7.
3-(Aziridin-l-ylmethyI)benzonitrile 50
Method A: A solution of 3-[N-(2 -Hydroxyethyl)methylaminojbenzonitrile 48 
(0.5 g, 2.8 mmol), dry carbon tetrachloride (0.29 ml, 2.8 mmol), 
triphenylphosphine (0.85 g, 3.2 mmol) and dry triethylamine (0.4 ml, 2.8 mmol) 
in dry acetonitrile (5 ml) was stirred at ambient temperature for 24 h. The
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reaction mixture was filtered and the solid washed with acetonitrile. The filtrate 
was concentrated and the residue exracted four times with hot petroleum ether. 
The combined extracts were stored at 4°C for 48 h. The crystals of 
triphenylphosphine oxide that formed were filtered and the filtrate concentrated 
to give a slightly yellow oil. NMR analysis showed that this was a mixture of 
the desired aziridine 50, the amino alcohol, 48, l,4-di-(3-cyanophen- 
ylmethyl)piperazine 54 and triphenyl phosphine oxide in the molar ratio; 12 : 4 : 
2 : 4 .  However attempts to separate these products by flash chromatography 
(alumina (as above), hexane / ethyl acetate, 7:3), yielded only triphenylphosphine 
oxide (22 mg) and the piperazine 54 (82 mg, 18%) as white crystals; Rf = 0.8 
(hexane / ethyl acetate, 1:1); mp 120-122°C; IR (KBr) 2230 (C=N); ‘H NMR 
(CDCI3) 6  2.48 ( 8  H, bs, piperazine CH2), 3.54 (4 H, s, ArCIfc), 7.41 (2 H, t, J  =
7.7 Hz, 5-H), 7.55 (4 H, m, 4, 6 -H2), 7.66 (2 H, s, 2-H); MS (Cl) 317.1766 
(MH*, 100) (C20H20N4 requires 317.1766), 279 (6 8 ), 203 (72). The estimated, 
un-isolated yield of 3-(aziridin-l-ylmethyl)benzonitrile 50 was (130 mg, 29%); 
‘H NMR (CDCI3) 8  1.30 (2 H, deft, trans-H), 1.69 (2 H, deft, cis-H), 3.36 (2 H, 
s, ArCH2), 7.55-7.8 (4 H, m, Ar H).
NH
CN 59 CN 72
5-Cyanoisoquinolin-l-one 59
Method A: 223 2,6-Dicyanotoluene 71 (2.0 g, 14 mmol) in freshly distilled ethyl 
formate (50 ml) was stirred at 0-5°C with potassium terf-butoxide (8.7 g, 77 
mmol) for 25 min. A yellow precipitate formed, diethyl ether was added and the 
suspension was filtered. The yellow solid was dissolved in water and the solution 
was acidified with acetic acid, saturated with sodium chloride and extracted with 
chloroform. The organic extract was dried and concentrated. Chromatography 
(twice) (chloroform / ethyl acetate, 2:1 , hexane / ethyl acetate, 4:1) yielded:
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5-CyanoisoquinoIin-l-one 59 (0.30 g, 12.5%); pale yellow solid; Rf = 0.22 
(chloroform / ethyl acetate, 2:1); mp 296-300°C (lit.223 275°C, sublimation at 
265°C); IR (KBr) 3500, 3300 (N-H), 2230 (C=N), 1690, 1660 (C=0); ‘H NMR 
((CD3)2SO) 5 6.60 (1 H , / =  7.0 Hz, 4-H), 7.47 (1 H, d, J  = 7.0 Hz, 3-H), 7.63 (1 
H, t, J  = 7.7 Hz, 7-H), 8.26 (1 H, d, J  = 7.7 Hz, 6 -H), 8.47 (1 H, d, J  = 7.7 Hz, 8 - 
H), 11.72 (1 H, bs, NH); MS (El) 171.0512 (M+, 10) (13CC9H6N20  requires 
171.0514), 170.0480 (M*. 100) (CioH6N20  requires 170.0480). 
5-Cyanoisocoumarin 72 (0.33 g, 14%); colourless crystals; Rf = 0.85 
(chloroform / ethyl acetate, 2:1); mp 212-214°C; IR (KBr) 2240 (C^N), 1735 
(C=0); 'H NMR (CDC13) 8  6 .8 8  (1 H, d, J  = 5.7 Hz, 4-H), 7.46 (1 H, d, J  = 5.7 
Hz, 3-H), 7.64 (1 H, t, J=  7.7 Hz, 7-H), 8.05 (1 H, d, J  = 7.7 Hz, 6 -H), 8.52 (1 H, 
d, J  = 7.7 Hz, 8 -H); MS (El) 171 (1VT, 50), 143 (100); MS (El) 172.0353 (M+, 5) 
(i3CC9H5N 0 2 requires 172.0353), 171.0319 (M \ 47) (CioH5N0 2 requires 
171.0320), 143 (100).
Method B: £'-2-(2,6-Dicyanophenyl)-Arr/Vr-dimethylethenamine 81 (0.30 g, 1.5 
mmol) in dry methanol (50 ml) was saturated with hydrogen chloride gas. The 
mixture was then boiled under reflux for 3 d. The solution was concentrated and 
stirred with 10% sodium carbonate solution for 30 min. The aqueous suspension 
was extracted several times with ethyl acetate and the extract was dried and 
concentrated. Recrystallisation of the residue from ethyl acetate and 
chromatography of the mother liquor (hexane / ethyl acetate, 4:1) gave 59 (141 
mg, 55%) as an off-white solid; Rf = 0.31 (hexane / ethyl acetate, 1:1); mp 296- 
300°C; data identical to those above (see method A). Chromatography of the 




Triethylamine (2.2 ml, 1.6 g, 16 mmol), in dry acetone (3 ml), was added to 104 
(3 g, 13 mmol), in dry acetone (35 ml) at 0°C. Ethyl chloroformate (1.5 ml, 1.72 
g, 16 mmol), in dry acetone (3 ml) was added and the mixture was stirred at 0°C 
for 30 min. Sodium azide (1.2 g, 19 mmol), in water (3 ml), was added 
portionwise over 15 min. The mixture was poured on to ice and was extracted 
with dichloromethane. The extract was dried (calcium chloride) and was added 
carefully to boiling diphenyl ether (10 ml). The solution was boiled under reflux 
for 1 h. Evaporation, chromatography (diethyl ether) and recrystallisation 
(acetonitrile) gave 62 (305 mg, 10%) as white needles; Rf = 0.1 (hexane / ethyl 
acetate, 1:1); mp 242-244°C; IR (KBr) 3300, 3170 (N-H), 1680, 1660 (C=0); ‘H 
NMR ((CD3)2SO) 5 6.65 (1 H, d, J  = 7.3 Hz, 4-H), 7.36 (1 H, t, J = 7 Hz, 7-H), 
7.42 (1 H, d, J  = 7.3 Hz, 3-H), 8.02 (1 H, d, J  = 7 Hz, 6 -H), 8.21 (1 H, d, J  = 7 
Hz, 8 -H), 11.55 (1 H, bs, NH); MS (El) 224.9628 ([81Br]M+, 100) (C9H68IBrNO 
requires 224.9612), 222.9635 ([79Br]M+, 100) (C9H679BrNO requires 222.9633); 




£-3-(2-Iodophenyl)propenoic acid 115 (4.00 g, 15 mmol) was stirred with thionyl 
chloride (10 ml) and dimethylformamide (5 fil) for 16 h. The thionyl chloride 
was removed by distillation at atmospheric pressure. The residue, in 1,4-dioxan
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(5 ml), was added in portions to sodium azide (2.85 g, 44 mmol) in water ( 6  ml) 
and 1,4-dioxan ( 6  ml) over 15 min. The mixture was stirred for 45 min and water 
(11 ml) was added. The suspension was extracted three times with 
dichloromethane. The combined extracts were dried and the solvent was 
evaporated. The residue, in dichloromethane (10 ml), was added carefully to 
boiling dry bis(2-(2-methoxyethoxy)ethyl) ether (12 ml) in portions. The solution 
was boiled under reflux for 1 h. The precipitate that formed on cooling was 
recrystallised from acetone to give 63 (1.65 mg, 42%) as white needles; Rf = 0.24 
(hexane / ethyl acetate, 1:1); mp 238-244°C (decomp.); IR (KBr) 3400 (N-H) 
1660, 1630 (C=0); *H NMR ((CD3)2SO) 5 6.57 (1 H, d, 7 = 7.7 Hz, 4-H), 7.25 (1 
H, t, J  = 7.7 Hz, 7-H), 7.32 (1 H, d, J  = 7.3 Hz, 3-H), 8.23 (2 H, m, 6 ,8 -H2), 11.5 
(1 H, bs, NH); MS (El) 270.9492 (M+, 100) (C9H6INO requires 270.9494); Anal. 
Calcd. for C9H6INO: C, 39.88; H, 2.23; N, 5.17. Found: C, 39.8; H, 2.32; N,
5.06.
NH
NH- HCI 65 
5-Aminoisoquinolin-l-one hydrochloride 65
To a solution of 5-nitroisoquinolin-l-one 6 8  (160 mg, 0.84 mmol) in ethanol (10 
ml) and concentrated hydrochloric acid (0.4 ml), a slurry of 10% palladium on 
charcoal (O.lo g) in ethanol (2 ml) was added. The mixture was stirred under H2 
for 1 h. The suspension was then filtered through Celite®. The Celite® pad and 
residue were suspended in water (200 ml) and heated. The hot suspension was 
filtered through a second Celite® pad. Concentration of the filtrate and drying 
gave 65 (110 mg, 6 6 %) as white crystals; Rf = 0.05 (methanol / chloroform, 1:9); 
mp 250-260°C dec. (lit.223 273-276°C dec. [blackening at 267°C]); IR (KBr) 
3410, 3180, 3040-2850 (N-H), 1685, 1650 (C=0); *H NMR (D20) 5 6.76 (1 H, 
d, J  = 7.5 Hz, 4-H), 7.39 (1 H, d, J  = 7.5 Hz, 3-H), 7.59 (1 H, t, J  = 8.0 Hz, 7-H),
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7.79 (1 H, d, J  = 8.0 Hz, 6 -H), 8.27 (1 H, d, J  = 8.0 Hz, 8 -H); MS (El) 161 (M+, 





5-Nitroisoquinolin-l-one N-oxide 67 (8 .6  g, 45 mmol) was suspended in acetic 
anhydride (150 ml) and stirred at 100°C for 7 d. The cooled solution was 
concentrated and the residue was boiled with 1 0 % w/v sodium carbonate solution 
(400 ml) for 1 h. The suspension was filtered, the filtrate was concentrated, taken 
up in enough water to dissolve the inorganics and filtered again. The dark brown 
solid remaining was purified by extraction, several times, with hot toluene, 
which, on cooling, gave 68 (2.6, 30 %) as buff crystals; Rf = 0.26 (methanol /
chloroform, 1:19); mp 250-252°C (softening at 230°C) (lit.267 250°C); ‘H NMR 
((CD3)2SO) 8  6.98 (1  H , d , ; =  7.7 Hz, 4-H), 7.45 (1  H, d, 7  = 7.7 Hz, 3-H), 7.67
5-Nitroisoquinoline /V-oxide 67
Finely divided 5-nitroisoquinolin-l-one (12.5 g, 72 mmol) was suspended in 
glacial acetic acid (125 ml) and 27.5% w/v hydrogen peroxide solution (45 ml, 
364 mmol) was added. The solution was stirred at ambient temperature for 3 h 
and was heated to reflux for 36 h. The acetic acid was evaporated under reduced 
pressure and the residue was suspended in water, filtered, washed thoroughly 
with water and dried to give 67 (12.8 g, 94%) as a yellow solid; Rf = 0.20
( l H , t , ; =  8.0 Hz, 7-H), 8.47 (1 H,d, J  = 7.7 Hz, 8 -H), 8.58 (1 H, d, /  = 8.0 Hz,
6 -H), 11.8 (1 H, bs, NH); MS (Cl) 191 (MH+, 100).
n o2 67
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(methanol / chloroform, 1:19); mp 221-223 (lit268 220°C); IR (KBr) 1280 (N+-0); 
'H NMR (CD3COD) 8  7.93 (1 H, t, J  = 7.5 Hz, 7-H), 8.40 (1 H, d, J  = 7.5 Hz, 8 - 
H), 8.61 (1 H, d, J = 7.5 Hz, 6 -H), 8.5-8.7 (2 H, m, 3,4-H2), 9.42 (1 H, s, 1-H); 
MS (El) 190 (M+, 100).
6-(Phenylmethoxycarbonylamino)hexanoyl chloride 69
6 -(Phenylmethoxycarbonylamino)hexanoic acid (187 mg, 0.71 mmol), 2.0 M 
oxalyl chloride solution in dichloromethane (0.7 ml, 1.41 mmol) and DMF (50 
|il) were stirred in dichloromethane (2 ml) at ambient temperature for 3 h. The 
solvent was evaporated and the residue was taken up in dichloromethane which 
was then evaporated. This process was repeated The yellow oil that remained 




The freshly prepared 6 -(phenylmethoxycarbonylamino)hexanoyl chloride 69 
(201 mg, 0.71 mmol) and 5-aminoisoquinolin-l-one 6 8  (100 mg, 0.51 mmol) 
were stirred in pyridine (4 ml) for 24 h. The mixture was partitioned between 2 
M hydrochloric acid and diethyl ether; a pale pink solid remained undissolved in 
both phases. This was collected and dried to give 70 (60 mg, 42%); Rf = 0.20 
(methanol / chloroform, 1:9); mp 186-188°C; 1.5 (4 H, m, CH?CH?CH?CO). 1.76
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(2 H, qu, J = 6.7 Hz, NHCH2CH2), 2.48 (2 H, t, J = 6.7 Hz, CH2CH2CO), 3.15 (2 
H, t, J = 6.7 Hz, NHCH2), 5.05 (2 H, s, PhCH2), 6.70 (1 H, d, J = 7.4 Hz, 
isoquinolinone 4-H), 7.20 (1 H, d, J= 7.4 Hz, isoquinolinone 3-H), 7.30 (5 H, m, 
Ph-H5), 7.50 (1 H, t, J  = 8.0 Hz, 7-H), 7.77 (1 H, d, J = 8.0 Hz, 8 -H), 8.20 (1 H, 





A suspension of 2.6-dicyanotoluene (1.0 g, 7.0 mmol) in dimethylformamide 
dimethylacetal (10 ml) was boiled under reflux for 4 d. The solvent was 
evaporated and the yellow-brown residue was reciystallised from ethanol to give 
81 (0.973 g, 71%) as a bright yellow solid; Rf = 0.65 (hexane / ethyl acetate, 7:3); 
mp 117-119°C; 'H NMR (CDCI3) 8  3.00 ( 6  H, s, NMe2), 5.36 (1 H, d, J  = 13.6 
Hz, ArCH=C), 6.94 (1 H, t, J  = 7.7 Hz, 5-H), 7.63 (2 H, d, J  = 7.7 Hz, 4,6 -H), 
7.77 (1 H, d, J  = 13.6 Hz, C=CHN); MS (El) 197.0960 (M+, 100) (Ci2H„N 3 
requires 197.0953), 182 (25), 155 (30).
.CONH2
2-Cyano-2-methylbenzamide 83
To 2,6-dicyanotoluene (13.0 g, 21 mmol) in ethanol (75 ml) and 0.5 M sodium 
hydroxide solution (10.5 ml), 27.5 % w/v hydrogen peroxide solution (7.0 ml, 57 
mmol) was added in small portions. The solution was stirred for 1 h. and was 
extracted several times with ethyl acetate. The combined organic extracts were
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dried and concentrated. The residue was recrystallised from ethyl acetate to give 
83 (1.62 g, 48%) as a white crystalline solid; Rf = 0.32 (methanol / chloroform, 
1:9); mp 186-188°C; IR (KBr) 3420, 3350 (N-H), 2218 (C=N), 1680 (amide I), 
1625 (amide II); *H NMR (CDC13, (CD3)2SO) 5 2.65 (3 H, s, CH3), 6.94 (1 H, 
bs, NH), 7.36 (1H, t, J = 7.7 Hz, 5-H), 7.52 (1 H, bs, NH), 7.65 (2 H, m, 4,6-H2); 





2-Cyano-2-methylbenzamide 83, dimethylformamide dimethyl acetal (0.183 ml, 
164 mg, 1.25 mmol) and dimethylformamide (1 ml) were boiled under reflux for 
3 h. Water was added and the mixture was extracted with dichloromethane four 
times. The organic extracts were washed with water and saturated sodium 
chloride solution, dried and concentrated to give 84 (114 mg, 83%) as a yellow 
solid; Rf = 0.57 (methanol/ chloroform, 1:9); mp 98-100°C; *H NMR (CDC13) 8  
2.81 (3 H, s, Ar-CH3), 3.19 (3 H, s, NCH3), 3.23 (3 H, s, NCH3), 7.33 (1 H, t, /  =
7.7 Hz, 5-H), 7.65 (1 H, d, J  = 7.7 Hz, 4-H), 8.18 (1 H, d, /  = 7.7 Hz, 6 -H), 8.62 





To anhydrous 4-methylbenzenesulphonic acid (0.361 g, 2.1 mmol) in toluene 
(10 ml), 84 (0.30 g, 1.4 mmol) was added and the resulting mixture was refluxed 
for 13 h. The solvent was evaporated and the residue, in dichloromethane, was 
washed with water and 1 0 % sodium carbonate solution and was dried. 
Concentration and recrystallisation from dichloromethane gave 85 (132 mg, 
27%) as white crystals; Rf = 0.33 (methanol / chloroform, 1:19); mp 160-162°C; 
IR (KBr) 3370, 3190 (N-H), 2210 (C^N), 1735 (C=0), 1690 (amide I), 
1655(amide II); NMR ((CD3)2SO) 6  2.59 (3 H, s, Ar-CH3), 2.63 (3 H, s, Ar- 
CH3), 7.50 (1 H, t, J  = 7.7 Hz, 5-H), 7.60 (1 H, t, /  = 7.7 Hz, 5'-H), 7.71 (1 H, d, 
J = 7.7 Hz, 4'-H), 7.72 (1 H, bs, CONH2), 7.90 (2 H, d, J  = 7.7 Hz, 4, 6 -H2), 8.00 
(1 H, bs, CONH2), 8.04 (1 H, d, / =  7.7 Hz, 6 '-H), 9.22 (1 H, s, CHC=N), 11.78 
(1 H, bs, NHC=N); MS (Cl) 349 (MIT, 40 %).
(l-OxoisoquinoIine-5-carboxylic acid 89
5-Cyanoisoquinolinl-one 59 (0.427 g, 2.5 mmol) was boiled under reflux with 
potassium hydroxide in ethanol (2 0 % w/v, 1 2  ml), under nitrogen, until the 
production of ammonia ceased (3 d). The mixture was acidified with
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concentrated hydrochloric acid and the solvent was evaporated. The residue was 
taken up into methanol and filtered. Concentration of the filtrate gave 89 (0.394 
g, 83%) as a pale yellow solid; Rf = 0.02 (chloroform / methanol / acetic acid, 
100:10:1); mp >300°C; IR (KBr) 3400 (N-H), 3400-2700 (O-H), 1705, 1655, 
1625 (C=0); ‘H NMR (CD3OD) 6  7.26 (1 H, d, J  = 7.7 Hz, 4-H), 7.58 (1 H, t, J 
= 7.7 Hz, 7-H), 7.75 (1 H, d, /  = 7.7 Hz, 3-H), 8.41 (1 H, d, /  = 7.7 Hz, 8 -H), 
8.55 (1 H, d, J  = 7.7 Hz, 6 -H); MS (El) 190.0458 (M+, 11) (13CC9H7N 0 3 requires 
190.0459), 189.0425 (M+, 100) (C10H7NO3 requires 189.0426). (This compound
'yyxhas been reported but only as an intermediate and was not characterised.)
5-Bromoisoquinoline 90
5-Aminoisoquinoline 91 (4.8 g, 33 mmol) was dissolved in 48% hydrobromic 
acid (12 ml), water (13 ml) was added and the solution was cooled to 0 °C. The 
solution was diazotised with sodium nitrite (2.3 g, 33 mmol) in water (15 ml) and 
was added slowly to a solution of cuprous bromide (5.8 g, 40 mmol) in 48% 
hydrobromic acid (48 ml) at 75 °C. The solution was then stirred at ambient 
temperature for 24 h. The reaction mixture was basified (2.5 M sodium 
hydroxide solution) and steam distilled. The aqueous distillate was extracted with 
ethyl acetate and the organic extracts were dried and concentrated to give 90 
(2.67 g, 39%) as white crystals; Rf = 0.58 (hexane / ethyl acetate, 1:1); mp 81-83 
°C (lit.269 82-84°C); lH NMR (CDC13) 5 7.48 (1 H, t, J  = 7.8 Hz, 7-H), 7.97 (3 H, 
m, 4,6,8-H3), 8.65 (1 H, d, / =  6.0 Hz, 3-H), 9.24 (1 H, s, 1-H).
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5-(l-Hydroxyphenylmethyl)isoquinoIine 93
5-Bromoisoquinoline 90 (208 mg, 1.0 mmol) in dry tetrahydrofuran (6.25 ml) 
was stirred under nitrogen and cooled to - 1 16°C (liquid N2 / Et2 0 ). Butyllithium 
in hexane (2.5 M, 0.4 ml, 1.0 mmol) was added and stirring continued for a 
further 10 min. Benzaldehyde (0.1 ml, 104 mg, 0.98 mmol) in dry 
tetrahydrofuran (1 .0  ml) was added and the mixture was allowed to reach 
ambient temperature. Ammonium chloride solution (20%, 1 ml) was added and 
after being stirred for 5 min, the solvent was evaporated. The residue, in 
dichloromethane, was basified (saturated sodium hydrogen carbonate solution). 
The organic extract was dried. Evaporation and chromatography (hexane / ethyl 
acetate, 3:2) gave:
Isoquinoline 94 (4 mg, 3 %); a pale yellow oil; Rf = 0.54 (hexane / ethyl acetate, 
1:1); 'H NMR (CDCI3) 5 7.66 (3 H, m, 4,6,7-H3), 7.82 (1 H, d, J=  8.1 Hz, 5-H), 
7.98 (1 H, d, J  = 8.1 Hz, 8 -H), 8.53 (1 H, d, /  = 5.9 Hz, 3-H), 9.26 (1 H, s, 1-H) 
(identical to an authentic sample).
5-Bromoisoquinoline 90 (26 mg, 13 %); Rf = 0.60 (hexane / ethyl acetate, 1:1);
NMR data was identical to those above. 
5-(l-Hydroxy-l-phenylmethyl)isoquinoline 93 (79 mg, 34%); off-white 
crystals; Rf = 0.24 (hexane / ethyl acetate, 1:1); mp 124-126°C; !H NMR 
(CDCI3) 6  1.7 (1 H, bs, OH), 6.48 (1 H, s, CHOH), 7.36 (5 H, m, Ph-H5), 7.65 (1 
H, t, J  = 7.7 Hz, isoquinoline 7-H), 7.78 (1 H, d, J  = 6.1 Hz, isoquinoline 4-H),
7.9 (2 H, m, isoquinoline 6 ,8 -H), 8.41 (1 H, d, J  = 6.1 Hz, isoquinoline 3-H), 
9.20 (1 H, s, isoquinoline 1-H); MS (El) 236.1030 (NT, 11) (13C12Ci5Hi3NO 




To 2,3,5-tri-O-benzyl-D-ribose (4.81 g, 11.4 mmol) in diy dimethylsulphoxide 
(17 ml), acetic anhydride (11.5 ml) was added and the solution was stirred at 
ambient temperature for 24 h. The solution was poured onto ice-water and the 
mixture was extracted with dichloromethane. After washing with water, the 
organic extract was dried and concentrated to give a viscous yellow liquid. 
Chromatography (hexane / ethyl acetate, 17:3) gave 95 (3.56 g, 74%) as off- 
white crystals; Rf = 0.17 (hexane / ethyl acetate, 17:3); mp 50-52°C (lit.240 mp 
54-55°C); *H NMR (CDC13) 5 3.55 (1  H, dd, J  = 1 1.0, 2.6 Hz, 5-Ha), 3.66 (1 H, 
dd, /  = 11.0, 2.8 Hz, 5-Hb), 4.08 (1 H, dd, J  = 5.5, 2.0 Hz, 3-H), 4.4 (1 H, m, 2- 
H), 4.5 (3 H, m, Ph-CH2), 4.55 (1  H, m, 4-H), 4.71 (2 H, m, Ph-CH2), 4.94 (1 H, 
d, J  = 11.9 Hz, Ph-CH), 7.3 (15 H, m, 3 x Ph-Hs).
OBn OBn ^
2,3,5-Tri-O-benzyl-D-ribose 96
To 2,3,5-tri-O-benzyl-D-riboside 99/100 (5.59 g, 13 mmol) in dioxane (125 ml), 
hydrochloric acid (0.1 M, 31 ml, 0.31 mmol) was added. The solution was boiled 
gently and the distillate was collected for 30 h. The mixture was then neutralised 
(1 M sodium hydroxide solution) and concentrated. The residue, in 
dichloromethane, was washed three times with water and was dried. Evaporation 
gave 96 (4.81 g, 89 %) as a colourless syrup; Rf = 0.18 (hexane / ethyl acetate, 
4:1); 'H NMR (CDC13) 5 3.5-3.6 (2 H, m, 5-H2), 3.7-3.9 (3 H, m, 2,3,4-H3), 4.5 




D-Ribose 97 (5 g, 33 mmol) in dry methanol was cooled to 0°C and treated with 
concentrated sulphuric acid (0.5 ml). After storage at 4°C for 14 h, the solution 
was neutralised by passage through a column of anion-exchange resin (Dowex 
1x8-200) in the free base form. The eluate was concentrated to give 98 (5.5 g, 
1 0 0 %) as a syrup; attempts to crystallise this syrup were unsuccessful; the 
mixture of a and (3 isomers (a:p, 1:3) was used for the next stage; *H NMR 
((CD3)2SO) 5 3.21 (3 H, s, P isomer OCH3), 3.27 (3 H, s, a isomer OCH3), 3.33 
(1 H, dd, J  = 12, 5 Hz, p 5-HaO), 3.4 (2 H, m, a CH2), 3.5 (1 H, m, P 5-HB), 3.75 
(3 H, m, a 2,3,4-H3 and 3 H, m, p 2,3,4-H3), 4.23 (1 H, d, J  = 8.4 Hz, a OH), 4.6 
(2 H, m, P 1-H, OH and 1 H, m, a  OH), 4.7 (2 H, m, a  1-H, OH), 4.80 (1 H, d, J  
= 6 .6  Hz, P OH), 5.01 (1 H, d, 7 = 4.4 Hz, P OH).
OBn OBn OBn OBn
Methyl 2,3,5-tri-O-benzyl-p-D-riboside 99
Methyl D-ribofuranoside 98 (5.42 g, 33 mmol) in dry tetrahydrofuran (40 ml) 
was stirred with powdered potassium hydroxide (22.5 g, 0.39 mol). Benzyl 
chloride (32.0 ml, 35.2 g, 278 mmol) was added and the mixture was heated 
under reflux for 36 h. The suspension was filtered and the residue was washed 
thoroughly with tetrahydrofuran. The filtrate was concentrated and the residue, in 
ethyl acetate, was washed with water, dried and concentrated. Distillation (56°C 
@ 0.2 Torr) to remove the excess benzyl chloride and chromatography (hexane / 
ethyl acetate, 9:1) of the remaining crude yellow liquid gave:
Methyl 2,3,5-tri-0-benzyI-a-£>-riboside 100 (2.83 g, 20%) as a colourless 
syrup; Rf = 0.10 (hexane / ethyl acetate, 1:1); ]H NMR (CDCI3) 5 3.4 (2 H, m, 5- 
H2), 3.46 (3 H, s, OCH3), 3.8 (2 H, m, 2,3-H2), 4.26 (1 H, q, J = 4.0 Hz, 4-H), 
4.4-4.7 ( 6  H, m, 3 x Ph-CH2), 4.88 (1 H, d, J  = 4.0 Hz, 1-H), 1.2-1 A  (15 H, m, 3 
x Ph-Hs). [The 1HNMR agrees with a literature report239]
Methyl 2,3,5-tri-O-benzyl-p-D-riboside 99 (8.21, 57%) as a colourless syrup 
(lit.238 bp 235°C); Rf = 0.27 (hexane / ethyl acetate, 1:1); ]H NMR (CDC13) 6  
3.31 (3 H, s, OCH3), 3.50 (1 H, dd, J = 10.6, 5.9 Hz, 5-HA), 3.61 (1 H, dd, J  = 
10.6, 3.8 Hz, 5-Hb), 3.83 (1 H, dd, J  = 4.8, 1.0 Hz, 2-H), 4.01 (1 H, dd, J = 7.1, 
4.8 Hz, 3-H), 4.35 (1 H, m, 4-H), 4.55 ( 6  H, m, 3 x Ph-CH2), 4.92 (1 H, bs, 1-H), 
1.2-1 A  (15 H, m, 3 x Ph-Hs). [The 1HNMR agrees with a literature report239]
.0
5-Bromoisoquinoline iV-oxide 103
5-Bromoisoquinoline (0.30 g, 1.4 mmol), acetic acid (3 ml) and 27.5% w/v 
hydrogen peroxide solution (1.5 ml) were stirred for 14 d. The solvent was 
evaporated to give 103 (314 mg, 100%) as an off-white solid; Rf = 0.13 
(methanol / chloroform, 1:19); mp 187-189°C; *H NMR ((CD3)2SO) 6  7.50 (1 H, 
t, J = 7.8 Hz, 7-H), 7.77 (1 H, d, J  = 7.7 Hz, 6 -H), 7.86 (1 H, d, J  = 7.7 Hz, 8 -H),
8.04 (1 H, d, J  = 7.0 Hz, 4-H), 8.21 (1 H, d, J = 7.0 Hz, 3-H), 8.82 (1 H, s, 1-H); 
MS (El) 224.9606 ([81Br]M+, 72) (C9H681BrNO requires 224.9612), 222.9632 
([79Br]M+, 79) (C9H679BrNO requires 222.9633).
197
£'-3-(2-Bromophenyl)propenoic acid 104
Method A: 2-(Diethoxymethyl)bromobenzene 105 (12.8 g, 50 mmol), 
propandioic acid (10.3 g, 99 mmol), pyridine ( 20 ml) and piperidine (1 ml) were 
heated at 100°C for 3 h and at 140°C for 30 min. The cooled mixture was poured 
onto a mixture of concentrated hydrochloric acid and ice. The white precipitate 
was filtered and the filtrate was extracted with diethyl ether. The organic extract 
was washed with 5% sodium carbonate solution.The aqueous layer was acidified 
and extracted with diethyl ether. The combined organic product, in diethyl ether, 
was dried and concentrated to give 104 (4.64 g, 41%) as an off-white solid; (data 
below).
Method B: 2-Bromoiodobenzene 107 (14.05 g, 50 mmol), propenoic acid (4.5 
ml, 4.73 g, 6 6  mmol), palladium (II) acetate (0.111 g, 0.49 mmol), triethylamine 
(17.3 ml, 12.55 g, 124 mmol) and propanenitrile (20 ml) were heated, to reflux, 
under nitrogen, for 1.5 h. Hydrochloric acid (2 M, 800 ml) was added to the 
cooled mixture. The precipitate, in hot ethanol, was filtered and the filtrate was 
allowed to cool slowly. The solid was collected and dried to give 104 (8.53 g, 
76%) as white crystals; Rf = 0.58 (hexane / ethyl acetate, 1:1); mp 202-204°C 
(decomp.) (lit.270 212-212.5°C); IR (KBr) 3000-2500 (O-H), 1690 (C=0); ‘H 
NMR ((CD3)2SO) 8  6.57 (1 H, d, J  = 16.1 Hz, 2-H), 7.35 (1 H, td, J  = 7.7, 1.5 
Hz, Ar4-H), 7.44(1 H, t, J = 7.7 Hz, Ar 5-H), 7.71 (1 H, dd, J  = 7.7, 1.5 Hz, Ar
6 -H), 7.83 (1 H, d, J  = 16.1 Hz, 3-H), 7.90 (1 H, dd, J  = 7.7, 1.5 Hz, Ar 3-H), 




Thionyl chloride (2 ml) was added slowly to 2-bromobenzaldehyde 106 (10.0 g,
55.0 mmol) in triethyl orthoformate (16.9 g, 19.0 ml, 114 mmol) and dry ethanol 
(25 ml). The mixture was boiled under reflux for 4 h. The cooled mixture was 
stirred with sodium carbonate (8.0 g) for 15 min; it was then diluted with diethyl 
ether. Filtration, concentration and distillation gave 105 (152.97 g, 93%) as a 
colourless oil; bp2.5 118°C; 'H NMR (CDCI3) 6  1.25 ( 6  H, t, 7 = 7.0 Hz, 2 x 
CH3), 3.64 (4 H, m, 2 x CH2), 5.66 (1 H, s, CH), 7.18 (1 H, td, 7 = 7.6,1.8 Hz, 5- 
H), 7.32 (1 H, td, 7 = 7.6, 1.8 Hz, 4-H), 7.54 (1 H, dd, 7 = 7.6,1.8 Hz, 3-H), 7.65 
(1 H, dd, 7 = 7.6,1.8 Hz, 6 -H); MS (El) 260.0227, ([81Br]M+, 92) (Cu HI581Br02 
requires 260.0234), 258.0248, ([79Br]M+, 100) (CnHi579Br02 requires
258.0255). (This is not a novel compound, however no spectroscopic data is 
reported in the literature.)
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5-Bromo-2-(4-methoxyphenylmethyl)isoquinolin-l-one 111
Lithium bis(trimethylsilyl)amide (1.0 M in tetrahydrofuran, 0.90 ml, 0.90 mmol) 
was added to a stirred suspension of 62 (100 mg, 0.45 mmol) in dry 
tetrahydrofuran (10 ml) under nitrogen. The mixture was stirred for 1.5 h. The 
solution was cooled to 0°C and l-(chloromethyl)-4-methoxybenzene (0.1 ml, 
0.12 g, 0.74 mmol) in dry tetrahydrofuran (10 ml) was added, followed by 
sodium iodide (7 mg, 47|imol). The reaction mixture was stirred under nitrogen
for 4 d. The solvent was evaporated and the residue, in ethyl acetate, was washed 
with water and with saturated brine. The organic solution was dried and purified 
by chromatography (hexane / ethyl acetate, 7:3) to give 111 (156 mg, 100 %) as 
white crystals; Rf = 0.47 (hexane / ethyl acetate, 1:1); mp 98-100°C; ]H NMR 
(CDCI3) 5 3.78 (3 H, s, CH3), 5.15 (2 H, s, CH2), 6.84 (3 H, m, 4-H + Ph 3,5-H2),
7.18 (1 H, d, J = 7.7 Hz, 3-H), 7.3 (3 H, m, 7-H + Ph 2,6-H2), 7.87 (1 H, d, J =
7.7 Hz, 6 -H), 8.43 (1 H, d, J  = 8  Hz, 8 -H); MS (Cl) 346 ([81Br]MH+, 38), 344 
([79Br]MH+, 38), 121 (100); Anal. Calcd. for C17Hi4BrN0 2: C, 59.32; H, 4.10; N,
4.07. Found: C, 59.4; H, 4.18; N, 3.88.
5-Iodo-2-(phenylmethyl)isoquinolin-l-one 112
Lithium bis(trimethylsilyl)amide (1.0 M in tetrahydrofuran, 0.60 ml, 0.60 mmol) 
was added to a stirred suspension of 63 (100 mg, 0.37 mmol) in dry 
tetrahydrofuran (10 ml) under nitrogen. The mixture was stirred for 2 h. The 
solution was cooled to 0°C and chloromethylbenzene (55 pi, 61 mg, 0.48 mmol) 
in dry tetrahydrofuran (10 ml) was added, followed by sodium iodide (7 mg, 
47*jimol). The reaction mixture was stirred at ambient temperature, under 
nitrogen, for 5 d. The solvent was evaporated and the residue, in ethyl acetate, 
was washed with water and with saturated brine. The organic solution was dried 
and purified by chromatography (hexane / ethyl acetate, 7:3) to give 112(123 mg, 
92 %) as white crystals; Rf = 0.52 (hexane / ethyl acetate, 1:1); mp 118-120°C; 
IR (KBr) 1650 (0=0), 1620 (C=0); lH NMR (CDC13) 5 5.22 (2 H, s, CH2), 6.72 
(1 H, d, J = 7.5 Hz, 4-H), 7.19 (2 H, m, 3,7-H2), 7.33 (5 H, m, Ph-H5), 8.15 (1 H, 
dd, J  = 7.7, 1.3 Hz, 6 -H), 8.47 (1 H, dd, J = 7.7, 1.3 Hz, 8 -H); 13C NMR (CDC13)
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8  51.90 (NCH2), 96.29 (Cq), 109.91 (CH), 127.21 (Cq), 127.96 (CH), 128.14 
(CH), 128.69 (CH), 128.86 (CH), 132.55 (CH), 136.41 (Cq), 139.02 (Cq), 143.01 
(CH), 161.45 (Cq); MS (El) 360.9960 (M+, 75) (Ci6Hi2INO requires 360.9964); 
Anal. Calcd. for Ci6Hi2INO: C, 53.21; H, 3.35; N, 3.88: C, 53.8; H, 3.46; N, 
3.82.
2-Iodobenzaldehyde 114
2-Iodobenzyl alcohol 113 (20.0 g, 8 6  mmol) in dichloromethane (55 ml) was 
added to a well stirred suspension of pyridinium dichromate (49.2 g, 130 mmol) 
in dichloromethane (140 ml). After 3 h, the mixture was diluted with diethyl 
ether (56 ml), filtered and distilled to give 114 (12.33 g, 62%) as a pale yellow 
wax; Rf = 0.58 (hexane / ethyl acetate, 9:1); bpu 109°C (lit.271 bpu 129°C @14 
mmHg, lit.272 mp 37°C); 'H NMR (CDC13) 6  7.29 (1 H, td, J  = 7.7, 1.8 Hz, 4-H), 
7.46 (1 H, t, J=  7.7 Hz, 5-H), 7.88 (1 H, dd, J  = 7.7, 1.8 Hz, 6 -H), 7.96 (1 H, d, J  
= 7.7 Hz, 3-H), 10.07 (1 H, s, CHO); MS (El) 232 (M \ 100).
E -3-(2-Iodophenyl)propenoic acid 115
2-Iodobenzaldehyde 114 (8.29 g, 36 mmol), propanedioic acid (8.11 g, 78 mmol) 
and piperidine (0.3 ml) in pyridine (17 ml) were boiled under reflux for 2 h. 
Hydrochloric acid (2 M, 250 ml) was added to the cooled solution. The white 
precipitate was collected, recrystallised from hot ethanol and dried to give 115 
(8.29"g, 85%) as colourless needles; Rf = 0.33 (hexane / ethyl acetate, 1:1); mp 
219-220°C (lit.273212-214°C); ‘H NMR ((CD3)2SO) 8  6.48 (1 H, d, J  = 15.8 Hz,
2-H), 7.16 (1 H, t, 7 = 8.1 Hz, Ar4-H), 7.44 (1 H, t, J=  8.1 Hz, Ar 5-H), 7.63 (1
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H, d, J  = 15.8 Hz, 3-H), 7.83 (1 H, d, J = 8.1 Hz) and 7.95 (1 H, d, J = 8.1 Hz) 
(Ar 3,6-H2), 12.67 (1 H, bs, CQ2H); MS (El) 274 (M+, 20), 147 (100).
121 124
5-Formyl-2-phenylmethylisoquinolin-l-one 121
5-Iodo-2-(phenylmethyl)isoquinolin-l-one 112 (79 mg, 0.2 mmol) in dry 
tetrahydrofuran (2 ml) was stirred under nitrogen and cooled to -78°C (acetone / 
C 02). Butyllithium in hexane (1.6 M, 0.15 ml, 0.24 mmol) was added and 
stirring was continued for a further 4 h. Dimethylformamide (0.028 ml, 0.029 g, 
0.4 mmol) in dry tetrahydrofuran (0.1 ml) was added. Stirring was continued for 
15 min before the mixture was allowed to reach ambient temperature. The 
reaction mixture was stirred for 1 h at ambient temperature and water (1  ml) was 
then added. The solution was stirred for 10 min and then extracted several times 
with ethyl acetate. The combined organic extracts were dried. Evaporation and 
chromatography gave only 124 (20 mg, 38%) as a colourless oil (lit274 mp 69- 
71°C); Rf = 0.31 (hexane / ethyl acetate, 4:1); *H NMR (CDC13) 5 5.23 (2 H, s, 
CH2), 6.49 (1 H, d, J = 7.5 Hz, isoquinoline 4-H), 7.09 (1 H , d , /  = 7.5 Hz. 
isoquinoline 3-H), 7.32 (5 H, m, Ph-Hs), 7.49 (2 H, m, isoquinoline 5,7-H2), 7.66 
(1 H, t, J = 7.3 Hz, isoquinoline 6 -H), 8.48 (1 H, d, J  = 7.3 Hz, isoquinoline 8 - 




5-Iodoisoquinolin-l-one 63 (100 mg, 0.37 mmol), propenoic acid (0.03 ml, 35 
mg, 0.49 mmol), palladium (II) acetate (8  mg, 37 pmol) and triethylamine (0.13 
ml, 93 mg, 0.92 mmol) in propanenitrile (0.3 ml) were boiled under reflux for 1 
h. Hydrochloric acid (2 M, 10 ml) was added and the precipitate was collected 
and dried to give 125 (76 mg, 97%) as a pale green solid; Rf = 0.05 (hexane / 
ethyl acetate, 1:1); mp 315-318°C; IR (KBr) 3550 (N-H), 1695, 1660 (C=0); *H 
NMR ((CD3)2SO) 8  6.57 (1 H, d, J  = 15.8 Hz, 2-H), 6.76 (1 H, d, J  = 7.3 Hz, 
isoquinoline 4-H), 7.28 (1 H, ca. t, isoquinoline 3-H), 7.52 (1 H, t, J  = 7.7 Hz, 
isoquinoline 7-H), 8.10 (1 H, d, J  = 15.8 Hz, 3-H), 8.12 (1 H, d, J  = 7.7 Hz) and
8.27 (1 H, d, J  = 7.7 Hz, isoquinoline 6 ,8 -H2), 11.47 (1 H, bs, NH), 12.60 (1 H, 
bs, C 0 2H); MS (Cl) 216 (MH+, 100); MS (FAB+) 216.0616 (MH*. 50) 





CHOCHOOH OH 128126 127
5-(l-Oxoisoquinolin-5-yl)-pent-4-enol 126
5-Iodoisoquinolin-l-one 63 (400 mg, 1.5 mmol), pent-4-enol (0.2 ml, 0.17 g, 1.9 
mmol), palladium (II) acetate (32 mg, 0.14 mmol), triethylamine (0.52 ml, 0.37 
g, 3.7 mmol) and propanenitrile (1.5 ml) were boiled under reflux for 2 h. The
203
solvent was evaporated and the residue, in dichloromethane, was washed, 
successively, with hydrochloric acid (2 M), water and saturated brine. The 
organic extract was dried and concentrated. Chromatography (ethyl acetate / 
methanol, 99:1) gave the starting material, 63 (221 mg, 55%) and two mixtures 
of isomers with identical Rf values which could not, therefore, be separated 
5-(l-Oxoisoquinolin-5-yl)-pent-4-enol 126 (44 mg, 13%) as an off-white solid; 
Rf = 0.11 (ethyl acetate / methanol, 99:1) [mixture with 127]; !H NMR 
((CD3)2SO) 5 1.6 (2 H, qu, J  = 6 .8  Hz, 2-H2), 2.3 (2 H, m, 3-H2), 3.5 (2 H, m, 1- 
H2), 6.3 (1 H, dt, J  = 15.6,7.2 Hz, 4-H), 6.75 (1 H, d, J = 7.5 Hz, isoquinoline 4- 
H), 6.93 (1 H, d, J= 15.6 Hz, 5-H), 7.18 (1 H, m, isoquinoline 3-H), 7.48 (1 H, 
m, isoquinoline 7-H), 7.80 (1 H, d, J = 7.5 Hz, isoquinoline 6 -H), 8.1 (1 H, m, 8 - 
H).
4-(l-Oxoisoquinolin-5-yl)-pent-4-enol 127 (37 mg, 11%) as an off-white solid; 
Rf = 0.11 (ethyl acetate / methanol, 99:l)[mixture with 126]; !H NMR 
((CD3)2SO) 6  2.1 (2 H, m, 2-H), 2.5 (2 H, m, 3-H), 3.5 (2 H, m, 1-H), 5.5 (2 H, 
m, 4,5-H2), 6.62 (1 H, d, J = 7.7 Hz, isoquinoline 4-H), 7.18 (1 H, m, 3-H), 7.48 
(2 H, m, 6,7-H2), 8.1 (1 H, m, 8 -H).
MS (FAB+) 230.1178 (MH+, 100) (Ci4Hi6N0 2 requires 230.1181).
5-(l-Oxoisoquinolin-5-yl)pentanal 128 (14 mg, 5%) as an off-white solid; Rf =
0.23 (ethyl acetate / methanol, 99:1) [mixture with 129]; 2H NMR ((CD3)2SO) 6
1.7 (4 H, m, 3,4-H4), 2.5 (2 H, m, 2-H2), 2.9 (2 H, m, 5-H2), 6.73 (1 H, d, J = 7.7 
Hz, isoquinoline 4-H), 7.23 (1 H, d, J  = 7.7 Hz, isoquinoline 3-H), 7.5 (2 H, m, 
isoquinoline 6,7-H2), 8.3 (1 H, m, isoquinoline 8-H), 9.78 (1 H, s, CHO), 11.37 
(1 H, bs, NH).
(±)-4-(l-Oxo-isoquinolin-5-yl)pentanal 129 (7 mg, 2%) as an off-white solid;
Rf = 0.23 (ethyl acetate / methanol, 99:1 [mixture with 128]; *H NMR 
((CD3)2SO) 6  1.3 (5 H, m, 3,5-Hs), 2.4 (2 H, t, J  = 7.7 Hz, 2-H2), 3.4 (1 H, m, 4- 
H), 6.83 (1 H, d, / =  7.7 Hz, isoquinoline 4-H), 7.5 (3 H, m, isoquinoline 3,6,7- 
H3), 8.3 (1 H, m, isoquinolinone 8-H), 9.74 (1 H, bs, CHO), 11.37 (1 H, bs, NH). 





Freshly prepared (4/?)-2,2-Dimethyl-1,3-dioxolan-4-carboxaldehyde 136 (3.89 g, 
30 mmol) in dry tetrahydrofuran (10 ml) was added, over 30 min, to a 1 M 
solution of vinylmagnesium bromide in tetrahydofuran (59 ml, 59 mmol) at -  
20°C (ice / sodium chloride). After 1 h, the solution was warmed to 0°C. Diethyl 
ether (15 ml) was added, followed by saturated ammonium chloride solution (25 
ml). The precipitate was filtered and washed with diethyl ether (4 x 25 ml). The 
combined organic solutes were dried and concentrated and the residue was 
distilled to give 135 (2.79 g, 59%) as a colourless oil; 'H NMR (CDCI3) 8  1.37 (3 
H, s, CH3 both diastereomers), 1.45 (3 H, s, CH3, both diastereomers), 2.45 (1 H, 
bs, OH, diastereomer I), 2.62 (1 H, bs, OH, diastereomer II), 3.78 (1 H, m, 4-H, 
diastereomer II), 3.90-4.06 (3 H, m, 5 -H2, l'-H, diastereomer II), 3.90-4.06 (2 H, 
m, 5 -H2, diastereomer I), 4.12 (1 H, m, l'-H, diastereomer I), 4.26 (1 H, m, 4-H, 
diastereomer I), 5.24 (1 H, d, J = 10 Hz, cis 3'-H, both diastereomers), 5.40 (1 H, 
d, J  = 17 Hz, trans 3'-H, both diastereomers), 5.8 (1 H, m, 2-H, both 
diastereomers) (molar ratio of diastereomers, 1:11, 1:1.5); 13C NMR (CDCI3) 8  
25.06 (CH3), 25.20 (CH3), 26.35 (CH3), 26.64 (CH3), 64.74 (CH2), 65.76 (CH2), 
71.84 (CH), 73.97 (CH), 78.52 (CH), 78.02 (CH), 109.35 (Cq), 109.74 (Cq), 
116.83 (=CH2), 117.71 (=CH2), 135.79 (=CH), 136.15 (=CH).
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(4/?)-2,2-Dimethyl- l,3-dioxolan-4-carboxaldehyde 136
To 1,2,5,6-Di-Oisopropylidene-D-mannitol 137 (5.00 g, 19 mmol), in 
dichloromethane (75 ml), at 0°C, sodium carbonate (20.2 g, 191mmol) was 
added followed by lead (IV) acetate (8.87 g, 20 mmol). The reaction mixture was 
stirred for 10 min (oxidation was monitored using starch-iodide paper). The 
suspension was filtered through Celite® / magnesium sulphate and the residue 
was washed three times with dichloromethane. The filtrate was concentrated and 
the residue was distilled to give 136 (3.89 g, 78%) as a colourless oil; bp3 45°C 
(lit. 258 bpis 39°C); IR (film) 1740 (C=0); 'H NMR (CDCI3) 8  1.43 (3 H, s, CH3),




Method A: Lithium bis(trimethylsilyl)amide in dry tetrahydrofuran (1.0 M, 19.0 
ml, 19 mmol) was added to 135 (1.5 g, 9.5 mmol) in dry tetrahydrofuran (150 
ml) under nitrogen. The solution was stirred for 1.5 h, then cooled to 0°C. 
Bromomethylbenzene (2.6 g, 1.8 ml, 15 mmol) in dry tetrahydrofuran (100 ml) 
was added and the resulting mixture was stirred at ambient temperature for 7 d. 
The reaction mixture was then heated under reflux for 4 d. The solvent was 
evaporated and the residue, in ethyl acetate, was washed with water and saturated 
brine. The solution was dried, concentrated and purified by chromatography 
(hexane / ethyl acetate, 9:1) to give 138 (655 mg, 28%) as a yellow oil; Rf = 0.6 
(hexane / ethyl acetate, 4:1); 'H NMR (CDC13) 8  1.38 (3 H, s, CH3), 1.41 (3 H, s, 
CH3), 3.7-4.1 (4 H, m, 5-H2, 4-H, l ’-H), 4.4 (1 H, m, PhOCH2), 4.7 (1 H, m, 
PhOCH2), 5.4 (2 H, m, 3'-H2), 5.8 (1 H, m, 2'-H), 7.32 (5 H, m, Ph-H5).
Method B: Sodium hydride (60 % in oil, 130 mg, 3.3 mmol) was added to 135 
(0.52 g, 3.3 mmol) in dry dimethylformamide (20 ml) under nitrogen. The 
mixture was stirred for 1 h. Bromomethylbenzene (0.43 ml, 615 mg, 3.6 mmol) 
was added and the mixture was stirred for 3 d. The solvent was evaporated and 
the residue, in ethyl acetate, was washed with water and was dried. Concentration 





Hydrochloric acid (2 M, 4.5 ml) was added to a solution of 135 (0.50 g, 3.2 
mmol) in tetrahydrofuran (4.5 ml). The resulting mixture was stirred at 60°C for 
2 h. The cooled solution was neutralised with sodium hydroxide solution (2 M) 
and filtered. The solvents were evaporated and the residue was dried by adding 
succesive aliquots of dry ethanol and removing the solvent by distillation at 






To (4/?)-Pentene-4-ene-l,2,3-triol 139 (0.37 g, 3.1 mmol) in dry
dimethylformamide (3 ml), (dimethoxymethyl)benzene (0.50 ml, 3.3 mmol) and
4-methylbenzenesulphonic acid (1 mg) were added. The reaction vessel was 
fitted with an air condenser attached to a water pump via a three-way tap. The 
apparatus was evacuated and the system was stirred at 70°C until methanol 
ceased to condense (6  h). The cooled mixture was concentrated and the residue,
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in diethyl ether, was washed with sodium carbonate solution ( 1 0 %) and water. 
The organic solution was dried, concentrated and chromatographed (hexane / 
ethyl acetate) to give 140 (413 mg, 64%) as a yellow oil; Rf = 0.26; mixture of 
diastereomers; 'H NMR (CDC13) 5 2.09 (1 H, bs, OH), 3.6-4.6 (4 H, m, 6-H2, 
4,5-H2), 5.4 (2 H, m, CH2=), 5.5 (1 H, s, 2-H, diastereomer I), 5.92 (1 H, m, 






5-Iodoisoquinolin-l-one 63 (400 mg, 1.5 mmol), (4R)-2,2-dimethyl-4-(l- 
hydroxyprop-2-enyl)-l,3-dioxolane 135 (315 mg, 1.9 mmol), triethylamine (0.52 
ml, 0.37 g, 3.7 mmol) and palladium (II) acetate (32 mg, 0.14 mmol) in 
propanenitrile (1.5 ml) were heated under reflux for 2 h. The solvent was 
evaporated and the residue, in ethyl acetate, was washed with 2 M hydrochloric 
acid and saturated brine. The dried organic solution was concentrated and 
purified by chromatography (ethyl acetate, then acetone / hexane, 2 :1) to give:
5-(3-(4R-2,2-Dimethyl-l,3-dioxolan-4-yl)-3-hydroxyprop-l-enyl)isoquinoIin- 
1-one 141 (76 mg, 18%) as an off-white solid; Rf = 0.18 (ethyl acetate); mp 164- 
166°C; ‘H NMR (CDCI3) 6  1.40 (3 H, s, CH3), 1.50 (3 H, s, CH3), 2.17 (1 H, bs, 
OH), 3.93 (1 H, dd, J = 8.4, 5.5 Hz, dioxolane 5-H aHb, diastereomer I), 4.04 (2 
H, d, J  = 6 .8  Hz, dioxolane 5 -H2, diastereomer II), 4.1 (1 H, dd, J  = 6.3, 8.4 Hz, 
dioxolane 5-H a H r. diastereomer I), 4.20 (1 H, m, dioxolane 4-H, diastereomer I),
4.28 (1 H, m, dioxolane 4-H, diastereomer II), 4.34 (1 H, td, J  = 6.3, 1.5 Hz,
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CHOH, diastereomer I), 4.56 (1 H, td, J = 5.5, 1.5 Hz, CHOH, diastereomer II),
6.18 (1 H, m, =CHCH, diastereomers I and II), 6.82 (1 H, d, J = 7.3 Hz) and 6.81 
(1 H, d, J  = 7.3 Hz, isoquinoline 4-H, diastereomers I and II), 7.19 (1 H, d, J  = 
7.3 Hz, isoquinoline 3-H, diastereomers I and II), 7.24 (1 H, m, ArCH=, 
diastereomers I and II), 7.48 (1 H, t, J= 7.8 Hz, isoquinoline 7-H, diastereomers I 
and II), 7.78 (1 H, d, 7 = 7.8 Hz, isoquinoline 6 -H, diastereomers I and II), 8.37 
(1 H, d, /  = 7.8 Hz, isoquinoline 8 -H, diastereomers I and II), 10.6 (1 H, bs, NH) 
[The ratio of diastereomers was 1 : 1.8 ( I : II)]; MS (FAB+) 302.1373 (MH+, 100) 
(C17H20NO4 requires 302.1392).
5-(3-(4/?-2,2-dimethyl-l,3-dioxolan-4-yl)-3-oxo-propyl)isoquinolin-l-one 142
(176 mg, 42%) as an off-white solid; Rf = 0.25 (ethyl acetate); mp 138-141°C; IR 
(KBr) 3300, 3160 (N-H), 1715 (ketone C=0), 1660, 1630 (isoquinolinone C=0); 
*H NMR (CDCI3) 8  1.38 (3 H, s, CH3), 1.43 (3 H, s, CH3), 3.00 (2 H, td, J  = 7.6,
2.7 Hz) and 3.20 (2 H, m) (2 x CH2), 3.96 (1 H, dd, J  = 8.5, 5.5 Hz, dioxolane 5- 
HaHb), 4.19 (1 H, dd, J  = 8.5, 7.8 Hz, dioxolane 5-HaHb), 4.45 (1 H, dd, J = 7.8, 
5.5 Hz, dioxolane 4-H), 6.87 (1 H, d, J= 7.3 Hz, isoquinoline 4-H), 7.29 (1 H, d, 
J  = 7.3 Hz, isoquinoline 3-H), 7.50 (1 H, t, J  = 7.9 Hz, isoquinoline 7-H), 7.61 (1 
H, d, J -  7.9 Hz, isoquinoline 6 -H), 8.34 (1 H, d, J = 7.9 Hz, isoquinoline 8 -H),
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APPENDIX A
'H NMR COSY Spectrum (399.65 MHz, CDCI3 ) 
4^-2,2-Dimethyl-4-( 1 -hydroxyprop-2-enyl)-1,3-dioxolane 1 3 5
226
'H NMR COSY Spectrum (399.65 MHz, CDCI3 )
3-(3-(4fl-2,2-Dimethyl-1,3-dioxolan-4-yl)-3-hydroxyprop-1 -en-yl)isoquinolin-1 - 
one 141.
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